


**CUMULATIVE
SUPPLEMENT 5
MAY 2013**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2013

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Cumulative Supplement 5

May 2013

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

**CUMULATIVE SUPPLEMENT 5
May 2013**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BIONICHE PHARMA USA LLC
(BIONICHE PHARMA USA)

MYLAN INSTITUTIONAL LLC
(MYLAN LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck

KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2012</u>	<u>MAR 2013</u>	<u>JUN 2013</u>	<u>SEPT 2013</u>	<u>DEC 2013</u>
DRUG PRODUCTS LISTED	15343	15445			
SINGLE SOURCE	2400 (15.9%)	2467 (16.0%)			
MULTISOURCE	12825 (83.6%)	12900 (83.5%)			
THERAPEUTICALLY EQUIVALENT	12683 (82.7%)	12758 (82.6%)			
NOT THERAPEUTICALLY EQUIVALENT	142 (0.9%)	142 (0.9%)			
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)			
NEW MOLECULAR ENTITIES					
APPROVED	17	9			
NUMBER OF APPLICANTS	835	844			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 33RD EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

1-1

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ MIRROR PHARMS LLC 500MG;50MG;40MG

A040883 001 Dec 23, 2008 Feb DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

@ MIKART 356.4MG;30MG;16MG

A040109 001 Aug 26, 1997 Feb DISC

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

@ MIKART 712.8MG;60MG;32MG

A040316 001 Apr 28, 1999 Feb DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA AUROLIFE PHARMA LLC 300MG;15MG

A202800 001 Apr 15, 2013 Apr NEWA

AA 300MG;30MG

A202800 002 Apr 15, 2013 Apr NEWA

AA 300MG;60MG

A202800 003 Apr 15, 2013 Apr NEWA

@ MIKART 650MG;30MG

A089231 001 Mar 03, 1986 Feb DISC

@ 650MG;60MG

A089363 001 Sep 09, 1991 Feb DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MIKART 500MG;5MG

A081067 001 Nov 30, 1989 Feb DISC

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA PAI 325MG/15ML;7.5MG/15ML

A040838 001 May 10, 2013 Apr NEWA

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A> AA CARACO 325MG;5MG

A090118 001 Dec 23, 2008 May CAHN

>A> AA 325MG;7.5MG

A090118 002 Dec 23, 2008 May CAHN

>A> AA 325MG;10MG

A090118 003 Dec 23, 2008 May CAHN

>A> AA 500MG;5MG

A090265 001 Dec 23, 2008 May CAHN

>A> AA 500MG;7.5MG

A090265 002 Dec 23, 2008 May CAHN

>A> AA 500MG;10MG

A090265 003 Dec 23, 2008 May CAHN

@ MIKART 500MG;2.5MG

A089698 001 Aug 25, 1989 Feb DISC

@ 650MG;5MG

A040849 001 Jun 09, 2010 Feb DISC

>D> AA SUN PHARM INDS INC 325MG;5MG

A090118 001 Dec 23, 2008 May CAHN

>D> AA 325MG;7.5MG

A090118 002 Dec 23, 2008 May CAHN

>D> AA 325MG;10MG

A090118 003 Dec 23, 2008 May CAHN

>D> AA 500MG;5MG

A090265 001 Dec 23, 2008 May CAHN

>D> AA 500MG;7.5MG

A090265 002 Dec 23, 2008 May CAHN

>D> AA 500MG;10MG

A090265 003 Dec 23, 2008 May CAHN

AA TRIS PHARMA INC 325MG;5MG

A202214 001 Mar 27, 2013 Mar NEWA

AA 325MG;7.5MG

A202214 002 Mar 27, 2013 Mar NEWA

AA 325MG;10MG

A202214 003 Mar 27, 2013 Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA ACTAVIS ELIZABETH 325MG;2.5MG

A201447 001 Apr 12, 2013 Apr NEWA

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS ELIZABETH	325MG;5MG	A201447 002	Apr 12, 2013	Apr	NEWA
AA		325MG;7.5MG	A201447 003	Apr 12, 2013	Apr	NEWA
AA		325MG;10MG	A201447 004	Apr 12, 2013	Apr	NEWA

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

@ WATSON LABS	250MG	A088882 001	Oct 22, 1985	Jan	DISC
---------------	-------	-------------	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT AGILA	EQ 500MG BASE/VIAL	A200880 001	May 09, 2012	Jan	CAHN
----	--------------	--------------------	-------------	--------------	-----	------

ACITRETIN

CAPSULE; ORAL

ACITRETIN

AB	BARR LABS INC	10MG	A091455 001	Apr 04, 2013	Mar	NEWA
AB		25MG	A091455 002	Apr 04, 2013	Mar	NEWA
AB	TEVA PHARMS USA	17.5MG	A202897 001	Apr 04, 2013	Mar	NEWA
AB		22.5MG	A202897 002	Apr 04, 2013	Mar	NEWA

SORIATANE

AB	STIEFEL LABS INC	10MG	N019821 001	Oct 28, 1996	Mar	CFTG
AB		17.5MG	N019821 003	Aug 06, 2009	Mar	CFTG
AB		22.5MG	N019821 004	Aug 06, 2009	Mar	CFTG
AB	+	25MG	N019821 002	Oct 28, 1996	Mar	CFTG

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

>A>	+	ACTIENT PHARMS	8MG;60MG	N019806 001	Mar 25, 1994	May	CAHN
>D>	+	UCB INC	8MG;60MG	N019806 001	Mar 25, 1994	May	CAHN

ACYCLOVIR

OINTMENT; TOPICAL

ACYCLOVIR

AB	MYLAN PHARMS INC	5%	A202459 001	Apr 03, 2013	Mar	NEWA
----	------------------	----	-------------	--------------	-----	------

ZOVIRAX

>A>	AB	+	VALEANT BERMUDA	5%	N018604 001	Mar 29, 1982	May	CAHN
>D>	AB	+	VALEANT INTL	5%	N018604 001	Mar 29, 1982	May	CAHN
	AB	+		5%	N018604 001	Mar 29, 1982	Mar	CFTG

TABLET; BUCCAL

SITAVIG

+	BIOALLIANCE PHARMA	50MG	N203791 001	Apr 12, 2013	Apr	NEWA
---	--------------------	------	-------------	--------------	-----	------

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+	VALEANT BERMUDA	5%;1%	N022436 001	Jul 31, 2009	Apr	CAHN
---	-----------------	-------	-------------	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION
ADENOSINE

@ TEVA PHARMS USA	3MG/ML	A078676	001	Jul 31, 2008	Apr	CAHN
@	3MG/ML	A076564	001	Jun 16, 2004	Apr	CAHN

ALBENDAZOLE

TABLET; ORAL
ALBENZA

+ AMEDRA PHARMS	200MG	N020666	001	Jun 11, 1996	Feb	CAHN
-----------------	-------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
PROAIR HFA

BX + TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Apr	CAHN
-------------------------	--------------------	---------	-----	--------------	-----	------

VENTOLIN HFA

>A> BX + GLAXO GRP LTD	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	May	CAHN
------------------------	--------------------	---------	-----	--------------	-----	------

>D> BX + GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	May	CAHN
--------------------------	--------------------	---------	-----	--------------	-----	------

SOLUTION; INHALATION

ALBUTEROL SULFATE

@ APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010	Apr	DISC
--------------	----------------	---------	-----	--------------	-----	------

@	EQ 0.042% BASE	A078623	002	Apr 05, 2010	Apr	DISC
---	----------------	---------	-----	--------------	-----	------

@	EQ 0.083% BASE	A075717	001	Feb 02, 2007	Apr	DISC
---	----------------	---------	-----	--------------	-----	------

@	EQ 0.5% BASE	A076391	001	Apr 01, 2003	Apr	DISC
---	--------------	---------	-----	--------------	-----	------

AN + MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Jan	CAHN
-------------------	----------------	---------	-----	--------------	-----	------

@ WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999	Mar	DISC
------------------------	----------------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ APOTEX INC	EQ 0.083% BASE;0.017%	A077117	001	Dec 31, 2007	Apr	DISC
--------------	-----------------------	---------	-----	--------------	-----	------

ALENDRONATE SODIUM

SOLUTION; ORAL

ALENDRONATE SODIUM

AA ROXANE	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Feb	NEWA
-----------	-------------------	---------	-----	--------------	-----	------

FOSAMAX

AA + MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Feb	CFTG
------------	-------------------	---------	-----	--------------	-----	------

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

AB + COVIS PHARMA SARL	10MG	N021287	001	Jun 12, 2003	Apr	CAHN
------------------------	------	---------	-----	--------------	-----	------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB ACCORD HLTHCARE	100MG	A203154	001	May 06, 2013	Apr	NEWA
--------------------	-------	---------	-----	--------------	-----	------

AB	300MG	A203154	002	May 06, 2013	Apr	NEWA
----	-------	---------	-----	--------------	-----	------

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013	Jan	NEWA
-------------------	----------------	---------	-----	--------------	-----	------

TABLET; ORAL

NESINA

	TAKEDA PHARMS USA	EQ 12.5MG BASE	N022271 002	Jan 25, 2013	Jan	NEWA
+		EQ 25MG BASE	N022271 003	Jan 25, 2013	Jan	NEWA

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

	TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414 001	Jan 25, 2013	Jan	NEWA
+		EQ 12.5MG BASE;1GM	N203414 002	Jan 25, 2013	Jan	NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE

TABLET; ORAL

OSEN

	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426 004	Jan 25, 2013	Jan	NEWA
		EQ 12.5MG BASE;EQ 30MG BASE	N022426 005	Jan 25, 2013	Jan	NEWA
		EQ 12.5MG BASE;EQ 45MG BASE	N022426 006	Jan 25, 2013	Jan	NEWA
		EQ 25MG BASE;EQ 15MG BASE	N022426 001	Jan 25, 2013	Jan	NEWA
		EQ 25MG BASE;EQ 30MG BASE	N022426 002	Jan 25, 2013	Jan	NEWA
+		EQ 25MG BASE;EQ 45MG BASE	N022426 003	Jan 25, 2013	Jan	NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN

	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426 004	Jan 25, 2013	Feb	CAIN
		EQ 12.5MG BASE;EQ 30MG BASE	N022426 005	Jan 25, 2013	Feb	CAIN
		EQ 12.5MG BASE;EQ 45MG BASE	N022426 006	Jan 25, 2013	Feb	CAIN
		EQ 25MG BASE;EQ 15MG BASE	N022426 001	Jan 25, 2013	Feb	CAIN
		EQ 25MG BASE;EQ 30MG BASE	N022426 002	Jan 25, 2013	Feb	CAIN
+		EQ 25MG BASE;EQ 45MG BASE	N022426 003	Jan 25, 2013	Feb	CAIN

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

AP	TEVA PHARMS USA	0.5MG/ML	A075196 001	Apr 30, 1999	Apr	CAHN
----	-----------------	----------	-------------	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@ HOSPIRA

EQ 250MG BASE/ML

A063264 001 Nov 30, 1994 Mar DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ APOTEX INC

50MG/ML

A076394 001 Apr 25, 2003 Apr DISC

AP	+	MYLAN INSTITUTIONAL	50MG/ML	A076217 001	Oct 15, 2002	Apr	CAHN
----	---	---------------------	---------	-------------	--------------	-----	------

@ TEVA PHARMS USA

50MG/ML

A076163 001 Sep 05, 2003 Apr CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB		ACCORD HLTHCARE	EQ 2.5MG BASE	A202553 001	Apr 29, 2013	Apr	NEWA
AB			EQ 5MG BASE	A202553 002	Apr 29, 2013	Apr	NEWA
AB			EQ 10MG BASE	A202553 003	Apr 29, 2013	Apr	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	PAR PHARM INC	EQ 5MG BASE;160MG	A090011 001	Mar 28, 2013	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090144 001	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090011 002	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090011 004	Mar 28, 2013	Mar	NEWA
EXFORGE						
AB	NOVARTIS	EQ 5MG BASE;160MG	N021990 002	Jun 20, 2007	Mar	CFTG
AB		EQ 5MG BASE;320MG	N021990 004	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;160MG	N021990 003	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;320MG	N021990 005	Jun 20, 2007	Mar	CFTG

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	CARDINAL HEALTH 414	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203700 001	Feb 25, 2013	Feb	NEWA
AP	+	FEINSTEIN	N022119 001	Aug 23, 2007	Feb	CFTG
AP	MCPRF	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203321 001	Feb 25, 2013	Feb	NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

@	RANBAXY	200MG/5ML	A065113 001	Nov 29, 2002	Feb	DISC
@		400MG/5ML	A065113 002	Nov 29, 2002	Feb	DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

@	DAVA PHARMS INC	125MG	A064139 001	Jan 29, 1996	Mar	DISC
@		250MG	A064139 002	Jan 29, 1996	Mar	DISC
@	RANBAXY	200MG	A065060 001	Nov 29, 2000	Feb	DISC
@		400MG	A065060 002	Nov 29, 2000	Feb	DISC

AMOXIL

@	DR REDDYS LABS INC	200MG	N050761 001	Apr 15, 1999	Feb	DISC
@		400MG	N050761 002	Apr 15, 1999	Feb	DISC

TABLET, FOR SUSPENSION; ORAL

AMOXICILLIN

@	AUROBINDO PHARMA LTD	200MG	A065324 001	Jan 17, 2007	Jan	DISC
@		400MG	A065324 002	Jan 17, 2007	Jan	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@	APOTEX INC	250MG;EQ 125MG BASE	A065333 001	Feb 24, 2009	Apr	DISC
@		500MG;EQ 125MG BASE	A065333 002	Feb 24, 2009	Apr	DISC
@		875MG;EQ 125MG BASE	A065317 003	Oct 20, 2008	Apr	DISC
@	RANBAXY LABS	500MG;EQ 125MG BASE	A065109 001	Nov 04, 2002	Apr	DISC
AB	TEVA PHARMS USA	875MG;EQ 125MG BASE	A065096 001	Oct 29, 2002	Apr	CRLD
AUGMENTIN '250'						
AB	+	DR REDDYS LABS INC	N050564 001	Aug 06, 1984	Apr	CRLD
AUGMENTIN '500'						
AB	+	DR REDDYS LABS INC	N050564 002	Aug 06, 1984	Apr	CRLD
AUGMENTIN '875'						
AB	+	DR REDDYS LABS INC	N050720 001	Feb 13, 1996	Apr	CRLD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488 001	Apr 29, 2013	Apr	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488 002	Apr 29, 2013	Apr	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488 003	Apr 29, 2013	Apr	NEWA
AB		5MG;5MG;5MG;5MG	A077488 004	Apr 29, 2013	Apr	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488 005	Apr 29, 2013	Apr	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488 006	Apr 29, 2013	Apr	NEWA

DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536 001	Feb 12, 2013	Jan	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076536 002	Feb 12, 2013	Jan	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076536 003	Feb 12, 2013	Jan	NEWA
AB		5MG;5MG;5MG;5MG	A076536 004	Feb 12, 2013	Jan	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076536 005	Feb 12, 2013	Jan	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076536 006	Feb 12, 2013	Jan	NEWA

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472 001	Sep 30, 2003	Jan	DISC
@		2.5MG;2.5MG;2.5MG;2.5MG	A040472 002	Sep 30, 2003	Jan	DISC
@		5MG;5MG;5MG;5MG	A040472 003	Sep 30, 2003	Jan	DISC
@		7.5MG;7.5MG;7.5MG;7.5MG	A040472 004	Sep 30, 2003	Jan	DISC

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	ACS DOBFAR SPA	EQ 500MG BASE/VIAL	A090884 001	Apr 03, 2013	Mar	NEWA
AP		EQ 1GM BASE/VIAL	A090884 002	Apr 03, 2013	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A090884 003	Apr 03, 2013	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A090889 001	Apr 03, 2013	Mar	NEWA

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	ACCORD HLTHCARE	1MG	A090568 001	Jun 28, 2010	Apr	CAHN
	@ KUDCO IRELAND	1MG	A091331 001	Jan 05, 2011	Feb	DISC

ARIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

	OTSUKA PHARM CO LTD	300MG/VIAL	N202971 001	Feb 28, 2013	Feb	NEWA
+		400MG/VIAL	N202971 002	Feb 28, 2013	Feb	NEWA

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@	PRINSTON INC	385MG;30MG;25MG	A075141 001	May 29, 1998	Apr	CAHN
---	--------------	-----------------	-------------	--------------	-----	------

ORPHENGESIC FORTE

@	PRINSTON INC	770MG;60MG;50MG	A075141 002	May 29, 1998	Apr	CAHN
---	--------------	-----------------	-------------	--------------	-----	------

ATENOLOL

TABLET; ORAL

ATENOLOL

@	WATSON LABS	50MG	A073352 001	Dec 27, 1991	Mar	DISC
---	-------------	------	-------------	--------------	-----	------

TABLET; ORAL

ATENOLOL

@ WATSON LABS

100MG

A073353 001 Dec 27, 1991 Mar DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB KUDCO IRELAND

EQ 10MG BASE

A091624 001 Apr 05, 2013 Mar NEWA

AB

EQ 20MG BASE

A091624 002 Apr 05, 2013 Mar NEWA

AB

EQ 40MG BASE

A091624 003 Apr 05, 2013 Mar NEWA

AB

EQ 80MG BASE

A091624 004 Apr 05, 2013 Mar NEWA

>A> ATORVASTATIN CALCIUM; EZETIMIBE

>A> TABLET; ORAL

>A> LIPTRUZET

>A> MERCK SHARP DOHME

EQ 10MG BASE;10MG

N200153 001 May 03, 2013 May NEWA

>A>

EQ 20MG BASE;10MG

N200153 002 May 03, 2013 May NEWA

>A>

EQ 40MG BASE;10MG

N200153 003 May 03, 2013 May NEWA

>A> +

EQ 80MG BASE;10MG

N200153 004 May 03, 2013 May NEWA

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

AP SUN PHARM INDS LTD

EQ 500MG BASE/VIAL

A090923 001 Apr 02, 2013 Mar NEWA

BACITRACIN

POWDER; FOR RX COMPOUNDING

BACI-RX

@ X GEN PHARMS

5,000,000 UNITS/BOT

A061580 001 Mar DISC

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

>D> AP CNS THERAPS INC

0.05MG/ML

N022462 001 Nov 19, 2010 May CAHN

>D> AP

0.5MG/ML

N022462 002 Nov 19, 2010 May CAHN

>D>

1MG/ML

N022462 004 Jun 22, 2012 May CAHN

>D> AP

2MG/ML

N022462 003 Nov 19, 2010 May CAHN

>A> AP MALLINCKRODT INC

0.05MG/ML

N022462 001 Nov 19, 2010 May CAHN

>A> AP

0.5MG/ML

N022462 002 Nov 19, 2010 May CAHN

>A>

1MG/ML

N022462 004 Jun 22, 2012 May CAHN

>A> AP

2MG/ML

N022462 003 Nov 19, 2010 May CAHN

BENZONATATE

CAPSULE; ORAL

BENZONATATE

>A> AA CARACO

100MG

A040587 001 Mar 19, 2008 May CAHN

>A> AA

200MG

A040587 002 Mar 19, 2008 May CAHN

>D> AA SUN PHARM INDS INC

100MG

A040587 001 Mar 19, 2008 May CAHN

>D> AA

200MG

A040587 002 Mar 19, 2008 May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

+ DOW PHARM

2.5%;1.2%

N050819 001 Oct 23, 2008 Apr CAHN

GEL; TOPICAL									
BENZACLIN									
AB	VALEANT BERMUDA	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Apr	CAHN		
BT	+	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Apr	CAHN		
<u>BENZPHETAMINE HYDROCHLORIDE</u>									
TABLET; ORAL									
BENZPHETAMINE HYDROCHLORIDE									
	@ COREPHARMA	50MG	A040714	001	Oct 29, 2007	Feb	DISC		
<u>BENZTROPINE MESYLATE</u>									
INJECTABLE; INJECTION									
BENZTROPINE MESYLATE									
AP	NAVINTA LLC	1MG/ML	A091525	001	Feb 05, 2013	Jan	NEWA		
TABLET; ORAL									
BENZTROPINE MESYLATE									
	@ PROSAM LABS	0.5MG	A040699	001	Feb 14, 2008	Mar	DISC		
	@	1MG	A040705	001	Feb 14, 2008	Mar	DISC		
	@	2MG	A040706	001	Feb 14, 2008	Mar	DISC		
<u>BETAMETHASONE</u>									
SYRUP; ORAL									
CELESTONE									
	@ MERCK SHARP DOHME	0.6MG/5ML	N014215	002		Apr	CAHN		
<u>BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE</u>									
INJECTABLE; INJECTION									
CELESTONE SOLUSPAN									
AB	+	MERCK SHARP DOHME	3MG/ML;EQ 3MG BASE/ML	N014602	001		Apr	CAHN	
<u>BETAMETHASONE VALERATE</u>									
AEROSOL, FOAM; TOPICAL									
BETAMETHASONE VALERATE									
AB	PERRIGO	0.12%	A078337	001	Nov 26, 2012	Apr	CPOT		
LUXIQ									
AB	+	STIEFEL	0.12%	N020934	001	Feb 28, 1999	Apr	CPOT	
<u>BETAXOLOL HYDROCHLORIDE</u>									
SOLUTION/DROPS; OPHTHALMIC									
BETAXOLOL HYDROCHLORIDE									
	@ APOTEX INC	EQ 0.5% BASE	A075446	001	Sep 28, 2000	Apr	DISC		
<u>BEXAROTENE</u>									
GEL; TOPICAL									
TARGRETIN									
	+	VALEANT PHARMS INC	1%	N021056	001	Jun 28, 2000	Feb	CAHN	
<u>BICALUTAMIDE</u>									
TABLET; ORAL									
BICALUTAMIDE									
AB	ACCORD HLTHCARE	50MG	A078917	001	Jul 06, 2009	Apr	CAHN		

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

@ PHARMACHEMIE BV

EQ 15 UNITS BASE/VIAL

A065201 001 Dec 13, 2007 Feb DISC

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

SIMBRINZA

+ ALCON RES LTD

0.2%;1%

N204251 001 Apr 19, 2013 Apr NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

+ ISTA PHARMS INC

EQ 0.09% ACID

N021664 002 Oct 16, 2010 Apr CPOT

BROMFENAC SODIUM

AT COASTAL PHARMS

EQ 0.09% ACID

A201211 001 May 11, 2011 Apr CPOT

AT LUITPOLD

EQ 0.09% ACID

A202030 001 Jan 09, 2013 Apr CPOT

AT 0.09%

A202030 001 Jan 09, 2013 Feb CAHN

PROLENSA

+ BAUSCH AND LOMB

EQ 0.07% ACID

N203168 001 Apr 05, 2013 Apr NEWA

XIBROM

@ ISTA PHARMS INC

EQ 0.09% ACID

N021664 001 Mar 24, 2005 Apr CPOT

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

@ APOTEX INC

0.25MG/2ML

A078202 001 Mar 30, 2009 Apr DISC

@

0.5MG/2ML

A078202 002 Mar 30, 2009 Apr DISC

TABLET, EXTENDED RELEASE; ORAL

UCERIS

+ SANTARUS

9MG

N203634 001 Jan 14, 2013 Jan NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE

AB ACTAVIS ELIZABETH

EQ 2MG BASE;EQ 0.5MG BASE

A091422 001 Feb 22, 2013 Feb NEWA

AB +

EQ 8MG BASE;EQ 2MG BASE

A091422 002 Feb 22, 2013 Apr CRLD

AB

EQ 8MG BASE;EQ 2MG BASE

A091422 002 Feb 22, 2013 Feb NEWA

AB AMNEAL PHARMS

EQ 2MG BASE;EQ 0.5MG BASE

A203136 001 Feb 22, 2013 Feb NEWA

AB

EQ 8MG BASE;EQ 2MG BASE

A203136 002 Feb 22, 2013 Feb NEWA

SUBOXONE

@ RECKITT BENCKISER

EQ 2MG BASE;EQ 0.5MG BASE

N020733 001 Oct 08, 2002 Mar DISC

AB

EQ 2MG BASE;EQ 0.5MG BASE

N020733 001 Oct 08, 2002 Feb CFTG

@

EQ 8MG BASE;EQ 2MG BASE

N020733 002 Oct 08, 2002 Mar DISC

AB +

EQ 8MG BASE;EQ 2MG BASE

N020733 002 Oct 08, 2002 Feb CFTG

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

VALEANT BERMUDA

174MG

N022108 001 Apr 23, 2008 Apr CAHN

+

348MG

N022108 002 Apr 23, 2008 Apr CAHN

522MG

N022108 003 Apr 23, 2008 Apr CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

@ TEVA 75MG
 @ 100MG

A075310 001 Nov 29, 1999 Feb CDFR
 A075310 002 Nov 29, 1999 Feb DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@ IMPAX LABS 300MG
 AB1 WATSON LABS INC 100MG
 AB3 150MG
 AB1 150MG
 AB1 200MG
 AB3 300MG

A077415 002 Dec 15, 2006 Apr DISC
 A077455 001 Jul 19, 2010 Apr CAHN
 A077285 001 Nov 26, 2008 Apr CAHN
 A077455 002 Mar 12, 2008 Apr CAHN
 A077455 003 Jul 19, 2010 Apr CAHN
 A077285 002 Aug 15, 2008 Apr CAHN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

+ PERRIGO ISRAEL 2%
 GYNAZOLE-1
 @ KV PHARM 2%

A200923 001 May 18, 2012 Mar CRLD
 N019881 001 Feb 07, 1997 Mar DISC

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

@ APOTEX INC 2MG/ML

A075697 001 Oct 23, 2001 Apr DISC

BUTORPHANOL TARTRATE PRESERVATIVE FREE

@ APOTEX INC 1MG/ML
 @ 2MG/ML

A075695 001 Oct 23, 2001 Apr DISC
 A075695 002 Oct 23, 2001 Apr DISC

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB APOTEX CORP 0.5MG

A201503 001 Mar 08, 2013 Feb NEWA

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

AA MIKART 100MG;1MG
 @ 100MG;1MG

A040590 001 Sep 16, 2005 Mar CMFD
 A040590 001 Sep 16, 2005 Jan DISC

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

>A> AB BANNER PHARMACAPS 0.25MCG
 >A> AB 0.5MCG

A091174 001 May 24, 2013 May NEWA
 A091174 002 May 24, 2013 May NEWA

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB INVAGEN PHARMS EQ 169MG CALCIUM

A203135 001 Feb 07, 2013 Jan NEWA

TABLET; ORAL

CALCIUM ACETATE

AB INVAGEN PHARMS EQ 169MG CALCIUM

A202420 001 Feb 05, 2013 Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 7	N019867 001	Dec 20, 1993	Mar	DISC
	4MG/100ML; 640MG/100ML; 500MG/100ML				
	; 74MG/100ML				

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/1	N020374 001	Jun 13, 1994	Feb	DISC
	00ML; 538MG/100ML; 448MG/100ML				

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 2.5GM/100ML; 5.08MG/1	N020374 002	Jun 13, 1994	Feb	DISC
	00ML; 538MG/100ML; 448MG/100ML				

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/1	N020374 003	Jun 13, 1994	Feb	DISC
	00ML; 538MG/100ML; 448MG/100ML				

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 4.25GM/100ML; 5.08MG/	N020374 004	Jun 13, 1994	Feb	DISC
	100ML; 538MG/100ML; 448MG/100ML				

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

JANSSEN PHARMS	100MG	N204042 001	Mar 29, 2013	Apr	CAHN
+	300MG	N204042 002	Mar 29, 2013	Apr	CAHN
JANSSEN RES AND DEV	100MG	N204042 001	Mar 29, 2013	Mar	NEWA
+	300MG	N204042 002	Mar 29, 2013	Mar	NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	ASTRAZENECA	4MG	N020838 001	Jun 04, 1998	Apr	CFTG
AB		8MG	N020838 002	Jun 04, 1998	Apr	CFTG
AB		16MG	N020838 003	Jun 04, 1998	Apr	CFTG
AB	+	32MG	N020838 004	Jun 04, 1998	Apr	CFTG

CANDESARTAN CILEXETIL

AB	SANDOZ	4MG	A078702 001	May 03, 2013	Apr	NEWA
AB		8MG	A078702 002	May 03, 2013	Apr	NEWA
AB		16MG	A078702 003	May 03, 2013	Apr	NEWA
AB		32MG	A078702 004	May 03, 2013	Apr	NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

>A>	AB	APOTEX INC	32MG; 25MG	A202884 003	Jun 03, 2013	May	NEWA
>A>	AB	DR REDDYS LABS LTD	16MG; 12.5MG	A202965 001	Jun 03, 2013	May	NEWA
>A>	AB		32MG; 12.5MG	A202965 002	Jun 03, 2013	May	NEWA
>A>	AB		32MG; 25MG	A202965 003	Jun 03, 2013	May	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	ACCORD HLTHCARE	25MG; 100MG	A202323 001	Feb 08, 2013	Jan	NEWA
AB		50MG; 200MG	A202323 002	Feb 08, 2013	Jan	NEWA

CARBINOXAMINE MALEATE

SUSPENSION, EXTENDED RELEASE; ORAL
KARBINAL ER

+	TRIS PHARMA INC	4MG/5ML	N022556	001	Mar 28, 2013	Mar	NEWA
---	-----------------	---------	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

@	PLIVA	50MG/VIAL	A076602	001	Nov 16, 2004	Feb	DISC
---	-------	-----------	---------	-----	--------------	-----	------

@		150MG/VIAL	A076602	002	Nov 16, 2004	Feb	DISC
---	--	------------	---------	-----	--------------	-----	------

@		450MG/VIAL	A076602	003	Nov 16, 2004	Feb	DISC
---	--	------------	---------	-----	--------------	-----	------

INJECTABLE; IV (INFUSION)

CARBOPLATIN

@	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar	DISC
---	--------------------	--------------------	---------	-----	--------------	-----	------

@		150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar	DISC
---	--	----------------------	---------	-----	--------------	-----	------

@	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Apr	DISC
---	-----------------	--------------------	---------	-----	--------------	-----	------

@		150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Apr	DISC
---	--	----------------------	---------	-----	--------------	-----	------

@		450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Apr	DISC
---	--	----------------------	---------	-----	--------------	-----	------

PARAPLATIN

@	CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar	CAHN
---	--------------	--------------------	---------	-----	--------------	-----	------

@		150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar	CAHN
---	--	----------------------	---------	-----	--------------	-----	------

@		450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar	CAHN
---	--	----------------------	---------	-----	--------------	-----	------

@		600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar	CAHN
---	--	----------------------	---------	-----	--------------	-----	------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

>A>	AA	ACCELRX LABS	350MG	A040576	001	Jun 07, 2005	May	CAHN
-----	----	--------------	-------	---------	-----	--------------	-----	------

>D>	AA	ADVENT PHARMS	350MG	A040576	001	Jun 07, 2005	May	CAHN
-----	----	---------------	-------	---------	-----	--------------	-----	------

@	COREPHARMA	350MG	A040397	001	Sep 21, 2000	Feb	DISC
---	------------	-------	---------	-----	--------------	-----	------

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+	ARBOR PHARMS LLC	7.7MG	N020637	001	Sep 23, 1996	Mar	CAHN
---	------------------	-------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

BICNU

+	EMCURE PHARMS LTD	100MG/VIAL	N017422	001		Jan	CAHN
---	-------------------	------------	---------	-----	--	-----	------

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

@	APOTEX INC	1%	A076097	001	Feb 06, 2002	Apr	DISC
---	------------	----	---------	-----	--------------	-----	------

CARVEDILOL

TABLET; ORAL

CARVEDILOL

@	WOCKHARDT LTD	3.125MG	A078786	001	Dec 22, 2009	Feb	DISC
---	---------------	---------	---------	-----	--------------	-----	------

@		6.25MG	A078786	002	Dec 22, 2009	Feb	DISC
---	--	--------	---------	-----	--------------	-----	------

@		12.5MG	A078786	003	Dec 22, 2009	Feb	DISC
---	--	--------	---------	-----	--------------	-----	------

@		25MG	A078786	004	Dec 22, 2009	Feb	DISC
---	--	------	---------	-----	--------------	-----	------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

AB	AUROBINDO	EQ 250MG BASE/5ML	A065349 001	Apr 25, 2013	Apr	NEWA
AB		EQ 500MG BASE/5ML	A065349 002	Apr 25, 2013	Apr	NEWA
	@ TEVA PHARMS USA	EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006	Mar	DISC
	@	EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006	Mar	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	+	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005	Feb	CRLD
AP	+		EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005	Feb	CRLD
AP	+		EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005	Feb	CRLD
AP	+		EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005	Feb	CRLD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

	@ SANDOZ	EQ 500MG BASE/VIAL	A090291 001	Dec 21, 2010	Mar	DISC
	@	EQ 1GM BASE/VIAL	A090291 002	Dec 21, 2010	Mar	DISC
	@	EQ 2GM BASE/VIAL	A090291 003	Dec 21, 2010	Mar	DISC

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

+	LUPIN LTD	500MG/5ML	N202091 001	Feb 20, 2013	Feb	CDFR
	LUPIN PHARMS	100MG/5ML	A065129 001	Feb 23, 2004	Feb	CDFR
		200MG/5ML	A065355 001	Apr 10, 2007	Feb	CDFR

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

>D>	AP	AUROBINDO PHARMA	EQ 250MG BASE/VIAL	A065505 001	Jul 31, 2008	May	DISC
>D>	AP		EQ 500MG BASE/VIAL	A065505 002	Jul 31, 2008	May	DISC
>D>	AP		EQ 1GM BASE/VIAL	A065505 003	Jul 31, 2008	May	DISC
>D>	AP		EQ 2GM BASE/VIAL	A065505 004	Jul 31, 2008	May	DISC
>A>		@ AUROBINDO PHARMA LTD	EQ 250MG BASE/VIAL	A065505 001	Jul 31, 2008	May	DISC
>A>		@	EQ 500MG BASE/VIAL	A065505 002	Jul 31, 2008	May	DISC
>A>		@	EQ 1GM BASE/VIAL	A065505 003	Jul 31, 2008	May	DISC
>A>		@	EQ 2GM BASE/VIAL	A065505 004	Jul 31, 2008	May	DISC
>D>	AP	TEVA PHARMS	EQ 250MG BASE/VIAL	A065227 001	Mar 15, 2007	May	CAHN
>D>	AP		EQ 500MG BASE/VIAL	A065227 002	Mar 15, 2007	May	CAHN
>D>	AP		EQ 1GM BASE/VIAL	A065227 003	Mar 15, 2007	May	CAHN
>D>	AP		EQ 2GM BASE/VIAL	A065227 004	Mar 15, 2007	May	CAHN
>A>	AP	TEVA PHARMS USA	EQ 250MG BASE/VIAL	A065227 001	Mar 15, 2007	May	CAHN
>A>	AP		EQ 500MG BASE/VIAL	A065227 002	Mar 15, 2007	May	CAHN
>A>	AP		EQ 1GM BASE/VIAL	A065227 003	Mar 15, 2007	May	CAHN
>A>	AP		EQ 2GM BASE/VIAL	A065227 004	Mar 15, 2007	May	CAHN

INJECTABLE; INJECTION

CEFTRIAXONE

>D>	AP	AUROBINDO PHARMA	EQ 10GM BASE/VIAL	A065504 001	Jul 31, 2008	May	DISC
>A>		@ AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504 001	Jul 31, 2008	May	DISC

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

		ALKEM LABS LTD	EQ 333MG BASE	A090836 003	Mar 29, 2013	Mar	NEWA
AB			EQ 750MG BASE	A090836 004	Mar 29, 2013	Mar	NEWA
		KEFLEX					
AB	+	SHIONOGI INC	EQ 750MG BASE	N050405 005	May 12, 2006	Mar	CTEC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

		@ APOTEX INC	5MG/5ML	A078412 001	Jun 18, 2008	Apr	DISC
		@ AUROBINDO PHARMA LTD	5MG/5ML	A090751 001	Dec 16, 2009	Feb	DISC
>A>	AA	BIO PHARM INC	5MG/5ML	A078870 001	Apr 27, 2009	May	CAHN
>D>	AA	DR REDDYS LABS LTD	5MG/5ML	A078870 001	Apr 27, 2009	May	CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

		@ APOTEX INC	0.12%	A075561 001	Nov 14, 2000	Apr	DISC
		PAROEX					
AT		SUNSTAR AMERICAS	0.12%	A076434 001	Nov 29, 2005	Apr	CTNA

CHLOROTHIAZIDE

TABLET; ORAL

DIURIL

		@ OAK PHARMS AKORN	250MG	N011145 004		Jan	CAHN
		@	500MG	N011145 002		Jan	CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP		PHARMAFORCE	EQ 500MG BASE/VIAL	A202561 001	Apr 22, 2013	Apr	NEWA
		DIURIL					
AP	+	OAK PHARMS AKORN	EQ 500MG BASE/VIAL	N011145 005		Jan	CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

VITUZ

	+	CYPRESS PHARM	4MG/5ML; 5MG/5ML	N204307 001	Feb 20, 2013	Feb	NEWA
--	---	---------------	------------------	-------------	--------------	-----	------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

		@ WATSON LABS INC	100MG	A088852 001	Sep 26, 1984	Jan	DISC
		@	250MG	A088826 001	Sep 26, 1984	Jan	DISC

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB		MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913 001	Mar 25, 2013	Mar	NEWA
AB			EQ 135MG FENOFIBRIC ACID	A200913 002	Mar 25, 2013	Mar	NEWA
		TRILIPIX					
AB		ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224 001	Dec 15, 2008	Mar	CFTG

CAPSULE, DELAYED RELEASE; ORAL

TRILIPIX

AB	+	ABBVIE	EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008	Mar	CFTG
----	---	--------	--------------------------	---------	-----	--------------	-----	------

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

		@ APOTEX INC	8%	A078172	001	Sep 18, 2007	Apr	DISC
--	--	--------------	----	---------	-----	--------------	-----	------

		@ TEVA PHARMS	8%	A078079	001	Sep 18, 2007	Jan	DISC
--	--	---------------	----	---------	-----	--------------	-----	------

PENLAC

>A>	AT	+	VALEANT BERMUDA	8%	N021022	001	Dec 17, 1999	May	CAHN
-----	----	---	-----------------	----	---------	-----	--------------	-----	------

>D>	AT	+	VALEANT INTL	8%	N021022	001	Dec 17, 1999	May	CAHN
-----	----	---	--------------	----	---------	-----	--------------	-----	------

	AT	+		8%	N021022	001	Dec 17, 1999	Feb	CAHN
--	----	---	--	----	---------	-----	--------------	-----	------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

>D>	AB		WATSON LABS	200MG	A074349	001	Aug 30, 1996	May	DISC
-----	----	--	-------------	-------	---------	-----	--------------	-----	------

>D>	AB			300MG	A074349	002	Aug 30, 1996	May	DISC
-----	----	--	--	-------	---------	-----	--------------	-----	------

>D>	AB			400MG	A074349	003	Aug 30, 1996	May	DISC
-----	----	--	--	-------	---------	-----	--------------	-----	------

>A>			@ WATSON LABS INC	200MG	A074349	001	Aug 30, 1996	May	DISC
-----	--	--	-------------------	-------	---------	-----	--------------	-----	------

>A>			@	300MG	A074349	002	Aug 30, 1996	May	DISC
-----	--	--	---	-------	---------	-----	--------------	-----	------

>A>			@	400MG	A074349	003	Aug 30, 1996	May	DISC
-----	--	--	---	-------	---------	-----	--------------	-----	------

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

		@ APOTEX INC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000	Apr	DISC
--	--	--------------	-------------------	---------	-----	--------------	-----	------

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

		@ TEVA PHARMS USA	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	Apr	CAHN
--	--	-------------------	----------------------	---------	-----	--------------	-----	------

		@	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	Apr	CAHN
--	--	---	----------------------	---------	-----	--------------	-----	------

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

		@ APOTEX INC	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Apr	DISC
--	--	--------------	--------------	---------	-----	--------------	-----	------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

>D>	AB	+	BAYER HLTHCARE	212.6MG;EQ 287.5MG BASE	N021473	001	Dec 13, 2002	May	DISC
-----	----	---	----------------	-------------------------	---------	-----	--------------	-----	------

>A>			@	212.6MG;EQ 287.5MG BASE	N021473	001	Dec 13, 2002	May	DISC
-----	--	--	---	-------------------------	---------	-----	--------------	-----	------

>D>	AB	+		425.2MG;EQ 574.9MG BASE	N021473	002	Aug 28, 2003	May	DISC
-----	----	---	--	-------------------------	---------	-----	--------------	-----	------

>A>			@	425.2MG;EQ 574.9MG BASE	N021473	002	Aug 28, 2003	May	DISC
-----	--	--	---	-------------------------	---------	-----	--------------	-----	------

CIPROFLOXACIN EXTENDED RELEASE

>D>	AB		MYLAN	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	May	CRLD
-----	----	--	-------	-------------------------	---------	-----	--------------	-----	------

>D>	AB			425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	May	CRLD
-----	----	--	--	-------------------------	---------	-----	--------------	-----	------

>A>	AB	+	MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	May	CRLD
-----	----	---	------------------	-------------------------	---------	-----	--------------	-----	------

>A>	AB	+		425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	May	CRLD
-----	----	---	--	-------------------------	---------	-----	--------------	-----	------

CISPLATIN

INJECTABLE; INJECTION

PLATINOL

@ HQ SPCLT PHARMA	10MG/VIAL	N018057 001		Jan	CAHN
-------------------	-----------	-------------	--	-----	------

@	50MG/VIAL	N018057 002		Jan	CAHN
---	-----------	-------------	--	-----	------

PLATINOL-AQ

@ HQ SPCLT PHARMA	0.5MG/ML	N018057 003	Jul 18, 1984	Jan	CAHN
-------------------	----------	-------------	--------------	-----	------

@	1MG/ML	N018057 004	Nov 08, 1988	Jan	CAHN
---	--------	-------------	--------------	-----	------

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

@ APOTEX INC	EQ 10MG BASE/5ML	A077601 001	Nov 15, 2005	Apr	DISC
--------------	------------------	-------------	--------------	-----	------

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@ COREPHARMA	EQ 10MG BASE	A077036 001	Oct 28, 2004	Feb	DISC
--------------	--------------	-------------	--------------	-----	------

@	EQ 20MG BASE	A077036 002	Oct 28, 2004	Feb	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 40MG BASE	A077036 003	Oct 28, 2004	Feb	DISC
---	--------------	-------------	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

>A>	AB	ALLIED PHARMA INC	250MG	A202710 001	Jun 10, 2013	May	NEWA
-----	----	-------------------	-------	-------------	--------------	-----	------

>A>	AB		500MG	A202710 002	Jun 10, 2013	May	NEWA
-----	----	--	-------	-------------	--------------	-----	------

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

@ APOTEX INC	EQ 0.5MG BASE/5ML	A075703 001	Nov 27, 2000	Apr	DISC
--------------	-------------------	-------------	--------------	-----	------

@ SILARX	EQ 0.5MG BASE/5ML	A074884 001	Dec 17, 1997	Mar	DISC
----------	-------------------	-------------	--------------	-----	------

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+	MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156 001	Aug 01, 2008	Feb	CAIN
---	--------------	----------------------	-------------	--------------	-----	------

+		50MG/100ML (0.5MG/ML)	N022156 002	Aug 01, 2008	Feb	CAIN
---	--	-----------------------	-------------	--------------	-----	------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	EQ 75MG BASE/5ML	A202409 001	Apr 30, 2013	Apr	NEWA
----	--	----------------------	------------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		AKORN INC	EQ 6MG BASE/ML	A203048 001	Apr 04, 2013	Mar	NEWA
----	--	-----------	----------------	-------------	--------------	-----	------

AP			EQ 12MG BASE/ML	A203048 002	Apr 04, 2013	Mar	NEWA
----	--	--	-----------------	-------------	--------------	-----	------

AP			EQ 18MG BASE/ML	A203048 003	Apr 04, 2013	Mar	NEWA
----	--	--	-----------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

>A>		@ ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811 001	Sep 01, 1988	May	CAHN
-----	--	------------------------	------------	-------------	--------------	-----	------

>D>		@ G AND W LABS INC	EQ 1% BASE	A062811 001	Sep 01, 1988	May	CAHN
-----	--	--------------------	------------	-------------	--------------	-----	------

		@ PERRIGO NEW YORK	EQ 1% BASE	A064050 001	Nov 30, 1995	Feb	DISC
--	--	--------------------	------------	-------------	--------------	-----	------

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB	ACCORD HLTHCARE	0.5MG	A077147 001	May 02, 2005	Apr	CAHN
AB		1MG	A077147 002	May 02, 2005	Apr	CAHN
AB		2MG	A077147 003	May 02, 2005	Apr	CAHN
	@ APOTEX INC	0.5MG	A075468 001	Oct 06, 2000	Feb	DISC
	@	1MG	A075468 002	Oct 06, 2000	Feb	DISC
	@	2MG	A075468 003	Oct 06, 2000	Feb	DISC

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

>A>	AB	CARLSBAD	0.1MG	A202297 001	Jun 13, 2013	May	NEWA
>A>	AB		0.2MG	A202297 002	Jun 13, 2013	May	NEWA
>A>	AB		0.3MG	A202297 003	Jun 13, 2013	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

JENLOGA

>A>		@ CONCORDIA PHARMS INC	0.1MG	N022331 001	Sep 30, 2009	May	CAHN
>A>		@	0.2MG	N022331 002	May 25, 2010	May	CAHN
>D>		@ SHIONOGI INC	0.1MG	N022331 001	Sep 30, 2009	May	CAHN
>D>		@	0.2MG	N022331 002	May 25, 2010	May	CAHN

KAPVAY

>A>	+	CONCORDIA PHARMS INC	0.1MG	N022331 003	Sep 28, 2010	May	CAHN
>A>			0.2MG	N022331 004	Sep 28, 2010	May	CAHN
>D>	+	SHIONOGI INC	0.1MG	N022331 003	Sep 28, 2010	May	CAHN
>D>			0.2MG	N022331 004	Sep 28, 2010	May	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	ACCORD HLTHCARE	EQ 75MG BASE	A202925 001	Mar 27, 2013	Mar	NEWA	
AB		EQ 300MG BASE	A202925 002	Mar 27, 2013	Mar	NEWA	
>A>	AB	ACTAVIS TOTOWA	EQ 75MG BASE	A090307 001	May 28, 2013	May	NEWA
>A>	AB	MUTUAL PHARM	EQ 75MG BASE	A078133 001	Jun 10, 2013	May	NEWA

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

>D>		@ LUNDBECK LLC	3.75MG	N017105 001		May	CAHN
>D>		@	7.5MG	N017105 002		May	CAHN
>D>		@	15MG	N017105 003		May	CAHN
>A>		@ RECORDATI RARE	3.75MG	N017105 001		May	CAHN
>A>		@	7.5MG	N017105 002		May	CAHN
>A>		@	15MG	N017105 003		May	CAHN

TABLET; ORAL

TRANXENE

>D>	AB	LUNDBECK LLC	3.75MG	N017105 006		May	CAHN
>D>	AB		7.5MG	N017105 007		May	CAHN
>D>	AB	+	15MG	N017105 008		May	CAHN
>A>	AB	RECORDATI RARE	3.75MG	N017105 006		May	CAHN
>A>	AB		7.5MG	N017105 007		May	CAHN
>A>	AB	+	15MG	N017105 008		May	CAHN
		TRANXENE SD					
>D>		@ LUNDBECK LLC	11.25MG	N017105 005		May	CAHN

TABLET; ORAL

	TRANXENE SD					
>D>	@ LUNDBECK LLC	22.5MG	N017105 004		May	CAHN
>A>	@ RECORDATI RARE	11.25MG	N017105 005		May	CAHN
>A>	@	22.5MG	N017105 004		May	CAHN

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

+	DOUGLAS PHARMS	50MG/ML	N203479 001	Feb 06, 2013	Feb	NEWA
+	JAZZ PHARMS III	50MG/ML	N203479 001	Feb 06, 2013	Mar	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	AMNEAL PHARMS	10MG/5ML;6.25MG/5ML	A200894 001	Apr 24, 2013	Apr	NEWA
>A>	AA	CARACO	A090180 001	Mar 17, 2010	May	CAHN
>D>	AA	SUN PHARM INDS INC	A090180 001	Mar 17, 2010	May	CAHN

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP	MYLAN LLC	0.25MG/VIAL	A090574 001	Dec 17, 2009	Feb	CAHN
----	-----------	-------------	-------------	--------------	-----	------

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

AA	MICRO LABS LTD INDIA	100MG/5ML	A202745 001	Apr 04, 2013	Mar	NEWA
----	----------------------	-----------	-------------	--------------	-----	------

SOLUTION; INHALATION

CROMOLYN SODIUM

@	APOTEX INC	10MG/ML	A075333 001	Apr 30, 2002	Apr	DISC
---	------------	---------	-------------	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

@	APOTEX INC	4%	A075615 001	Jan 26, 2001	Apr	DISC
---	------------	----	-------------	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB	IVAX INTL	15MG	N021777 001	Feb 01, 2007	Jan	CAHN
AB	+	30MG	N021777 002	Feb 01, 2007	Jan	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

AB	TWI PHARMS INC	15MG	A091281 001	Jan 31, 2013	Jan	NEWA
AB		30MG	A091281 002	Jan 31, 2013	Jan	NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	7.5MG	A073144 003	Mar 25, 2013	Mar	NEWA
	@ PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Mar	DISC
	@ SANDOZ	5MG	A072854 002	Feb 03, 2006	Apr	DISC
	@	10MG	A072854 001	Nov 19, 1991	Apr	DISC

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

@	AKORN	2%	A040165 001	Jan 13, 1997	Mar	DISC
---	-------	----	-------------	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC
CYCLOGYL

+ ALCON LABS INC 2% A084108 001 Mar CTEC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
CYTOXAN (LYOPHILIZED)

AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142 003		Mar	CTNA
		@	500MG/VIAL	N012142 008	Jan 04, 1984	Jan	CTNA
AP	+		1GM/VIAL	N012142 004	Aug 30, 1982	Mar	CTNA
		@	1GM/VIAL	N012142 010	Sep 24, 1985	Jan	CTNA
AP	+		2GM/VIAL	N012142 005	Aug 30, 1982	Mar	CTNA
		@	2GM/VIAL	N012142 009	Dec 10, 1985	Jan	CTNA

CYCLOSPORINE

SOLUTION; ORAL
CYCLOSPORINE

@ APOTEX INC 100MG/ML A065167 001 Jan 05, 2005 Apr DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA PHARM ASSOC 2MG/5ML A091295 001 Mar 28, 2013 Mar NEWA

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE; ORAL
PROCYSBI

		RAPTOR PHARMS	EQ 25MG BASE	N203389 001	Apr 30, 2013	Apr	NEWA
	+		EQ 75MG BASE	N203389 002	Apr 30, 2013	Apr	NEWA

>A> DABRAFENIB MESYLATE

>A> CAPSULE; ORAL

>A> TAFINLAR

>A>		GLAXOSMITHKLINE	EQ 50MG BASE	N202806 001	May 29, 2013	May	NEWA
-----	--	-----------------	--------------	-------------	--------------	-----	------

>A>	+		EQ 75MG BASE	N202806 002	May 29, 2013	May	NEWA
-----	---	--	--------------	-------------	--------------	-----	------

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE

AP		TEVA PHARMS USA	200MG/VIAL	A075259 002	Aug 27, 1998	Apr	CAHN
AP	+		500MG/VIAL	A075259 001	Sep 22, 2000	Apr	CAHN

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN

>D>	AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682 001		May	CAHN
>A>	AP	+	RECORDATI RARE	0.5MG/VIAL	N050682 001		May	CAHN

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HYDROCHLORIDE

AP		TEVA PHARMS USA	EQ 5MG BASE/ML	A065035 001	Jan 24, 2000	Apr	CAHN
----	--	-----------------	----------------	-------------	--------------	-----	------

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

AP	SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013	Jan	NEWA
AP	TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Apr	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
ENSKYCE

AB	LUPIN LTD	0.15MG;0.03MG	A201887	001	Mar 07, 2013	Feb	NEWA
----	-----------	---------------	---------	-----	--------------	-----	------

DESOXIMETASONE

SPRAY; TOPICAL
TOPICORT

+	TARO	0.25%	N204141	001	Apr 11, 2013	Apr	NEWA
---	------	-------	---------	-----	--------------	-----	------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE

+	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	Apr	CRLD
		50MG	N204150	001	Mar 04, 2013	Mar	NEWA
+		100MG	N204150	002	Mar 04, 2013	Mar	NEWA

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE

>D>	AA	+	WOCKHARDT	0.5MG/5ML	A088254	001	Jul 27, 1983	May	CRLD
>A>	AA		WOCKHARDT EU OPERATN	0.5MG/5ML	A088254	001	Jul 27, 1983	May	CRLD

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE
@ ALCON PHARMS LTD 0.1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML

A062721	001	Nov 17, 1986	Jan	DISC
---------	-----	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
PRECEDEX

+	HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002	Mar 13, 2013	Mar	NEWA
+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003	Mar 13, 2013	Mar	NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
TOTECT

>D>		+	APRICUS PHARMS	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	May	CAHN
>A>		+	BIOCODEX INC	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	May	CAHN

DEXTROAMPHETAMINE SULFATE

SOLUTION; ORAL
DEXTROAMPHETAMINE SULFATE

>D>		+	OUTLOOK PHARMS	5MG/5ML	A040776	001	Jan 29, 2008	May	CFTG
>A>	AA	+		5MG/5ML	A040776	001	Jan 29, 2008	May	CFTG
>A>	AA		TRIS PHARMA INC	5MG/5ML	A203644	001	May 29, 2013	May	NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;220MG/100ML	N018744 003	Nov 09, 1982	Jan	DISC
-----------	-----------------------	-------------	--------------	-----	------

DIAZOXIDE

SUSPENSION; ORAL

PROGLYCEM

+ TEVA BRANDED PHARM	50MG/ML	N017453 001		Apr	CAHN
----------------------	---------	-------------	--	-----	------

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

@ APOTEX INC	0.1%	A077600 001	Nov 13, 2008	Apr	DISC
--------------	------	-------------	--------------	-----	------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	SANDOZ	50MG;0.2MG	A200158 001	May 09, 2013	Apr	NEWA
----	--------	------------	-------------	--------------	-----	------

AB		75MG;0.2MG	A200158 002	May 09, 2013	Apr	NEWA
----	--	------------	-------------	--------------	-----	------

DIDANOSINE

TABLET, FOR SUSPENSION; ORAL

DIDANOSINE

AUROBINDO	100MG	A077275 001	Aug 14, 2012	Apr	CDFR
-----------	-------	-------------	--------------	-----	------

	150MG	A077275 002	Aug 14, 2012	Apr	CDFR
--	-------	-------------	--------------	-----	------

+	200MG	A077275 003	Aug 14, 2012	Apr	CDFR
---	-------	-------------	--------------	-----	------

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

>D>	AB1	+ FOUGERA PHARMS	0.05%	A075187 001	Mar 30, 1998	May	DISC
-----	-----	------------------	-------	-------------	--------------	-----	------

>A>		@	0.05%	A075187 001	Mar 30, 1998	May	DISC
-----	--	---	-------	-------------	--------------	-----	------

>D>	AB1	TARO	0.05%	A075508 001	Apr 24, 2000	May	CRLD
-----	-----	------	-------	-------------	--------------	-----	------

>A>	BX	+	0.05%	A075508 001	Apr 24, 2000	May	CRLD
-----	----	---	-------	-------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB3	PAR PHARM	120MG	A074984 001	Dec 20, 1999	Jan	CAHN
-----	-----------	-------	-------------	--------------	-----	------

AB3		180MG	A074984 002	Dec 20, 1999	Jan	CAHN
-----	--	-------	-------------	--------------	-----	------

AB3		240MG	A074984 003	Dec 20, 1999	Jan	CAHN
-----	--	-------	-------------	--------------	-----	------

AB3		300MG	A074984 004	Dec 20, 1999	Jan	CAHN
-----	--	-------	-------------	--------------	-----	------

AB4	SANDOZ	120MG	A091022 001	Sep 28, 2012	Feb	CAHN
-----	--------	-------	-------------	--------------	-----	------

AB4		180MG	A091022 002	Sep 28, 2012	Feb	CAHN
-----	--	-------	-------------	--------------	-----	------

AB4		240MG	A091022 003	Sep 28, 2012	Feb	CAHN
-----	--	-------	-------------	--------------	-----	------

AB4		300MG	A091022 004	Sep 28, 2012	Feb	CAHN
-----	--	-------	-------------	--------------	-----	------

AB4		360MG	A091022 005	Sep 28, 2012	Feb	CAHN
-----	--	-------	-------------	--------------	-----	------

AB4		420MG	A091022 006	Sep 28, 2012	Feb	CAHN
-----	--	-------	-------------	--------------	-----	------

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

AP	@ APOTEX INC	5MG/ML	A075375 001	Sep 30, 1999	Apr	DISC
----	--------------	--------	-------------	--------------	-----	------

	@ TEVA PHARMS USA	5MG/ML	A074894 001	Aug 26, 1997	Apr	CAHN
--	-------------------	--------	-------------	--------------	-----	------

+		10MG/ML	A074894 002	Apr 19, 2002	Apr	CAHN
---	--	---------	-------------	--------------	-----	------

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

@ DAVA PHARMS INC	30MG	A074093 001	Nov 05, 1992	Jan	DISC
@	60MG	A074093 002	Nov 05, 1992	Jan	DISC
@	90MG	A074093 003	Nov 05, 1992	Jan	DISC
@	120MG	A074093 004	Nov 05, 1992	Jan	DISC

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

+ FRESenius KABI USA	50MG/ML	A040519 001	Jun 23, 2004	Apr	CRLD
@ WATSON LABS	50MG/ML	A080615 001		Apr	DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA

BIOGEN IDEC INC	120MG	N204063 001	Mar 27, 2013	Mar	NEWA
+	240MG	N204063 002	Mar 27, 2013	Mar	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ WATSON LABS INC	10MG/ML	A080873 001		Mar	DISC
@	50MG/ML	A080873 002		Mar	DISC

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP	BD RX	50MG/ML	A091526 001	Mar 26, 2013	Mar	NEWA
	@ WATSON LABS INC	50MG/ML	A080873 003		Mar	DISC

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

>D>	@ APOTEX INC	5MG/ML	A075769 001	Nov 27, 2002	Apr	DISC
>A>	@ TEVA PARENTERAL	5MG/ML	A074952 001	Nov 26, 1997	May	CAHN
>A>	@ TEVA PHARMS USA	5MG/ML	A074952 001	Nov 26, 1997	May	CAHN

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

@ TEVA PHARMS USA	EQ 500MG VALPROIC ACID	A078700 001	Aug 03, 2009	Mar	DISC
-------------------	------------------------	-------------	--------------	-----	------

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACTAVIS INC	20MG/ML (20MG/ML)	N203551 001	Apr 12, 2013	Apr	NEWA	
AP		80MG/4ML (20MG/ML)	N203551 002	Apr 12, 2013	Apr	NEWA	
		140MG/7ML (20MG/ML)	N203551 003	Apr 12, 2013	Apr	NEWA	
>D>	AP	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	May	DISC
>A>		@	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	May	DISC
>D>	AP		80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	May	DISC
>A>		@	80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	May	DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

@ ACCORD HLTHCARE	5MG	A201335 001	Aug 29, 2011	Jan	DISC
-------------------	-----	-------------	--------------	-----	------

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

	@ ACCORD HLTHCARE	10MG	A201335 002	Aug 29, 2011	Jan	DISC
AB	ACTAVIS GRP PTC	5MG	A090551 001	May 31, 2011	Apr	CAHN
AB		10MG	A090551 002	May 31, 2011	Apr	CAHN
AB	ALEMBIC PHARMS LTD	5MG	A201724 001	Feb 25, 2013	Feb	NEWA
AB		10MG	A201724 002	Feb 25, 2013	Feb	NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

@ APOTEX INC	EQ 2% BASE	A078395 001	Oct 28, 2008	Apr	DISC
--------------	------------	-------------	--------------	-----	------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@ APOTEX INC	EQ 2% BASE;EQ 0.5% BASE	A078201 001	Oct 28, 2008	Apr	DISC
--------------	-------------------------	-------------	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ WATSON LABS INC	EQ 1MG BASE	A075426 001	Oct 18, 2000	Jan	DISC
@	EQ 2MG BASE	A075426 002	Oct 18, 2000	Jan	DISC
@	EQ 4MG BASE	A075426 003	Oct 18, 2000	Jan	DISC
@	EQ 8MG BASE	A075426 004	Oct 18, 2000	Jan	DISC

DOXEPIH HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIH HYDROCHLORIDE

>D>	AB	MYLAN	EQ 10MG BASE	A070791 002	May 13, 1986	May	CRLD	
>A>	AB	+	MYLAN PHARMS INC	EQ 10MG BASE	A070791 002	May 13, 1986	May	CRLD
>D>	AB	PAR PHARM	EQ 10MG BASE	A071697 001	Nov 09, 1987	May	DISC	
>A>		@	EQ 10MG BASE	A071697 001	Nov 09, 1987	May	DISC	
>D>	AB	+	EQ 25MG BASE	A071437 001	Nov 09, 1987	May	DISC	
>A>		@	EQ 25MG BASE	A071437 001	Nov 09, 1987	May	DISC	
>D>	AB		EQ 50MG BASE	A071595 001	Nov 09, 1987	May	DISC	
>A>		@	EQ 50MG BASE	A071595 001	Nov 09, 1987	May	DISC	
>D>	AB		EQ 75MG BASE	A071608 001	Nov 09, 1987	May	DISC	
>A>		@	EQ 75MG BASE	A071608 001	Nov 09, 1987	May	DISC	
>D>	AB	+	EQ 100MG BASE	A071422 001	Nov 09, 1987	May	DISC	
>A>		@	EQ 100MG BASE	A071422 001	Nov 09, 1987	May	DISC	
>D>	AB	WATSON LABS	EQ 10MG BASE	A071485 001	Apr 30, 1987	May	DISC	
>A>		@	EQ 10MG BASE	A071485 001	Apr 30, 1987	May	DISC	
>D>	AB		EQ 25MG BASE	A071486 001	Apr 30, 1987	May	DISC	
>A>		@	EQ 25MG BASE	A071486 001	Apr 30, 1987	May	DISC	
>D>	AB		EQ 50MG BASE	A071238 001	Apr 30, 1987	May	DISC	
>A>		@	EQ 50MG BASE	A071238 001	Apr 30, 1987	May	DISC	
>D>	AB		EQ 75MG BASE	A071326 001	Apr 30, 1987	May	DISC	
>A>		@	EQ 75MG BASE	A071326 001	Apr 30, 1987	May	DISC	
>D>	AB		EQ 100MG BASE	A071239 001	Apr 30, 1987	May	DISC	
>A>		@	EQ 100MG BASE	A071239 001	Apr 30, 1987	May	DISC	

CONCENTRATE; ORAL

DOXEPIH HYDROCHLORIDE

@ PHARM ASSOC	EQ 10MG BASE/ML	A075924 001	Jan 15, 2004	Mar	DISC
---------------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

SILENOR

	PERNIX THERAPS LLC	EQ 3MG BASE	N022036 001	Mar 17, 2010	Apr	CAHN
+		EQ 6MG BASE	N022036 002	Mar 17, 2010	Apr	CAHN

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	SAGENT PHARMS	2MG/ML	A091495 001	Mar 18, 2013	Mar	NEWA
----	---------------	--------	-------------	--------------	-----	------

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

AB	+	JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Jan	CFTG
AB	+		50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Jan	CFTG

DOXIL (LIPOSOMAL)

AB	+	JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Apr	CTNA
AB	+		50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Apr	CTNA

DOXORUBICIN HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263 001	Feb 04, 2013	Jan	NEWA
AB		50MG/25ML (2MG/ML)	A203263 002	Feb 04, 2013	Jan	NEWA

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263 001	Feb 04, 2013	Apr	CTNA
AB		50MG/25ML (2MG/ML)	A203263 002	Feb 04, 2013	Apr	CTNA

DOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCYCLINE

AB	LUPIN LTD	EQ 25MG BASE/5ML	A201678 001	Mar 18, 2013	Mar	NEWA
----	-----------	------------------	-------------	--------------	-----	------

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

>A>	AB	HIKMA PHARMS	EQ 50MG BASE	A062396 002	Nov 07, 1984	May	CAHN
>A>	AB		EQ 100MG BASE	A062396 001	May 07, 1984	May	CAHN
>D>	AB	WEST WARD	EQ 50MG BASE	A062396 002	Nov 07, 1984	May	CAHN
>D>	AB		EQ 100MG BASE	A062396 001	May 07, 1984	May	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

	@	BLU CARIBE INC	EQ 50MG BASE	A062269 003		Mar	CAHN	
	@		EQ 100MG BASE	A062269 002	Nov 08, 1982	Mar	CAHN	
>A>	AB	+	HIKMA PHARMS	EQ 100MG BASE	A065095 001	Jul 02, 2003	May	CAHN
>D>	AB	+	WEST-WARD PHARM CORP	EQ 100MG BASE	A065095 001	Jul 02, 2003	May	CAHN

TABLET, DELAYED RELEASE; ORAL

DORYX

	MAYNE PHARMA	EQ 80MG BASE	N050795 004	Apr 11, 2013	Apr	NEWA
		EQ 200MG BASE	N050795 005	Apr 11, 2013	Apr	NEWA

DOXYCYCLINE HYCLATE

AB	HERITAGE PHARMS INC	EQ 75MG BASE	A200856 001	Apr 30, 2013	Apr	NEWA
AB		EQ 100MG BASE	A200856 002	Apr 30, 2013	Apr	NEWA
AB		EQ 150MG BASE	A200856 003	Apr 30, 2013	Apr	NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL

DICLEGIS

+	DUCHESNAY	10MG;10MG	N021876 001	Apr 08, 2013	Apr	NEWA
---	-----------	-----------	-------------	--------------	-----	------

DUTASTERIDECAPSULE; ORAL
DUTASTERIDE

>A>	AB	BANNER PHARMACAPS	0.5MG	A200899 001	May 30, 2013	May	NEWA
-----	----	-------------------	-------	-------------	--------------	-----	------

ECONAZOLE NITRATECREAM; TOPICAL
ECONAZOLE NITRATE

	AB	IGI LABS INC	1%	A076574 001	Dec 17, 2004	Mar	CAHN
--	----	--------------	----	-------------	--------------	-----	------

ENALAPRILATINJECTABLE; INJECTION
ENALAPRILAT

>D>	AP	TEVA PARENTERAL	1.25MG/ML	A075578 001	Aug 22, 2000	May	CAHN
>A>	AP	TEVA PHARMS USA	1.25MG/ML	A075578 001	Aug 22, 2000	May	CAHN

ENTACAPONETABLET; ORAL
ENTACAPONE

	AB	MYLAN PHARMS INC	200MG	A202394 001	May 13, 2013	Apr	NEWA
--	----	------------------	-------	-------------	--------------	-----	------

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

		@ MYLAN LLC	50MG/25ML (2MG/ML)	A065371 001	Nov 28, 2007	Feb	DISC
		@	200MG/100ML (2MG/ML)	A065371 002	Nov 28, 2007	Feb	DISC
AP		TEVA PHARMS USA	200MG/100ML (2MG/ML)	A065331 002	Aug 09, 2007	Apr	CAHN
AP			50MG/25ML (2MG/ML)	A065331 001	Aug 09, 2007	Apr	CAHN

EPOPROSTENOL SODIUMINJECTABLE; INJECTION
EPOPROSTENOL SODIUM

AP		TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396 001	Apr 23, 2008	Apr	CAHN
AP			EQ 1.5MG BASE/VIAL	A078396 002	Apr 23, 2008	Apr	CAHN

ERYTHROMYCINCAPSULE, DELAYED REL PELLETS; ORAL
ERYC

AB	+	MAYNE PHARMA	250MG	N050536 001		Mar	CAHN
		@ WARNER CHILCOTT LLC	250MG	A062338 001		Apr	DISC

SOLUTION; TOPICAL
SANSAC

		@ DOW PHARM	2%	A062522 001	Jan 24, 1985	Apr	CAHN
--	--	-------------	----	-------------	--------------	-----	------

ESCITALOPRAM OXALATESOLUTION; ORAL
ESCITALOPRAM OXALATE

>A>	AA	SILARX PHARMS INC	EQ 5MG BASE/5ML	A090477 001	Jun 12, 2013	May	NEWA
-----	----	-------------------	-----------------	-------------	--------------	-----	------

ESOMEPRAZOLE SODIUMINJECTABLE; INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP		SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882 001	Mar 18, 2013	Mar	NEWA
AP			EQ 40MG BASE/VIAL	A200882 002	Mar 18, 2013	Mar	NEWA

INJECTABLE; INTRAVENOUS

NEXIUM IV

AP	+	ASTRAZENECA	EQ 20MG BASE/VIAL	N021689 001	Mar 31, 2005	Mar	CFTG
AP	+		EQ 40MG BASE/VIAL	N021689 002	Mar 31, 2005	Mar	CFTG

ESTROPIRATE

TABLET; ORAL

ORTHO-EST

@	CARACO	0.75MG	A089567 001	Feb 27, 1991	Apr	DISC
@		1.5MG	A089582 001	Jul 17, 1991	Apr	DISC

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

AB		MYLAN PHARMS INC	1MG	A091151 001	Mar 26, 2013	Mar	NEWA
AB			2MG	A091151 002	Mar 26, 2013	Mar	NEWA
AB			3MG	A091151 003	Mar 26, 2013	Mar	NEWA
AB		SUN PHARMA GLOBAL	1MG	A091103 001	Apr 03, 2013	Mar	NEWA
AB			2MG	A091103 002	Apr 03, 2013	Mar	NEWA
AB			3MG	A091103 003	Apr 03, 2013	Mar	NEWA
		LUNESTA					
AB		SUNOVION PHARMS INC	1MG	N021476 001	Dec 15, 2004	Mar	CTEC
AB			2MG	N021476 002	Dec 15, 2004	Mar	CTEC
AB	+		3MG	N021476 003	Dec 15, 2004	Mar	CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

DAYSEE

AB		LUPIN LTD	0.03MG,0.01MG;0.15MG,N/A	A091467 001	Apr 10, 2013	Mar	NEWA
		QUARTETTE					
+		TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061 001	Mar 28, 2013	Mar	NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1		LUPIN LTD	0.02MG;0.1MG	A091425 001	Jan 18, 2013	Jan	NEWA
-----	--	-----------	--------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

PIRMELLA 1/35

AB		LUPIN LTD	0.035MG;1MG	A201512 001	Apr 24, 2013	Apr	NEWA
		PIRMELLA 7/7/7					
AB		LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510 001	Apr 24, 2013	Apr	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

MINASTRIN 24 FE

>D>							
>D>	+	WARNER CHILCOTT	0.02MG;1MG	N204426 001	Apr 19, 2013	May	DISC
	+		0.02MG;1MG	N204426 001	Apr 19, 2013	Apr	NEWA
>D>		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
>A>	@	WARNER CHILCOTT	0.02MG;1MG	N204426 001	Apr 19, 2013	May	DISC

TABLET; ORAL

FEMHRT

@	WARNER CHILCOTT LLC	0.005MG;1MG	N021065 002	Oct 15, 1999	Jan	DISC
---	---------------------	-------------	-------------	--------------	-----	------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

+	BARR LABS INC	0.005MG;1MG	A076221 001	Nov 06, 2009	Jan	CRLD
---	---------------	-------------	-------------	--------------	-----	------

>A> TABLET, CHEWABLE; ORAL
 >A> NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
 >A> + WARNER CHILCOTT LLC 0.02MG;1MG N203667 001 May 08, 2003 May NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28
 ESTARYLLA
 AB SANDOZ 0.035MG;0.25MG A090794 001 Jan 30, 2013 Jan NEWA
 TRI LO SPRINT
 @ BARR LABS INC 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG A076784 001 Jun 29, 2009 Apr DISC
 TRI-ESTARYLLA
 AB SANDOZ 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG A090793 001 Jan 30, 2013 Jan NEWA

ETHOTOIN

TABLET; ORAL
 PEGANONE
 >D> + LUNDBECK LLC 250MG N010841 001 May CAHN
 >A> + RECORDATI RARE 250MG N010841 001 May CAHN

ETODOLAC

TABLET; ORAL
 ETODOLAC
 @ PROSAM LABS 400MG A074819 001 Feb 28, 1997 Mar DISC
 @ 500MG A074819 002 Apr 28, 1998 Mar DISC

ETOPOSIDE

INJECTABLE; INJECTION
 ETOPOSIDE
 AP ACCORD HLTHCARE 20MG/ML A074513 001 Mar 14, 1996 Apr CAHN
 @ PHARMACHEMIE 20MG/ML A074227 001 Feb 22, 1996 Apr DISC
 >D> AP TEVA PARENTERAL 20MG/ML A074284 001 Feb 10, 1994 May CAHN
 >A> AP TEVA PHARMS USA 20MG/ML A074284 001 Feb 10, 1994 May CAHN
 AP 20MG/ML A074529 001 Jul 24, 1996 Apr CAHN

FAMOTIDINE

INJECTABLE; INJECTION
 FAMOTIDINE
 @ APOTEX INC 10MG/ML A075942 001 Aug 02, 2002 Apr DISC
 FAMOTIDINE PRESERVATIVE FREE
 AP AKORN INC 10MG/ML A076324 001 Nov 27, 2002 Mar CAHN
 @ APOTEX INC 10MG/ML A076324 001 Nov 27, 2002 Apr DISC
 FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)
 AP AKORN INC 10MG/ML A076322 001 Nov 27, 2002 Mar CAHN
 @ APOTEX INC 10MG/ML A076322 001 Nov 27, 2002 Apr DISC
 PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER
 @ MERCK SHARP DOHME 0.4MG/ML N020249 001 Feb 18, 1994 Apr CAHN

FENOFIBRIC ACID

TABLET; ORAL
 FIBRICOR
 MUTUAL PHARM CO INC 35MG N022418 001 Aug 14, 2009 Feb CAHN
 + 105MG N022418 002 Aug 14, 2009 Feb CAHN

FENOPROFEN CALCIUM

TABLET; ORAL

FENOPROFEN CALCIUM

@	IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988	Mar	DISC
+	MYLAN PHARMS INC	EQ 600MG BASE	A072267	001	Aug 17, 1988	Mar	CTEC

FENTANYL CITRATE

FILM; BUCCAL

>D>	ONSOLIS						
>D>	MEDA PHARMS	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	May	DISC
>A>	@	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	May	DISC
>D>	+	EQ 0.4MG BASE	N022266	002	Jul 16, 2009	May	DISC
>A>	+ @	EQ 0.4MG BASE	N022266	002	Jul 16, 2009	May	DISC
>D>		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	May	DISC
>A>	@	EQ 0.6MG BASE	N022266	003	Jul 16, 2009	May	DISC
>D>		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	May	DISC
>A>	@	EQ 0.8MG BASE	N022266	004	Jul 16, 2009	May	DISC
>D>		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	May	DISC
>A>		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	May	DISC

TABLET; BUCCAL, SUBLINGUAL

FENTORA

AB	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Feb	CDFR
AB		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Feb	CDFR
	@	EQ 0.3MG BASE	N021947	006	Mar 02, 2007	Feb	CDFR
AB	+	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Feb	CDFR
AB		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Feb	CDFR
AB		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Feb	CDFR

TABLET; SUBLINGUAL

ABSTRAL

>A>	GALENA BIOPHARMA	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	May	CAHN
>A>		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	May	CAHN
>A>		EQ 0.3MG BASE	N022510	003	Jan 07, 2011	May	CAHN
>A>	+	EQ 0.4MG BASE	N022510	004	Jan 07, 2011	May	CAHN
>A>		EQ 0.6MG BASE	N022510	005	Jan 07, 2011	May	CAHN
>A>		EQ 0.8MG BASE	N022510	006	Jan 07, 2011	May	CAHN
>D>	PROSTRAKAN INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	May	CAHN
>D>		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	May	CAHN
>D>		EQ 0.3MG BASE	N022510	003	Jan 07, 2011	May	CAHN
>D>	+	EQ 0.4MG BASE	N022510	004	Jan 07, 2011	May	CAHN
>D>		EQ 0.6MG BASE	N022510	005	Jan 07, 2011	May	CAHN
>D>		EQ 0.8MG BASE	N022510	006	Jan 07, 2011	May	CAHN

FERUMOXSI

SUSPENSION; ORAL

GASTROMARK

@	AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996	Feb	DISC
---	-----------------	--------------------	---------	-----	--------------	-----	------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB	ACCORD HLTHCARE	5MG	A090121	001	Feb 23, 2010	Apr	CAHN
AB	HETERO LABS LTD III	5MG	A090061	001	Jun 07, 2010	Apr	CAHN

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

		@ APOTEX INC	50MG	A079164 001	Jul 09, 2009	Apr	DISC
		@	100MG	A079164 002	Jul 09, 2009	Apr	DISC
		@	150MG	A079164 003	Jul 09, 2009	Apr	DISC
>D>	AB	ROXANE	150MG	A076278 003	Jan 14, 2003	May	CRLD
>A>	AB	+	150MG	A076278 003	Jan 14, 2003	May	CRLD
>D>		TAMBOCOR					
>D>	AB	MEDICIS	50MG	N018830 004	Aug 23, 1988	May	DISC
>A>		@	50MG	N018830 004	Aug 23, 1988	May	DISC
>D>	AB		100MG	N018830 001	Oct 31, 1985	May	DISC
>A>		@	100MG	N018830 001	Oct 31, 1985	May	DISC
>D>	AB	+	150MG	N018830 003	Jun 03, 1988	May	DISC
>A>		@	150MG	N018830 003	Jun 03, 1988	May	DISC

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

		@ TARO PHARM INDS	50MG/5ML	A076918 001	Dec 18, 2006	Mar	DISC
		@	200MG/5ML	A076918 002	Dec 18, 2006	Mar	DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

		@ APOTEX INC	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005	Apr	DISC
		@	400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005	Apr	DISC

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

>D>	AP	TEVA PARENTERAL	200MG/100ML (2MG/ML)	A076653 001	Jul 29, 2004	May	CAHN
>D>	AP		400MG/200ML (2MG/ML)	A076653 002	Jul 29, 2004	May	CAHN
>A>	AP	TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653 001	Jul 29, 2004	May	CAHN
>A>	AP		400MG/200ML (2MG/ML)	A076653 002	Jul 29, 2004	May	CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		@ APOTEX INC	200MG/100ML (2MG/ML)	A076889 001	Mar 25, 2005	Apr	DISC
		@	400MG/200ML (2MG/ML)	A076889 002	Mar 25, 2005	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP	+	FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393 001	Oct 15, 2007	Jan	CRLD
AP		TEVA PARENTERAL	50MG/2ML (25MG/ML)	A076661 001	Apr 28, 2004	Jan	CRLD
AP		TEVA PHARMS USA	50MG/VIAL	A076349 001	Aug 28, 2003	Apr	CAHN
AP			50MG/2ML (25MG/ML)	A076661 001	Apr 28, 2004	Apr	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

+		FEINSTEIN	20-300mCi/ML	N021870 002	Nov 21, 2008	Jan	CFTG
		HOUSTON CYCLOTRON	20-500mCi/ML	A203665 001	Feb 14, 2013	Jan	NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

		@ APOTEX INC	0.5MG/5ML (0.1MG/ML)	A076755 002	Oct 12, 2004	Apr	DISC
		@	1MG/10ML (0.1MG/ML)	A076755 001	Oct 12, 2004	Apr	DISC
		@ TEVA PHARMS USA	0.5MG/5ML (0.1MG/ML)	A076589 002	Oct 12, 2004	Apr	CAHN
		@	1MG/10ML (0.1MG/ML)	A076589 001	Oct 12, 2004	Apr	CAHN

FLUOCINONIDE

CREAM; TOPICAL

LIDEX

@ CNTY LINE PHARMS	0.05%	N016908 002		Jan	CAHN
--------------------	-------	-------------	--	-----	------

LIDEX-E

@ CNTY LINE PHARMS	0.05%	N016908 003		Jan	CAHN
--------------------	-------	-------------	--	-----	------

GEL; TOPICAL

FLUOCINONIDE

AB + TARO	0.05%	A074935 001	Jul 29, 1997	Jan	CRLD
-----------	-------	-------------	--------------	-----	------

LIDEX

@ CNTY LINE PHARMS	0.05%	N017373 001		Jan	CAHN
--------------------	-------	-------------	--	-----	------

OINTMENT; TOPICAL

FLUOCINONIDE

AB + TARO	0.05%	A075008 001	Jun 30, 1999	Jan	CRLD
-----------	-------	-------------	--------------	-----	------

LIDEX

@ CNTY LINE PHARMS	0.05%	N016909 002		Jan	CAHN
--------------------	-------	-------------	--	-----	------

SOLUTION; TOPICAL

FLUOCINONIDE

>A> AT ACTAVIS MID ATLANTIC	0.05%	A071535 001	Dec 02, 1988	May	CAHN
-----------------------------	-------	-------------	--------------	-----	------

>D> AT G AND W LABS INC	0.05%	A071535 001	Dec 02, 1988	May	CAHN
-------------------------	-------	-------------	--------------	-----	------

AT + TARO	0.05%	A074799 001	Dec 31, 1996	Jan	CRLD
-----------	-------	-------------	--------------	-----	------

LIDEX

>A> @ CNTY LINE PHARMS	0.05%	N018849 001	Apr 06, 1984	May	CAHN
------------------------	-------	-------------	--------------	-----	------

>D> @ MEDICIS	0.05%	N018849 001	Apr 06, 1984	May	CAHN
---------------	-------	-------------	--------------	-----	------

@	0.05%	N018849 001	Apr 06, 1984	Jan	DISC
---	-------	-------------	--------------	-----	------

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP + MYLAN LLC	500MG/10ML (50MG/ML)	A040743 002	Apr 26, 2007	Feb	CAHN
----------------	----------------------	-------------	--------------	-----	------

AP +	1GM/20ML (50MG/ML)	A040743 001	Apr 26, 2007	Feb	CAHN
------	--------------------	-------------	--------------	-----	------

>D> AP + TEVA PARENTERAL	500MG/10ML (50MG/ML)	A040333 001	Jan 27, 2000	May	CAHN
--------------------------	----------------------	-------------	--------------	-----	------

>D> AP +	2.5GM/50ML (50MG/ML)	A040334 001	Feb 25, 2000	May	CAHN
----------	----------------------	-------------	--------------	-----	------

>D> AP +	5GM/100ML (50MG/ML)	A040334 002	Feb 25, 2000	May	CAHN
----------	---------------------	-------------	--------------	-----	------

>A> AP + TEVA PHARMS USA	500MG/10ML (50MG/ML)	A040333 001	Jan 27, 2000	May	CAHN
--------------------------	----------------------	-------------	--------------	-----	------

>A> AP +	2.5GM/50ML (50MG/ML)	A040334 001	Feb 25, 2000	May	CAHN
----------	----------------------	-------------	--------------	-----	------

>A> AP +	5GM/100ML (50MG/ML)	A040334 002	Feb 25, 2000	May	CAHN
----------	---------------------	-------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

@ CARLSBAD	EQ 10MG BASE	A076022 001	Jan 30, 2002	Mar	DISC
------------	--------------	-------------	--------------	-----	------

@	EQ 20MG BASE	A076022 002	Jan 30, 2002	Mar	DISC
---	--------------	-------------	--------------	-----	------

@ CR DOUBLE CRANE	EQ 10MG BASE	A076165 001	Feb 01, 2002	Apr	DISC
-------------------	--------------	-------------	--------------	-----	------

AB1	EQ 10MG BASE	A076165 001	Feb 01, 2002	Mar	CAHN
-----	--------------	-------------	--------------	-----	------

@	EQ 20MG BASE	A076165 002	Feb 01, 2002	Apr	DISC
---	--------------	-------------	--------------	-----	------

AB1	EQ 20MG BASE	A076165 002	Feb 01, 2002	Mar	CAHN
-----	--------------	-------------	--------------	-----	------

@ WOCKHARDT LTD	EQ 10MG BASE	A078143 001	Jan 16, 2008	Feb	DISC
-----------------	--------------	-------------	--------------	-----	------

@	EQ 20MG BASE	A078143 002	Jan 16, 2008	Feb	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 40MG BASE	A078143 003	Jan 16, 2008	Feb	DISC
---	--------------	-------------	--------------	-----	------

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

@ APOTEX INC	EQ 20MG BASE/5ML	A075292 001	Feb 07, 2002	Apr	DISC
--------------	------------------	-------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB	TEVA PHARMS	EQ 25MG BASE;EQ 3MG BASE	A202074	001	Mar 25, 2013	Mar	NEWA
----	-------------	--------------------------	---------	-----	--------------	-----	------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

@ APOTEX INC	25MG/ML	A075918	001	Aug 17, 2001	Apr	DISC
--------------	---------	---------	-----	--------------	-----	------

>A> FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

>A> POWDER; INHALATION

>A> BREO ELLIPTA

>A>	+	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275	001	May 10, 2013	May	NEWA
-----	---	---------------	-------------------------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

POWDER; INHALATION

FLOVENT DISKUS 100

>A>	+	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000	May	CAHN
-----	---	---------------	-----------	---------	-----	--------------	-----	------

>D>	+	GLAXOSMITHKLINE	0.1MG/INH	N020833	002	Sep 29, 2000	May	CAHN
-----	---	-----------------	-----------	---------	-----	--------------	-----	------

FLOVENT DISKUS 250

>A>	+	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000	May	CAHN
-----	---	---------------	------------	---------	-----	--------------	-----	------

>D>	+	GLAXOSMITHKLINE	0.25MG/INH	N020833	003	Sep 29, 2000	May	CAHN
-----	---	-----------------	------------	---------	-----	--------------	-----	------

FLOVENT DISKUS 50

>A>	+	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000	May	CAHN
-----	---	---------------	------------	---------	-----	--------------	-----	------

>D>	+	GLAXOSMITHKLINE	0.05MG/INH	N020833	001	Sep 29, 2000	May	CAHN
-----	---	-----------------	------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

>A>	+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006	May	CAHN
-----	---	---------------	---------------------------------	---------	-----	--------------	-----	------

>A>	+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006	May	CAHN
-----	---	--	---------------------------------	---------	-----	--------------	-----	------

>A>	+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006	May	CAHN
-----	---	--	--------------------------------	---------	-----	--------------	-----	------

>D>	+	GLAXOSMITHKLINE	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006	May	CAHN
-----	---	-----------------	---------------------------------	---------	-----	--------------	-----	------

>D>	+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006	May	CAHN
-----	---	--	---------------------------------	---------	-----	--------------	-----	------

>D>	+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006	May	CAHN
-----	---	--	--------------------------------	---------	-----	--------------	-----	------

POWDER; INHALATION

ADVAIR DISKUS 100/50

>A>	+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000	May	CAHN
-----	---	---------------	------------------------------	---------	-----	--------------	-----	------

>D>	+	GLAXOSMITHKLINE	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000	May	CAHN
-----	---	-----------------	------------------------------	---------	-----	--------------	-----	------

ADVAIR DISKUS 250/50

>A>	+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000	May	CAHN
-----	---	---------------	-------------------------------	---------	-----	--------------	-----	------

>D>	+	GLAXOSMITHKLINE	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000	May	CAHN
-----	---	-----------------	-------------------------------	---------	-----	--------------	-----	------

ADVAIR DISKUS 500/50

>A>	+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000	May	CAHN
-----	---	---------------	------------------------------	---------	-----	--------------	-----	------

>D>	+	GLAXOSMITHKLINE	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000	May	CAHN
-----	---	-----------------	------------------------------	---------	-----	--------------	-----	------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB	ACTAVIS ELIZABETH	100MG	A091482	001	Apr 23, 2013	Apr	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

AB	ANCHEN PHARMS	100MG	A091476	001	Mar 13, 2013	Mar	NEWA
----	---------------	-------	---------	-----	--------------	-----	------

AB		150MG	A091476	002	Mar 13, 2013	Mar	NEWA
----	--	-------	---------	-----	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

AB	JAZZ PHARMS	100MG	N022033 001	Feb 28, 2008	Mar	CFTG
AB	+	150MG	N022033 002	Feb 28, 2008	Mar	CFTG

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	WATSON LABS	10MG	A076987 001	Dec 23, 2004	Mar	DISC
@		20MG	A076987 002	Dec 23, 2004	Mar	DISC
@		40MG	A076987 003	Dec 23, 2004	Mar	DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

>A>	AP	AMNEAL PHARMS	EQ 50MG PNEYTOIN NA/ML	A078476 001	Mar 18, 2008	May	CAHN
		@ APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126 001	Aug 06, 2007	Apr	DISC
>D>	AP	PFIZER	EQ 50MG PNEYTOIN NA/ML	A078476 001	Mar 18, 2008	May	CAHN
>D>		@ TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007	May	CAHN
>A>		@ TEVA PHARMS USA	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007	May	CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@	INTL MEDICATION	10MG/ML	N018025 001		Jan	DISC
---	-----------------	---------	-------------	--	-----	------

TABLET; ORAL

FUROSEMIDE

@	DAVA PHARMS INC	20MG	N018415 001	Jul 27, 1982	Feb	DISC
@		40MG	N018415 002	Jul 27, 1982	Feb	DISC
@		80MG	N018415 003	Nov 26, 1984	Feb	DISC

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

>D>		GLAXO GRP LTD	300MG	N022399 002	Dec 13, 2011	May	CAHN
>D>	+		600MG	N022399 001	Apr 06, 2011	May	CAHN
>A>		XENOPORT INC	300MG	N022399 002	Dec 13, 2011	May	CAHN
>A>	+		600MG	N022399 001	Apr 06, 2011	May	CAHN

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

DOTAREM

+	GUERBET	37.69GM/100ML (376.9MG/ML)	N204781 001	Mar 20, 2013	Mar	NEWA
+		3.769GM/10ML (376.9MG/ML)	N204781 002	Mar 20, 2013	Mar	NEWA
+		5.6535GM/15ML (376.9MG/ML)	N204781 003	Mar 20, 2013	Mar	NEWA
+		7.538GM/20ML (376.9MG/ML)	N204781 004	Mar 20, 2013	Mar	NEWA

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

	BAYER HLTHCARE	2.72145GM/15ML (181.43MG/ML)	N022090 002	Feb 04, 2013	Feb	NEWA
--	----------------	------------------------------	-------------	--------------	-----	------

GANCICLOVIR

IMPLANT; IMPLANTATION

>D>	VITRASERT							
>D>	+	BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04,	1996	May DISC
>A>	@		4.5MG	N020569	001	Mar 04,	1996	May DISC

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

@	APOTEX INC	0.3%	A079084	001	Aug 19,	2011	Apr DISC
---	------------	------	---------	-----	---------	------	----------

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 2GM BASE/VIAL	A202997	001	May 07,	2013	Apr NEWA
AP	JIANGSU HANSON PHARM	EQ 200MG BASE/VIAL	A202485	001	May 07,	2013	Apr NEWA
AP		EQ 1GM BASE/VIAL	A202485	002	May 07,	2013	Apr NEWA
AP	PHARMAFORCE	EQ 200MG BASE/VIAL	A202031	001	May 07,	2013	Apr NEWA
AP		EQ 1GM BASE/VIAL	A202031	002	May 07,	2013	Apr NEWA
AP	SAGENT PHARMS	EQ 200MG BASE/VIAL	A091597	001	May 07,	2013	Apr NEWA
AP		EQ 1GM BASE/VIAL	A091597	002	May 07,	2013	Apr NEWA

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

@	TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20,	1996	Apr CAHN
---	-----------------	-----------	---------	-----	---------	------	----------

INJECTABLE; SUBCUTANEOUS

COPAXONE

+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12,	2002	Apr CAHN
---	-----------------	---------	---------	-----	---------	------	----------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@	COREPHARMA	1MG	A077274	001	Oct 06,	2005	Feb DISC
---	------------	-----	---------	-----	---------	------	----------

@		2MG	A077274	002	Oct 06,	2005	Feb DISC
---	--	-----	---------	-----	---------	------	----------

@		4MG	A077274	003	Oct 06,	2005	Feb DISC
---	--	-----	---------	-----	---------	------	----------

AB	INDOCO REMEDIES	1MG	A202112	001	Apr 17,	2013	Apr NEWA
----	-----------------	-----	---------	-----	---------	------	----------

AB		2MG	A202112	002	Apr 17,	2013	Apr NEWA
----	--	-----	---------	-----	---------	------	----------

AB		4MG	A202112	003	Apr 17,	2013	Apr NEWA
----	--	-----	---------	-----	---------	------	----------

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	ACCORD HLTHCARE	5MG	A074550	001	Sep 11,	1997	Apr CAHN
----	-----------------	-----	---------	-----	---------	------	----------

AB		10MG	A074550	002	Sep 11,	1997	Apr CAHN
----	--	------	---------	-----	---------	------	----------

>A>	@	BARR LABS INC	5MG	A074619	001	Apr 04,	1997	May CAHN
-----	---	---------------	-----	---------	-----	---------	------	----------

>A>	@		10MG	A074619	002	Apr 04,	1997	May CAHN
-----	---	--	------	---------	-----	---------	------	----------

>D>	@	PLIVA	5MG	A074619	001	Apr 04,	1997	May CAHN
-----	---	-------	-----	---------	-----	---------	------	----------

>D>	@		10MG	A074619	002	Apr 04,	1997	May CAHN
-----	---	--	------	---------	-----	---------	------	----------

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+	HYPERION THERAP INC	1.1GM/ML	N203284	001	Feb 01,	2013	Feb NEWA
---	---------------------	----------	---------	-----	---------	------	----------

GLYCOPYRROLATE

INJECTABLE; INJECTION
ROBINUL

AP + HIKMA MAPLE 0.2MG/ML N017558 001 Apr CAHN

TABLET; ORAL

GLYCOPYRROLATE

AA AUROLIFE PHARMA LLC 1MG A202675 001 Apr 15, 2013 Apr NEWA
@ COREPHARMA 1MG A040568 001 Dec 22, 2004 Mar DISC
@ 2MG A040568 002 Dec 22, 2004 Mar DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

@ APOTEX INC EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078197 001 Dec 31, 2007 Apr DISC

@ EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078198 001 Jun 30, 2008 Apr DISC

@ EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078198 002 Jun 30, 2008 Apr DISC

@ EBEWE PHARMA EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078808 001 Apr 29, 2008 Feb DISC

>D> AP + TEVA PARENTERAL EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078392 001 Dec 31, 2007 May CAHN

>D> AP + EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077963 001 Jan 03, 2008 May CAHN

>D> AP + EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A077297 001 Jun 30, 2008 May CAHN

>A> AP + TEVA PHARMS USA EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078392 001 Dec 31, 2007 May CAHN

>A> AP + EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077963 001 Jan 03, 2008 May CAHN

>A> AP + EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A077297 001 Jun 30, 2008 May CAHN

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

>D> @ TEVA PARENTERAL EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077165 001 Dec 31, 2007 May CAHN

>A> @ TEVA PHARMS USA EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077165 001 Dec 31, 2007 May CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRIFULVIN V

AB + VALEANT LUXEMBOURG 125MG/5ML A062483 001 Jan 26, 1984 Apr CAHN

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

@ FOUGERA PHARMS 0.05% A076903 001 Dec 16, 2004 Apr DISC

@ TARO 0.05% A076994 001 Dec 16, 2004 Mar DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@ APOTEX INC EQ 50MG BASE/ML A075440 001 Feb 28, 2000 Apr DISC

@ EQ 100MG BASE/ML A075440 002 Feb 28, 2000 Apr DISC

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

@ APOTEX INC EQ 5MG BASE/ML A076828 001 Aug 25, 2004 Apr DISC

@ EQ 5MG BASE/ML A076791 001 Aug 25, 2004 Apr DISC

HYALURONIDASE

INJECTABLE; INJECTION
VITRASE

>A>	+	BAUSCH AND LOMB	200 UNITS/VIAL	N021640 002	Dec 02, 2004	May	CAHN
>A>	@		6,200 UNITS/VIAL	N021640 001	May 05, 2004	May	CAHN
>D>	+	ISTA PHARMS	200 UNITS/VIAL	N021640 002	Dec 02, 2004	May	CAHN
>D>	@		6,200 UNITS/VIAL	N021640 001	May 05, 2004	May	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

AP		NAVINTA LLC	20MG/ML	A202938 001	Mar 28, 2013	Mar	NEWA
----	--	-------------	---------	-------------	--------------	-----	------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA		ACTAVIS GRP PTC	10MG	A091679 001	Mar 04, 2013	Apr	CAHN
AA			25MG	A091679 002	Mar 04, 2013	Apr	CAHN
AA			50MG	A091679 003	Mar 04, 2013	Apr	CAHN
AA			100MG	A091679 004	Mar 04, 2013	Apr	CAHN
AA		ACTAVIS PHARMA	10MG	A091679 001	Mar 04, 2013	Feb	NEWA
AA			25MG	A091679 002	Mar 04, 2013	Feb	NEWA
AA			50MG	A091679 003	Mar 04, 2013	Feb	NEWA
AA			100MG	A091679 004	Mar 04, 2013	Feb	NEWA
AA		ALKEM LABS LTD	10MG	A200737 001	Dec 07, 2012	Apr	CTEC
AA			25MG	A200737 002	Dec 07, 2012	Apr	CTEC
AA			50MG	A200737 003	Dec 07, 2012	Apr	CTEC
AA			100MG	A200737 004	Dec 07, 2012	Apr	CTEC
AA		HETERO LABS LTD III	10MG	A040901 001	Sep 12, 2008	Apr	CAHN
AA			25MG	A040901 002	Sep 12, 2008	Apr	CAHN
AA			50MG	A040901 003	Sep 12, 2008	Apr	CAHN
AA			100MG	A040901 004	Sep 12, 2008	Apr	CAHN
AA		STRIDES ARCOLAB LTD	25MG	A200770 001	May 03, 2013	Apr	NEWA
AA			50MG	A200770 002	May 03, 2013	Apr	NEWA
AA			100MG	A200770 003	May 03, 2013	Apr	NEWA

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	WATSON LABS	25MG	A081189 001	Jan 24, 1992	Mar	DISC
---	-------------	------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA LTD	12.5MG;150MG	A203630 001	Feb 22, 2013	Feb	NEWA
AB			12.5MG;300MG	A203630 002	Feb 22, 2013	Feb	NEWA
AB		LUPIN LTD	12.5MG;150MG	A201524 001	Feb 27, 2013	Feb	NEWA
AB			12.5MG;300MG	A201524 002	Feb 27, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		IPCA LABS LTD	12.5MG;50MG	A201682 001	Mar 01, 2013	Feb	NEWA
AB			12.5MG;100MG	A201682 002	Mar 01, 2013	Feb	NEWA
AB			25MG;100MG	A201682 003	Mar 01, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX CORP	12.5MG;EQ 10MG BASE	A091524 001	Mar 12, 2013	Mar	NEWA
AB		12.5MG;EQ 20MG BASE	A091524 002	Mar 12, 2013	Mar	NEWA
AB		25MG;EQ 20MG BASE	A091524 003	Mar 12, 2013	Mar	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

MAXZIDE

>D>	AB	+	MYLAN BERTEK	50MG;75MG	N019129 001	Oct 22, 1984	May	CAHN
>A>	AB	+	MYLAN PHARMS INC	50MG;75MG	N019129 001	Oct 22, 1984	May	CAHN

MAXZIDE-25

>D>	AB		MYLAN BERTEK	25MG;37.5MG	N019129 003	May 13, 1988	May	CAHN
>A>	AB		MYLAN PHARMS INC	25MG;37.5MG	N019129 003	May 13, 1988	May	CAHN

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

		@ WATSON LABS	50MG;75MG	A071969 001	Apr 17, 1988	Jan	DISC
--	--	---------------	-----------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;80MG	A201662 001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A201662 002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A201662 003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A201662 004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A201662 005	Mar 21, 2013	Mar	NEWA
AB	APOTEX INC	12.5MG;80MG	A203026 001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A203026 002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A203026 003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A203026 004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A203026 005	Mar 21, 2013	Mar	NEWA
AB	AUROBINDO PHARMA LTD	12.5MG;80MG	A202519 001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A202519 002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A202519 003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A202519 004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A202519 005	Mar 21, 2013	Mar	NEWA
AB	LUPIN LTD	12.5MG;80MG	A078946 003	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A078946 004	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A078946 001	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A078946 005	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A078946 002	Mar 21, 2013	Mar	NEWA
AB	MACLEODS PHARMS LTD	12.5MG;80MG	A203145 001	Apr 19, 2013	Apr	NEWA
AB		12.5MG;160MG	A203145 002	Apr 19, 2013	Apr	NEWA
AB		12.5MG;320MG	A203145 003	Apr 19, 2013	Apr	NEWA
AB		25MG;160MG	A203145 004	Apr 19, 2013	Apr	NEWA
AB		25MG;320MG	A203145 005	Apr 19, 2013	Apr	NEWA
AB	WATSON LABS INC	12.5MG;80MG	A091519 001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A091519 002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A091519 003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A091519 004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A091519 005	Mar 21, 2013	Mar	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

>A>	AB	SUN PHARM INDS INC	2.5MG;200MG	A091633 001	May 28, 2013	May	NEWA
>A>	AB		5MG;200MG	A091633 002	May 28, 2013	May	NEWA
>A>	AB		7.5MG;200MG	A091633 003	May 28, 2013	May	NEWA
>A>	AB		10MG;200MG	A091633 004	May 28, 2013	May	NEWA
REPREXAIN							
>D>		AMNEAL PHARMS NY	2.5MG;200MG	A076642 003	Oct 19, 2007	May	CFTG
>A>	AB		2.5MG;200MG	A076642 003	Oct 19, 2007	May	CFTG
>D>			10MG;200MG	A076642 004	Oct 19, 2007	May	CFTG
>A>	AB		10MG;200MG	A076642 004	Oct 19, 2007	May	CFTG

HYDROCORTISONE

LOTION; TOPICAL

STIE-CORT

@ PERRIGO CO

1%

A089066 001 Nov 25, 1985 Feb DISC

OINTMENT; TOPICAL

HYDROCORTISONE

@ TARO

2.5%

A040310 001 Dec 29, 2000 Mar DISC

HYDROCORTISONE ACETATE

PASTE; TOPICAL

ORABASE HCA

@ COLGATE

0.5%

A083205 001 Mar DISC

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

@ FOUGERA PHARMS

0.2%

A075085 001 Jul 31, 2001 Feb DISC

+ TARO

0.2%

A075043 001 Aug 25, 1998 Feb CRLD

WESTCORT

@ RANBAXY

0.2%

N018726 001 Aug 08, 1983 Feb DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

MALLINCKRODT INC

16MG

N021217 003 Mar 01, 2010 Jan CRLD

+

32MG

N021217 004 Aug 24, 2012 Jan CRLD

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB HETERO LABS LTD III 10MG

A040805 001 May 29, 2008 Apr CAHN

AB 25MG

A040805 002 May 29, 2008 Apr CAHN

AB 50MG

A040805 003 May 29, 2008 Apr CAHN

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

>A> AB EMCURE PHARMS USA 25MG

A201507 001 Jun 03, 2013 May NEWA

>A> AB 50MG

A201507 002 Jun 03, 2013 May NEWA

IBUPROFENSOLUTION; INTRAVENOUS
CALDOLOR

>D>		CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348 001	Jun 11, 2009	May	DISC
>A>		@	400MG/4ML (100MG/ML)	N022348 001	Jun 11, 2009	May	DISC

IBUPROFEN LYSINEINJECTABLE; INTRAVENOUS
NEOPROFEN

>D>	+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	May	CAHN
>A>	+	RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	May	CAHN

IDARUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
IDARUBICIN HYDROCHLORIDE PFS

AP		TEVA PHARMS USA	1MG/ML	A065036 001	May 01, 2002	Apr	CAHN
----	--	-----------------	--------	-------------	--------------	-----	------

IFOSFAMIDEINJECTABLE; INJECTION
IFOSFAMIDE

>D>	AP	+	TEVA PARENTERAL	1GM/20ML (50MG/ML)	A076657 001	Apr 04, 2007	May	CAHN
>D>	AP	+		3GM/60ML (50MG/ML)	A076657 002	Apr 04, 2007	May	CAHN
>A>	AP	+	TEVA PHARMS USA	1GM/20ML (50MG/ML)	A076657 001	Apr 04, 2007	May	CAHN
>A>	AP	+		3GM/60ML (50MG/ML)	A076657 002	Apr 04, 2007	May	CAHN

IFOSFAMIDE; MESNAINJECTABLE; INTRAVENOUS
IFOSFAMIDE/MESNA KIT

>D>	+	TEVA PARENTERAL	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874 001	Feb 26, 2002	May	CAHN
>D>	+		3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874 002	Feb 26, 2002	May	CAHN
>A>	+	TEVA PHARMS USA	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874 001	Feb 26, 2002	May	CAHN
>A>	+		3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874 002	Feb 26, 2002	May	CAHN

IMIPRAMINE HYDROCHLORIDETABLET; ORAL
IMIPRAMINE HYDROCHLORIDE

	@	PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Mar	DISC
	@		25MG	A040752 001	Feb 28, 2008	Mar	DISC
	@		50MG	A040751 001	Feb 28, 2008	Mar	DISC

INDOMETHACINCAPSULE; ORAL
INDOCIN

	@	ICEUTICA OPERATIONS	25MG	N016059 001		Mar	CAHN
	@		50MG	N016059 002		Mar	CAHN

INDOMETHACIN

AB		HETERO LABS LTD III	25MG	A091240 001	Apr 12, 2011	Apr	CAHN
AB			50MG	A091240 002	Apr 12, 2011	Apr	CAHN
AB		SUN PHARM INDS INC	25MG	A091401 001	Mar 28, 2013	Mar	NEWA
AB			50MG	A091401 002	Mar 28, 2013	Mar	NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION
INDOCIN

>D>	AP	+	LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985	May	CAHN
>A>	AP	+	RECORDATI RARE	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985	May	CAHN

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE

@	APOTEX INC	0.02%	A075441	001	Mar 28, 2001	Apr	DISC
@	TEVA PHARMS USA	0.02%	A075313	001	Feb 07, 2000	Mar	DISC

SPRAY, METERED; NASAL
IPRATROPIUM BROMIDE

@	APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Apr	DISC
@		0.042MG/SPRAY	A076155	001	Apr 18, 2003	Apr	DISC

IRON SUCROSE

INJECTABLE; INTRAVENOUS
VENOFER

LUITPOLD	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Mar	NEWA
----------	---------------------------------------	---------	-----	--------------	-----	------

ISONIAZID; RIFAMPIN

CAPSULE; ORAL
RIFAMATE

+	SANOFI AVENTIS US	150MG;300MG	A061884	001		Apr	CTEC
---	-------------------	-------------	---------	-----	--	-----	------

RIFAMPIN AND ISONIAZID

@	WEST WARD PHARM CORP	150MG;300MG	A065221	001	Jul 29, 2005	Apr	DISC
---	----------------------	-------------	---------	-----	--------------	-----	------

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE

@	INTL MEDICATION	0.2MG/ML	A083724	001		Mar	DISC
---	-----------------	----------	---------	-----	--	-----	------

ISUPREL

+	HOSPIRA	0.2MG/ML	N010515	001		Mar	CTEC
---	---------	----------	---------	-----	--	-----	------

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

>A>	+	ACTIENT PHARMS	40MG	N019790	001	Sep 02, 1988	May	CAHN
>D>	+	SCHWARZ PHARMA	40MG	N019790	001	Sep 02, 1988	May	CAHN

TABLET; ORAL

ISORDIL

AB		VALEANT BERMUDA	5MG	N012093	007	Jul 29, 1988	Apr	CAHN
AB			10MG	N012093	002	Jul 29, 1988	Apr	CAHN
AB			20MG	N012093	006	Jul 29, 1988	Apr	CAHN
AB	+		30MG	N012093	005	Jul 29, 1988	Apr	CAHN
	+		40MG	N012093	001	Jul 29, 1988	Apr	CAHN
AB		VALEANT PHARM NORTH	5MG	N012093	007	Jul 29, 1988	Mar	CAHN
AB			10MG	N012093	002	Jul 29, 1988	Mar	CAHN
AB			20MG	N012093	006	Jul 29, 1988	Mar	CAHN
AB	+		30MG	N012093	005	Jul 29, 1988	Mar	CAHN
	+		40MG	N012093	001	Jul 29, 1988	Mar	CAHN

ISOSORBIDE DINITRATE

AB		PAR PHARM	5MG	A086923	001	Mar 12, 1987	Apr	CMFD
----	--	-----------	-----	---------	-----	--------------	-----	------

TABLET; ORAL

ISOSORBIDE DINITRATE

@ PAR PHARM	5MG	A086923 001	Mar 12, 1987	Feb	DISC
@ WATSON LABS	5MG	A086034 001	Jan 06, 1988	Apr	DISC
@	10MG	A086032 001	Jan 07, 1988	Apr	DISC

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

BX	RANBAXY	10MG	N021951 001	May 25, 2012	Feb	CAHN
BX		20MG	N021951 002	May 25, 2012	Feb	CAHN
BX		30MG	N021951 003	May 25, 2012	Feb	CAHN
BX		40MG	N021951 004	May 25, 2012	Feb	CAHN

AMNESTEEM

AB	MYLAN PHARMS INC	20MG	A075945 002	Nov 08, 2002	Apr	CRLD
----	------------------	------	-------------	--------------	-----	------

CLARAVIS

>D>	AB	BARR	10MG	A076356 001	Apr 11, 2003	May	CAHN
>A>	AB	TEVA PHARMS USA	10MG	A076356 001	Apr 11, 2003	May	CAHN
	AB		30MG	A076135 003	May 11, 2006	Apr	CRLD
	AB	+	40MG	A076135 001	Apr 11, 2003	Apr	CRLD

ZENATANE

AB	DR REDDYS LABS LTD	10MG	A202099 001	Mar 25, 2013	Mar	NEWA
AB		20MG	A202099 002	Mar 25, 2013	Mar	NEWA
AB		40MG	A202099 003	Mar 25, 2013	Mar	NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

@ APOTEX INC	15MG/ML	A075631 002	Jun 29, 2001	Apr	DISC
@	30MG/ML	A075631 001	Jun 29, 2001	Apr	DISC
@	30MG/ML	A075626 001	Jul 24, 2001	Apr	DISC
@	30MG/ML	A077201 001	Oct 14, 2005	Apr	DISC

SOLUTION/DROPS; OPHTHALMIC

>D>		ACULAR PRESERVATIVE FREE					
>D>	+	ALLERGAN	0.5%	N020811 001	Nov 03, 1997	May	DISC
>A>	@		0.5%	N020811 001	Nov 03, 1997	May	DISC

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

@ APOTEX INC	5MG/ML	A076051 001	Jul 05, 2002	Apr	DISC
--------------	--------	-------------	--------------	-----	------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	+	SANDOZ	200MG	A075113 002	Aug 04, 1998	Jan	CRLD
		TRANDATE					
	@	PROMETHEUS LABS	100MG	N018716 001	May 24, 1985	Jan	DISC
	@		200MG	N018716 002	Aug 01, 1984	Jan	DISC

LACTULOSE

SOLUTION; ORAL

LACTULOSE

@ APOTEX INC	10GM/15ML	A075911 001	Feb 21, 2002	Apr	DISC
--------------	-----------	-------------	--------------	-----	------

SOLUTION; ORAL, RECTAL

LACTULOSE

@ APOTEX INC	10GM/15ML	A076645 001	Jul 28, 2003	Apr	DISC
--------------	-----------	-------------	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

AB	+	GLAXOSMITHKLINE LLC	25MG	N020241 005	Dec 27, 1994	Mar	CAHN
	@		50MG	N020241 006	Dec 27, 1994	Mar	CAHN
AB			100MG	N020241 001	Dec 27, 1994	Mar	CAHN
AB			150MG	N020241 002	Dec 27, 1994	Mar	CAHN
AB			200MG	N020241 003	Dec 27, 1994	Mar	CAHN
	@		250MG	N020241 004	Dec 27, 1994	Mar	CAHN

TABLET, CHEWABLE; ORAL

LAMICTAL CD

AB		GLAXOSMITHKLINE LLC	2MG	N020764 004	Sep 08, 2000	Mar	CAHN
AB			5MG	N020764 001	Aug 24, 1998	Mar	CAHN
AB	+		25MG	N020764 002	Aug 24, 1998	Mar	CAHN
	@		100MG	N020764 003	Aug 24, 1998	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

AB		GLAXOSMITHKLINE LLC	25MG	N022115 001	May 29, 2009	Mar	CAHN
AB	+		50MG	N022115 002	May 29, 2009	Mar	CAHN
AB			100MG	N022115 003	May 29, 2009	Mar	CAHN
AB			200MG	N022115 004	May 29, 2009	Mar	CAHN
AB			250MG	N022115 006	Jun 21, 2011	Mar	CAHN
AB			300MG	N022115 005	Apr 14, 2010	Mar	CAHN

LAMOTRIGINE

AB		PAR PHARM	25MG	A201791 001	Jan 18, 2013	Jan	NEWA
AB			50MG	A201791 002	Jan 18, 2013	Jan	NEWA
AB			100MG	A201791 003	Jan 18, 2013	Jan	NEWA
AB			200MG	A201791 004	Jan 18, 2013	Jan	NEWA
AB			250MG	A201791 005	Jan 18, 2013	Jan	NEWA
AB			300MG	A201791 006	Jan 18, 2013	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

LAMICTAL ODT

		GLAXOSMITHKLINE LLC	25MG	N022251 001	May 08, 2009	Mar	CAHN
	+		50MG	N022251 002	May 08, 2009	Mar	CAHN
			100MG	N022251 003	May 08, 2009	Mar	CAHN
			200MG	N022251 004	May 08, 2009	Mar	CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

	@	APOTEX INC	0.005%	A077697 001	Mar 22, 2011	Apr	DISC
AT		DR REDDYS LABS LTD	0.005%	A202077 001	Feb 11, 2013	Jan	NEWA

LETROZOLE

TABLET; ORAL

LETROZOLE

AB		JIANGSU HENGRUI MED	2.5MG	A202716 001	May 16, 2013	Apr	NEWA
----	--	---------------------	-------	-------------	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

AP		TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277 001	Sep 28, 1993	Mar	CAHN
AP			EQ 350MG BASE/VIAL	A040174 001	Jun 12, 1997	Mar	CAHN

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

AP	TEVA PHARMS USA	1MG/0.2ML	A075471	001	Oct 25, 2000	Mar	CAHN
	LUPRON DEPOT						
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL	N020011	001	Oct 22, 1990	Apr	CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	DEY	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Mar	NEWA
AN		EQ 0.021% BASE	A077800	002	Mar 15, 2013	Mar	NEWA
AN		EQ 0.042% BASE	A077800	003	Mar 15, 2013	Mar	NEWA
AN	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr	NEWA
AN		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr	NEWA
AN		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr	NEWA

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

	@ APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011	Apr	DISC
AA	HETERO DRUGS LTD	100MG/ML	A203052	001	Feb 28, 2013	Feb	NEWA
AA	HETERO LABS LTD III	100MG/ML	A203052	001	Feb 28, 2013	Apr	CAHN
AA	ORIT LABS LLC	100MG/ML	A203067	001	May 09, 2013	Apr	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	HETERO LABS LTD III	250MG	A090515	001	Oct 08, 2010	Apr	CAHN
AB		500MG	A090515	002	Oct 08, 2010	Apr	CAHN
AB		750MG	A090515	003	Oct 08, 2010	Apr	CAHN
AB		1GM	A090515	004	Oct 08, 2010	Apr	CAHN
AB	PRINSTON INC	250MG	A078106	001	Feb 10, 2009	Apr	CAHN
AB		500MG	A078106	002	Feb 10, 2009	Apr	CAHN
AB		750MG	A078106	003	Feb 10, 2009	Apr	CAHN
AB		1GM	A078106	004	Feb 10, 2009	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	@ SANDOZ	500MG	A091668	001	Nov 01, 2012	Mar	DISC
	@	750MG	A091668	002	Nov 01, 2012	Mar	DISC
AB	VINTAGE PHARMS LLC	500MG	A202533	001	Jul 20, 2012	Jan	NEWA
AB		750MG	A202533	002	Jul 20, 2012	Jan	NEWA

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

	@ APOTEX INC	0.25%	A075473	001	Aug 03, 2000	Apr	DISC
	@	0.5%	A075475	001	Aug 03, 2000	Apr	DISC

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

>D>	AP	TEVA PARENTERAL	200MG/ML	A075881	001	Mar 29, 2001	May	CAHN
>A>	AP	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	May	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	SANDOZ	5MG	A090486	001	Mar 26, 2013	Mar	NEWA
AB	SUN PHARMA GLOBAL	5MG	A090362	001	Jan 31, 2013	Jan	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Jan	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Jan	NEWA
>A> AP	CLARIS LIFESCIENCES	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	May	NEWA
AP	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Jan	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Jan	NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

@ APOTEX INC	0.5%	A078282	001	Dec 20, 2010	Apr	DISC
--------------	------	---------	-----	--------------	-----	------

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

SKYLA

+	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013	Jan	NEWA
---	----------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

LEVONORGESTREL

AB	LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013	Jan	NEWA
AB	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013	Feb	NEWA
PLAN B ONE-STEP							
AB	+ TEVA BRANDED PHARM	1.5MG	N021998	001	Jul 10, 2009	Apr	CAHN

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVOXYL

AB1, AB3	KING PHARMS R AND D	0.025MG	N021301	001	May 25, 2001	Mar	CAHN
AB1, AB3		0.05MG	N021301	002	May 25, 2001	Mar	CAHN
AB1, AB3		0.075MG	N021301	003	May 25, 2001	Mar	CAHN
AB1, AB3		0.088MG	N021301	004	May 25, 2001	Mar	CAHN
AB1, AB3		0.1MG	N021301	005	May 25, 2001	Mar	CAHN
AB1, AB3		0.112MG	N021301	006	May 25, 2001	Mar	CAHN
AB1, AB3		0.125MG	N021301	007	May 25, 2001	Mar	CAHN
AB1, AB3		0.137MG	N021301	008	May 25, 2001	Mar	CAHN
AB1, AB3		0.15MG	N021301	009	May 25, 2001	Mar	CAHN
AB1, AB3		0.175MG	N021301	010	May 25, 2001	Mar	CAHN
AB1, + AB3		0.2MG	N021301	011	May 25, 2001	Mar	CAHN
@		0.3MG	N021301	012	May 25, 2001	Mar	CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

@ LUITPOLD 2%

A083198 001 Mar DISC

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP AUROBINDO PHARMA LTD 1%

A203082 001 Mar 14, 2013 Mar NEWA

AP 1%

A203040 001 Mar 14, 2013 Mar NEWA

AP 2%

A203082 002 Mar 14, 2013 Mar NEWA

AP 2%

A203040 002 Mar 14, 2013 Mar NEWA

JELLY; TOPICAL

>D> ANESTACON

>D> AT POLYMEDICA 2%

A080429 001 May DISC

>A> @ 2%

A080429 001 May DISC

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB KING PHARMS R AND D EQ 0.005MG BASE

N010379 001 Mar CAHN

AB EQ 0.025MG BASE

N010379 002 Mar CAHN

AB + EQ 0.05MG BASE

N010379 003 Mar CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

@ SANDOZ 2.5MG

A075999 001 Jul 01, 2002 Jan CAHN

@ 5MG

A075999 002 Jul 01, 2002 Jan CAHN

@ 10MG

A075999 003 Jul 01, 2002 Jan CAHN

@ 20MG

A075999 004 Jul 01, 2002 Jan CAHN

@ 30MG

A075999 005 Jul 01, 2002 Jan CAHN

@ 40MG

A075999 006 Jul 01, 2002 Jan CAHN

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

@ APOTEX INC 300MG

A076795 001 Nov 22, 2004 Feb DISC

AB HETERO LABS LTD III 150MG

A090702 001 Sep 25, 2009 Apr CAHN

AB 300MG

A090702 002 Sep 25, 2009 Apr CAHN

AB 600MG

A090702 003 Sep 25, 2009 Apr CAHN

LOMUSTINE

CAPSULE; ORAL

CEENU

CORDEN PHARMA 10MG

N017588 001 Apr CAHN

40MG

N017588 002 Apr CAHN

+ 100MG

N017588 003 Apr CAHN

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA LUPIN LTD 2MG/ML

A091407 001 Feb 19, 2013 Feb NEWA

TABLET; ORAL

LORAZEPAM

@ SANDOZ 0.5MG

A071193 001 Apr 15, 1988 Apr DISC

@ 1MG

A071194 001 Apr 15, 1988 Apr DISC

TABLET; ORAL

LORAZEPAM

@ SANDOZ

2MG

A071195 001 Apr 15, 1988 Apr DISC

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB ACTAVIS GRP PTC

25MG

A090382 001 Oct 06, 2010 Mar CAHN

AB

50MG

A090382 002 Oct 06, 2010 Mar CAHN

AB

100MG

A090382 003 Oct 06, 2010 Mar CAHN

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB + CARLSBAD

40MG

A075991 003 Jun 05, 2002 Feb CRLD

MEVACOR

@ MERCK

20MG

N019643 003 Aug 31, 1987 Feb DISC

@

40MG

N019643 004 Dec 14, 1988 Feb DISC

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

>D> @ MIKAH PHARMA

EQ 5MG BASE

A076868 001 Aug 04, 2005 May CMFD

>A> AB

EQ 5MG BASE

A076868 001 Aug 04, 2005 May CMFD

>D> @

EQ 10MG BASE

A076868 002 Aug 04, 2005 May CMFD

>A> AB

EQ 10MG BASE

A076868 002 Aug 04, 2005 May CMFD

>D> @

EQ 25MG BASE

A076868 003 Aug 04, 2005 May CMFD

>A> AB

EQ 25MG BASE

A076868 003 Aug 04, 2005 May CMFD

>D> @

EQ 50MG BASE

A076868 004 Aug 04, 2005 May CMFD

>A> AB

EQ 50MG BASE

A076868 004 Aug 04, 2005 May CMFD

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLLON

>A> + MYLAN INSTITUTIONAL

EQ 85MG BASE/GM

N016763 001

May CAHN

>D> + MYLAN LLC

EQ 85MG BASE/GM

N016763 001

May CAHN

FOR SOLUTION; TOPICAL

MAFENIDE ACETATE

AB PAR FORM

5%

A201511 001 Feb 12, 2013 Jan NEWA

SULFAMYLLON

>A> AB + MYLAN INSTITUTIONAL

5%

N019832 003 Jun 05, 1998 May CAHN

>D> AB + MYLAN LLC

5%

N019832 003 Jun 05, 1998 May CAHN

AB +

5%

N019832 003 Jun 05, 1998 Jan CFTG

MAGNESIUM SULFATE, POTASSIUM SULFATE, SODIUM SULFATE; POLYETHYLENE GLYCOL 3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

SOLUTION, FOR SOLUTION; ORAL, ORAL

SUCLEAR

+ BRAINTREE LABS

1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM

N203595 001 Jan 18, 2013 Jan NEWA

MANNITOL

INJECTABLE; INJECTION

MANNITOL 20%

@ B BRAUN

20GM/100ML

N014738 001

Jan DISC

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

NEXGEN PHARMA

2.5MG

A204054 001 Mar 19, 2013 Mar NEWA

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

MUSTARGEN

>D> + LUNDBECK INC 10MG/VIAL

N006695 001

May CAHN

>A> + RECORDATI RARE 10MG/VIAL

N006695 001

May CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

>D> AB TEVA PARENTERAL 150MG/ML

A076553 001 Jul 28, 2004 May CAHN

>D> @ 150MG/ML

A076552 001 Oct 27, 2004 May CAHN

>A> @ TEVA PHARMS USA 150MG/ML

A076552 001 Oct 27, 2004 May CAHN

>A> AB 150MG/ML

A076553 001 Jul 28, 2004 May CAHN

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB CYPRESS PHARM

250MG

A090359 001 Feb 05, 2013 Jan NEWA

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

@ APOTEX INC

40MG/ML

A077404 001 Feb 16, 2006 Apr DISC

MELOXICAM

TABLET; ORAL

MELOXICAM

@ COREPHARMA

7.5MG

A077930 001 Jul 19, 2006 Feb DISC

@

15MG

A077930 002 Jul 19, 2006 Feb DISC

@ CR DOUBLE CRANE

7.5MG

A078039 001 Dec 14, 2006 Apr DISC

AB 7.5MG

A078039 001 Dec 14, 2006 Mar CAHN

@

15MG

A078039 002 Dec 14, 2006 Apr DISC

AB 15MG

A078039 002 Dec 14, 2006 Mar CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ TARO

200MG

A200998 001 May 23, 2011 Jan DISC

@

400MG

A200998 002 May 23, 2011 Jan DISC

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+ WARNER CHILCOTT LLC 400MG

N204412 001 Feb 01, 2013 Feb NEWA

SUPPOSITORY; RECTAL

CANASA

+ APTALIS PHARMA US 1GM

N021252 002 Nov 05, 2004 Feb CRLD

MESNAINJECTABLE; INTRAVENOUS
MESNA

>D>	AP	TEVA PARENTERAL	100MG/ML	A075764	001	Apr 27, 2001	May	CAHN
>A>	AP	TEVA PHARMS USA	100MG/ML	A075764	001	Apr 27, 2001	May	CAHN

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

@	APOTEX INC	0.4%	A075402	001	Feb 28, 2001	Apr	DISC
@		0.6%	A075403	001	Feb 28, 2001	Apr	DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

@	APOTEX INC	10MG/5ML	A075235	001	Jan 27, 2000	Apr	DISC
@	NOVEX	10MG/5ML	A075235	001	Jan 27, 2000	Feb	DISC
+	SILARX	10MG/5ML	A073632	001	Jul 22, 1992	Feb	CTEC

TABLET; ORAL

METAPROTERENOL SULFATE

	PAR PHARM	10MG	A072024	001	Jun 28, 1988	Mar	CTEC
+		20MG	A072025	001	Jun 28, 1988	Mar	CTEC
@	WATSON LABS	10MG	A073013	001	Jan 31, 1991	Mar	DISC
@		20MG	A072795	001	Jan 31, 1991	Mar	DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>D>		@ SANDOZ	500MG	A075965	001	Jan 25, 2002	May	CMFD
>A>	AB		500MG	A075965	001	Jan 25, 2002	May	CMFD
		@	500MG	A075965	001	Jan 25, 2002	Mar	DISC
>D>		@	850MG	A075965	002	Jan 25, 2002	May	CMFD
>A>	AB		850MG	A075965	002	Jan 25, 2002	May	CMFD
		@	850MG	A075965	002	Jan 25, 2002	Mar	DISC
>D>		@	1GM	A075965	003	Jan 25, 2002	May	CMFD
>A>	AB		1GM	A075965	003	Jan 25, 2002	May	CMFD
		@	1GM	A075965	003	Jan 25, 2002	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

@	WATSON LABS INC	500MG	A076818	001	Dec 14, 2004	Mar	DISC
---	-----------------	-------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	500MG;EQ 15MG BASE	A200823	001	Feb 13, 2013	Jan	NEWA
AB		850MG;EQ 15MG BASE	A200823	002	Feb 13, 2013	Jan	NEWA
AB	SANDOZ	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Apr	NEWA
AB		850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Apr	NEWA
AB	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	Jan	NEWA
AB		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	Jan	NEWA

METHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

AA	MALLINCKRODT INC	40MG	A077142	001	Jul 12, 2005	Mar	CDFR
AA	+	ROXANE	40MG	N017058	001		Mar CDFR
AA	SANDOZ	40MG	A075082	001	Mar 25, 1998	Mar	CDFR

TABLET, FOR SUSPENSION; ORAL
METHADOSE

AA MALLINCKRODT 40MG A074184 001 Apr 29, 1993 Mar CDFR

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL
DESOXYN

>D> AA + LUNDBECK INC 5MG N005378 002 May CAHN
>A> AA + RECORDATI RARE 5MG N005378 002 May CAHN

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

>D> @ AUSTARPHARMA LLC 500MG A200958 001 Oct 21, 2011 May CMFD
>A> AA 500MG A200958 001 Oct 21, 2011 May CMFD
@ 500MG A200958 001 Oct 21, 2011 Jan DISC
>D> @ 750MG A200958 002 Oct 21, 2011 May CMFD
>A> AA 750MG A200958 002 Oct 21, 2011 May CMFD
@ 750MG A200958 002 Oct 21, 2011 Jan DISC
AA HETERO LABS LTD III 500MG A090200 001 Nov 06, 2009 Apr CAHN
AA 750MG A090200 002 Nov 06, 2009 Apr CAHN
AA PRINSTON INC 500MG A086989 001 Feb CMFD
AA 750MG A086988 001 Feb CAHN
@ SOLCO HLTHCARE 500MG A086989 001 Jan DISC

METHOXSALLEN

CAPSULE; ORAL
OXSORALEN-ULTRA

+ DOW PHARM 10MG N019600 001 Oct 30, 1986 Apr CAHN

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE

+ MYLAN PHARMS INC 5MG A087672 001 Aug 17, 1982 Jan CTEC
@ WATSON LABS 5MG A088724 001 Sep 06, 1984 Jan DISC

METHYLDOPA

TABLET; ORAL
METHYLDOPA

@ ACCORD HLTHCARE 125MG A070070 003 Oct 15, 1985 Apr CAHN
AB 250MG A070084 001 Oct 15, 1985 Apr CAHN
AB 500MG A070085 001 Oct 15, 1985 Apr CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB1 WATSON LABS INC 20MG A078458 001 Dec 01, 2011 Apr CAHN
AB1 30MG A078458 002 Dec 01, 2011 Apr CAHN
AB1 40MG A078458 003 Dec 01, 2011 Apr CAHN

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A> AB CARACO 5MG A090710 001 Mar 15, 2012 May CAHN
>A> AB 10MG A090710 002 Mar 15, 2012 May CAHN
>A> AB 20MG A090710 003 Mar 15, 2012 May CAHN
>D> AB SUN PHARM INDS INC 5MG A090710 001 Mar 15, 2012 May CAHN

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	SUN PHARM INDS INC	10MG	A090710	002	Mar 15, 2012	May	CAHN
>D>	AB		20MG	A090710	003	Mar 15, 2012	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

METHYLIN ER

		MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	Feb	CTEC
--	--	------------------	------	---------	-----	--------------	-----	------

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

>D>	AB	TEVA PARENTERAL	40MG/ML	A040620	001	Oct 27, 2006	May	CAHN
>D>	AB		40MG/ML	A040557	001	Feb 23, 2005	May	CAHN
>D>	AB		80MG/ML	A040620	002	Oct 27, 2006	May	CAHN
>D>	AB		80MG/ML	A040557	002	Feb 23, 2005	May	CAHN
>A>	AB	TEVA PHARMS USA	40MG/ML	A040557	001	Feb 23, 2005	May	CAHN
>A>	AB		40MG/ML	A040620	001	Oct 27, 2006	May	CAHN
>A>	AB		80MG/ML	A040557	002	Feb 23, 2005	May	CAHN
>A>	AB		80MG/ML	A040620	002	Oct 27, 2006	May	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

	AP	BD RX	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Apr	NEWA
>D>		@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	May	CAHN
		@	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Feb	DISC
>A>		@ TEVA PHARMS USA	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	May	CAHN

METOLAZONE

TABLET; ORAL

METOLAZONE

		@ TEVA	2.5MG	A076600	001	Jan 06, 2004	Mar	DISC
>D>	AB		10MG	A075543	003	Dec 24, 2003	May	DISC
>A>		@	10MG	A075543	003	Dec 24, 2003	May	DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

		@ NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008	Feb	DISC
>D>	AB		EQ 50MG TARTRATE	A077176	001	May 14, 2008	May	DISC
>A>		@	EQ 50MG TARTRATE	A077176	001	May 14, 2008	May	DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

	AP	CLARIS LIFESCIENCES	1MG/ML	A078950	001	Apr 29, 2013	Apr	NEWA
		@ WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993	Mar	DISC

TABLET; ORAL

METOPROLOL TARTRATE

>A>	AB	ALEMBIC PHARMS LTD	25MG	A202871	001	May 28, 2013	May	NEWA
>A>	AB		50MG	A202871	002	May 28, 2013	May	NEWA
>A>	AB		100MG	A202871	003	May 28, 2013	May	NEWA
		@ PRINSTON INC	50MG	A074453	001	Apr 27, 1995	Mar	CAHN
		@	100MG	A074453	002	Apr 27, 1995	Mar	CAHN

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

AB	TEVA PHARMS USA	250MG	A070027	001	Nov 06, 1984	Mar	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

	@ APOTEX INC	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr	DISC
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr	DISC
	@ CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Jan	DISC
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Jan	DISC
>D>	AP	INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004	May DISC
>A>	@	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004	May	DISC
>D>	AP	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004	May	DISC
>A>	@	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004	May	DISC

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

@ APOTEX INC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005	Apr	DISC
--------------	----------------	---------	-----	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

@ APOTEX INC	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Apr	DISC
--------------	----------------	---------	-----	--------------	-----	------

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

@ APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Apr	DISC
--------------	---------------------------------------	---------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	CARACO	EQ 50MG BASE	A090867	001	May 13, 2013	Apr	NEWA
AB		EQ 75MG BASE	A090867	002	May 13, 2013	Apr	NEWA
AB		EQ 100MG BASE	A090867	003	May 13, 2013	Apr	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

>D>	XIMINO						
>D>	RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	May	DISC
>A>	@	EQ 45MG BASE	N201922	001	Jul 11, 2012	May	DISC
>D>		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	May	DISC
>A>	@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	May	DISC
>D>		EQ 90MG BASE	N201922	003	Jul 11, 2012	May	DISC
>A>	@	EQ 90MG BASE	N201922	003	Jul 11, 2012	May	DISC
>D>		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	May	DISC
>A>	@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	May	DISC
>D>	+	EQ 135MG BASE	N201922	005	Jul 11, 2012	May	DISC
>A>	@	EQ 135MG BASE	N201922	005	Jul 11, 2012	May	DISC

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

@ MEDICIS	EQ 45MG BASE	N050808	001	May 08, 2006	Apr	DISC
+	EQ 55MG BASE	N050808	008	Aug 27, 2010	Apr	CRLD
+	EQ 80MG BASE	N050808	007	Aug 27, 2010	Apr	CRLD
@	EQ 135MG BASE	N050808	003	May 08, 2006	Apr	DISC

MIPOMERSEN SODIUMSOLUTION; SUBCUTANEOUS
KYNAMRO

+ GENZYME CORP 200MG/ML (200MG/ML) N203568 001 Jan 29, 2013 Jan NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	ONCO THERAPIES LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014 001	Dec 11, 2012	Mar	CAIN
>D>	AP	TEVA PARENTERAL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A077356 001	Apr 11, 2006	May CAHN
>D>	AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A077356 002	Apr 11, 2006	May CAHN
>D>	AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A077356 003	Apr 11, 2006	May CAHN
>A>	AP	TEVA PHARMS USA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A077356 001	Apr 11, 2006	May CAHN
>A>	AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A077356 002	Apr 11, 2006	May CAHN
>A>	AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A077356 003	Apr 11, 2006	May CAHN

MOMETASONE FUROATECREAM; TOPICAL
ELOCON

AB MERCK SHARP DOHME 0.1% N019625 002 Apr 19, 2013 Apr NEWA

OINTMENT; TOPICAL

MOMETASONE FUROATE

>D>	AB	TARO	0.1%	A076624 001	Dec 03, 2004	May DISC
>A>	@		0.1%	A076624 001	Dec 03, 2004	May DISC

MORPHINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
KADIAN

>D>	+	WATSON LABS INC	10MG	N020616 008	Apr 20, 2007	May CTEC
>A>	AB1	+	10MG	N020616 008	Apr 20, 2007	May CTEC
		+	10MG	N020616 008	Apr 20, 2007	Apr CAHN
	AB1		20MG	N020616 001	Jul 03, 1996	Apr CAHN
	AB1		30MG	N020616 004	Mar 09, 2001	Apr CAHN
			40MG	N020616 009	Jul 09, 2012	Apr CAHN
	AB1		50MG	N020616 002	Jul 03, 1996	Apr CAHN
	AB1		60MG	N020616 005	Mar 09, 2001	Apr CAHN
			70MG	N020616 010	Jul 09, 2012	Apr CAHN
	AB1		80MG	N020616 006	Oct 27, 2006	Apr CAHN
	AB1	+	100MG	N020616 003	Jul 03, 1996	Apr CAHN
			130MG	N020616 011	Jul 09, 2012	Apr CAHN
			150MG	N020616 012	Jul 09, 2012	Apr CAHN
>D>	+		200MG	N020616 007	Feb 27, 2007	May CTEC
>A>	AB1	+	200MG	N020616 007	Feb 27, 2007	May CTEC
		+	200MG	N020616 007	Feb 27, 2007	Apr CAHN

MORPHINE SULFATE

AB1	PAR PHARM INC	20MG	A200812 001	Nov 10, 2011	Apr CTEC
AB1		30MG	A200812 002	Nov 10, 2011	Apr CTEC
AB1		50MG	A200812 003	Nov 10, 2011	Apr CTEC
AB1		60MG	A200812 004	Nov 10, 2011	Apr CTEC
AB1		80MG	A200812 005	Nov 10, 2011	Apr CTEC

CAPSULE, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB1	PAR PHARM INC	100MG	A200812 006	Nov 10, 2011	Apr	CTEC
>A>	AB1	UPSHER SMITH	10MG	A202104 001	Jun 03, 2013	May NEWA
>A>	AB1		20MG	A202104 002	Jun 03, 2013	May NEWA
>A>	AB1		30MG	A202104 003	Jun 03, 2013	May NEWA
>A>	AB1		50MG	A202104 004	Jun 03, 2013	May NEWA
>A>	AB1		60MG	A202104 005	Jun 03, 2013	May NEWA
>A>	AB1		80MG	A202104 006	Jun 03, 2013	May NEWA
>A>	AB1		100MG	A202104 007	Jun 03, 2013	May NEWA

MUPIROCIN CALCIUMCREAM; TOPICAL
BACTROBAN

AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746 001	Dec 11, 1997	Jan CFTG
AB		GLENMARK GENERICS	EQ 2% BASE	A201587 001	Jan 24, 2013	Jan NEWA

MYCOPHENOLATE MOFETILCAPSULE; ORAL
MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	250MG	A090253 001	May 04, 2009	Apr CAHN
----	--	-----------------	-------	-------------	--------------	----------

NABUMETONETABLET; ORAL
NABUMETONE

@	DR REDDYS LABS LTD	500MG	A078420 001	Sep 24, 2008	Apr	DISC
@		750MG	A078420 002	Sep 24, 2008	Apr	DISC
@	PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Mar	DISC
@		750MG	A079093 002	Feb 27, 2009	Mar	DISC

NALTREXONE HYDROCHLORIDETABLET; ORAL
NALTREXONE HYDROCHLORIDE
@ SANDOZ

50MG	A075434 001	Mar 08, 2000	Apr	DISC
------	-------------	--------------	-----	------

NAPROXENTABLET; ORAL
NAPROXEN

AB	WEST WARD PHARM CORP	250MG	A076494 001	Jan 14, 2004	Apr	CAHN
AB		375MG	A076494 002	Jan 14, 2004	Apr	CAHN
AB		500MG	A076494 003	Jan 14, 2004	Apr	CAHN

NARATRIPTAN HYDROCHLORIDETABLET; ORAL
AMERGE

AB	GLAXOSMITHKLINE LLC	EQ 1MG BASE	N020763 002	Feb 10, 1998	Mar	CAHN
AB	+	EQ 2.5MG BASE	N020763 001	Feb 10, 1998	Mar	CAHN

NEOMYCIN SULFATEPOWDER; FOR RX COMPOUNDING
NEO-RX

@	X GEN PHARMS	100%	A061579 001		Mar	DISC
---	--------------	------	-------------	--	-----	------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPTHALMIC

>D> POLY-PRED

>D>	+	ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081 002	May	DISC
-----	---	----------	---------------------------------------	-------------	-----	------

>A>	@		EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081 002	May	DISC
-----	---	--	---------------------------------------	-------------	-----	------

>A> NEOSTIGMINE METHYLSULFATE

>A> SOLUTION; INTRAVENOUS

>A> BLOXIVERZ

>A>	+	ECLAT PHARMS LLC	5MG/10ML (0.5MG/ML)	N204078 001	May 31, 2013	May	NEWA
-----	---	------------------	---------------------	-------------	--------------	-----	------

>A>	+		10MG/10ML (1MG/ML)	N204078 002	May 31, 2013	May	NEWA
-----	---	--	--------------------	-------------	--------------	-----	------

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB		ACTAVIS ELIZABETH	20MG	A072556 001	Sep 20, 1990	Apr	CTEC
----	--	-------------------	------	-------------	--------------	-----	------

	@	CATALENT	10MG	A073250 001	Oct 08, 1991	Apr	DISC
--	---	----------	------	-------------	--------------	-----	------

AB		EMCURE PHARMS USA	10MG	A202644 001	Apr 25, 2013	Apr	NEWA
----	--	-------------------	------	-------------	--------------	-----	------

AB			20MG	A202644 002	Apr 25, 2013	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

NILUTAMIDE

TABLET; ORAL

NILANDRON

@	COVIS PHARMA SARL	50MG	N020169 001	Sep 19, 1996	Apr	CAHN
---	-------------------	------	-------------	--------------	-----	------

+		150MG	N020169 002	Apr 30, 1999	Apr	CAHN
---	--	-------	-------------	--------------	-----	------

NIMODIPINE

>A> SOLUTION; ORAL

>A> NYMALIZE

>A>	+	ARBOR PHARMS INC	60MG/20ML	N203340 001	May 10, 2013	May	NEWA
-----	---	------------------	-----------	-------------	--------------	-----	------

NITISINONE

CAPSULE; ORAL

ORFADIN

>D>		RARE DIS	2MG	N021232 001	Jan 18, 2002	May	CAHN
-----	--	----------	-----	-------------	--------------	-----	------

>D>			5MG	N021232 002	Jan 18, 2002	May	CAHN
-----	--	--	-----	-------------	--------------	-----	------

>D>	+		10MG	N021232 003	Jan 18, 2002	May	CAHN
-----	---	--	------	-------------	--------------	-----	------

>A>		SWEDISH ORPHAN	2MG	N021232 001	Jan 18, 2002	May	CAHN
-----	--	----------------	-----	-------------	--------------	-----	------

>A>			5MG	N021232 002	Jan 18, 2002	May	CAHN
-----	--	--	-----	-------------	--------------	-----	------

>A>	+		10MG	N021232 003	Jan 18, 2002	May	CAHN
-----	---	--	------	-------------	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

ALVOGEN INC

		25MG	N016620 003	Mar	CTEC
--	--	------	-------------	-----	------

AB		25MG	N016620 003	Feb	CAHN
----	--	------	-------------	-----	------

AB		50MG	N016620 001	Feb	CAHN
----	--	------	-------------	-----	------

AB	+	100MG	N016620 002	Feb	CAHN
----	---	-------	-------------	-----	------

NITROFURANTOIN

@	WATSON LABS	25MG	A073696 001	Dec 31, 1992	Mar	DISC
---	-------------	------	-------------	--------------	-----	------

@		50MG	A073696 002	Dec 31, 1992	Mar	DISC
---	--	------	-------------	--------------	-----	------

@		100MG	A073696 003	Dec 31, 1992	Mar	DISC
---	--	-------	-------------	--------------	-----	------

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE; ORAL
MACROBID

AB	+	ALVOGEN INC	75MG;25MG	N020064	001	Dec 24, 1991	Mar	CAHN
----	---	-------------	-----------	---------	-----	--------------	-----	------

NITROGLYCERINFILM, EXTENDED RELEASE; TRANSDERMAL
NITRO-DUR

AB1	+	MERCK SHARP DOHME	0.1MG/HR	N020145	001	Apr 04, 1995	Mar	CAHN
AB1	+		0.2MG/HR	N020145	002	Apr 04, 1995	Mar	CAHN
	+		0.3MG/HR	N020145	003	Apr 04, 1995	Mar	CAHN
AB1	+		0.4MG/HR	N020145	004	Apr 04, 1995	Mar	CAHN
AB1	+		0.6MG/HR	N020145	005	Apr 04, 1995	Mar	CAHN
	+		0.8MG/HR	N020145	006	Apr 04, 1995	Mar	CAHN

NIZATIDINECAPSULE; ORAL
NIZATIDINE

@	APOTEX INC	150MG	A076383	001	Jan 23, 2003	Feb	DISC
@		300MG	A076383	002	Jan 23, 2003	Feb	DISC

NOREPINEPHRINE BITARTRATEINJECTABLE; INJECTION
NOREPINEPHRINE BITARTRATE

>D>	AP	TEVA PARENTERAL	EQ 1MG BASE/ML	A040455	001	Mar 03, 2003	May	CAHN
>A>	AP	TEVA PHARMS USA	EQ 1MG BASE/ML	A040455	001	Mar 03, 2003	May	CAHN

NORETHINDRONETABLET; ORAL-28
JENCYCLA

AB2		LUPIN LTD	0.35MG	A091323	001	Mar 28, 2013	Apr	CTEC
AB			0.35MG	A091323	001	Mar 28, 2013	Mar	NEWA
>A>	AB2	FAMY CARE LTD	0.35MG	A200980	001	Jun 12, 2013	May	NEWA

NYSTATINSUSPENSION; ORAL
NILSTAT

@	GLENMARK GENERICS	100,000 UNITS/ML	N050299	001		Feb	DISC
---	-------------------	------------------	---------	-----	--	-----	------

OCTREOTIDE ACETATEINJECTABLE; INJECTION
OCTREOTIDE ACETATE

>D>	AP	TEVA PARENTERAL	EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	May	CAHN
>D>	AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	May	CAHN
>D>	AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	May	CAHN
>D>	AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	May	CAHN
>D>	AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	May	CAHN
>A>	AP	TEVA PHARMS USA	EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	May	CAHN
>A>	AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	May	CAHN
>A>	AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	May	CAHN
>A>	AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	May	CAHN
>A>	AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	May	CAHN

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

AT	ALTAIRE PHARMS INC	0.3%	A202692	001	Apr 29, 2013	Apr	NEWA
	@ APOTEX INC	0.3%	A076513	001	May 14, 2004	Apr	DISC

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Apr	NEWA
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Apr	NEWA
	ZEGERID						
AB	SANTARUS	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr	CFTG
AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr	CFTG

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

	@ APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006	Apr	DISC
AP	CLARIS LIFESCIENCES	2MG/ML	A078288	001	Feb 22, 2013	Feb	NEWA
	@ LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006	Mar	DISC
	@ PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006	Feb	DISC
	ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER						
	@ CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308	001	Mar 17, 2008	Jan	DISC
	@ HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Jan	DISC
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
	@ APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006	Apr	DISC
AP	CLARIS LIFESCIENCES	2MG/ML	A078287	001	Feb 22, 2013	Feb	NEWA
	@ LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006	Mar	DISC

OSPEMIFENE

TABLET; ORAL

OSPHENA

+	SHIONOGI INC	60MG	N203505	001	Feb 26, 2013	Feb	NEWA
---	--------------	------	---------	-----	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A201539	001	Jan 18, 2013	Jan	NEWA
AP		EQ 2GM BASE/VIAL	A201539	002	Jan 18, 2013	Jan	NEWA
AP		EQ 10GM BASE/VIAL	A201538	001	Jan 18, 2013	Jan	NEWA

OXAPROZIN

TABLET; ORAL

OXAPROZIN

@	CARACO	600MG	A075844	001	Jan 03, 2002	Jan	DISC
---	--------	-------	---------	-----	--------------	-----	------

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

@	TEVA PHARMS USA	150MG	A078005	001	Dec 11, 2007	Mar	DISC
@		300MG	A078005	002	Dec 11, 2007	Mar	DISC
@		600MG	A078005	003	Dec 11, 2007	Mar	DISC

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

@ APOTEX INC

5MG/5ML

A074997 001 Oct 15, 1997 Apr DISC

TABLET; ORAL

OXYBUTYNIN CHLORIDE

AB TEVA PHARMS USA

5MG

A071655 001 Nov 14, 1988 Mar CAHN

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

@ NESHER PHARMS

5MG

A077290 001 Dec 08, 2005 Mar DISC

@

10MG

A077290 002 Dec 08, 2005 Mar DISC

@

15MG

A077290 003 Dec 08, 2005 Mar DISC

@

20MG

A077290 004 Dec 08, 2005 Mar DISC

@

30MG

A077290 005 Dec 08, 2005 Mar DISC

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB AVANTHI INC

5MG

A203601 001 Jan 30, 2013 Jan NEWA

AB

10MG

A203601 002 Jan 30, 2013 Jan NEWA

AB MALLINCKRODT INC

5MG

A202321 001 Apr 25, 2013 Apr NEWA

AB

10MG

A202321 002 Apr 25, 2013 Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

AB ACTAVIS ELIZABETH

7.5MG

A079046 001 Dec 13, 2010 Apr CAHN

AB

15MG

A079046 002 Dec 13, 2010 Apr CAHN

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP HIKMA FARMACEUTICA

10USP UNITS/ML (10USP UNITS/ML)

A200219 001 Feb 13, 2013 Jan NEWA

>D>

@ TEVA PARENTERAL

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008 May CAHN

>D>

@

100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008 May CAHN

>A>

@ TEVA PHARMS USA

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008 May CAHN

>A>

@

100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008 May CAHN

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

@ ACCORD HLTHCARE

6MG/ML

A075436 001 Nov 12, 2004 Apr DISC

>D>

@ TEVA PARENTERAL

6MG/ML

A075297 001 Jan 25, 2002 May CAHN

>A>

@ TEVA PHARMS USA

6MG/ML

A075297 001 Jan 25, 2002 May CAHN

TAXOL

AP HQ SPCLT PHARMA

6MG/ML

N020262 001 Dec 29, 1992 Apr CMFD

@

6MG/ML

N020262 001 Dec 29, 1992 Jan CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP TEVA PHARMS USA

30MG/10ML (3MG/ML)

A076153 001 Mar 27, 2002 Mar CAHN

AP

90MG/10ML (9MG/ML)

A076153 002 Mar 27, 2002 Mar CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBVIE

180,000USP UNITS;36,000USP
UNITS;114,000USP UNITS

N020725 005 Mar 14, 2013 Mar NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

>D>	AP	+	TEVA PARENTERAL	1MG/ML	A072759 001	Jul 31, 1990	May	CAHN
>A>	AP	+	TEVA PHARMS USA	1MG/ML	A072759 001	Jul 31, 1990	May	CAHN
	AP	+		2MG/ML	A072760 001	Jul 31, 1990	Mar	CAHN

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

@ APOTEX INC

EQ 10MG BASE/5ML

A077395 001 Dec 05, 2006 Apr DISC

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

>D>	OMONTYS							
>D>	+	TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	May	DISC	
>A>	@		EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	May	DISC	
	+		EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Apr	CAHN	
>D>	+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	May	DISC	
>A>	@		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	May	DISC	
	+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Apr	CAHN	
>D>	OMONTYS PRESERVATIVE FREE							
>D>	+	TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	May	DISC	
>A>	@		EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	May	DISC	
	+		EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Apr	CAHN	
>D>	+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	May	DISC	
>A>	@		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	May	DISC	
	+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Apr	CAHN	
>D>	+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	May	DISC	
>A>	@		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	May	DISC	
	+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Apr	CAHN	
>D>	+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	May	DISC	
>A>	@		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	May	DISC	
	+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Apr	CAHN	
>D>	+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	May	DISC	
>A>	@		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	May	DISC	
	+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Apr	CAHN	
>D>	+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	May	DISC	

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

>D> OMONTYS PRESERVATIVE FREE

>A> @ TAKEDA PHARMS USA EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) N202799 006 Mar 27, 2012 May DISC

+ EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) N202799 006 Mar 27, 2012 Apr CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

PARAGON BIOTECK 2.5% N203510 001 Mar 21, 2013 Mar NEWA

+ 10% N203510 002 Mar 21, 2013 Mar NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

@ HOSPIRA 50MG/ML A089744 001 Dec 18, 1987 Mar DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 15MG BASE	A200044 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A200044 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A200044 003	Feb 13, 2013	Jan	NEWA
AB	AUROBINDO PHARMA LTD	EQ 15MG BASE	A200268 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A200268 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A200268 003	Feb 13, 2013	Jan	NEWA
AB	DR REDDYS LABS LTD	EQ 15MG BASE	A078383 001	Mar 12, 2013	Mar	NEWA
AB		EQ 30MG BASE	A078383 002	Mar 12, 2013	Mar	NEWA
AB		EQ 45MG BASE	A078383 003	Mar 12, 2013	Mar	NEWA
AB	MACLEODS PHARMS LTD	EQ 15MG BASE	A202467 001	Feb 06, 2013	Jan	NEWA
AB		EQ 30MG BASE	A202467 002	Feb 06, 2013	Jan	NEWA
AB		EQ 45MG BASE	A202467 003	Feb 06, 2013	Jan	NEWA
AB	SANDOZ	EQ 15MG BASE	A078670 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A078670 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A078670 003	Feb 13, 2013	Jan	NEWA
AB	SYNTHON PHARMS	EQ 15MG BASE	A078472 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A078472 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A078472 003	Feb 13, 2013	Jan	NEWA
AB	TORRENT PHARMS LTD	EQ 15MG BASE	A091298 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A091298 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A091298 003	Feb 13, 2013	Jan	NEWA
AB	ZYDUS PHARMS USA INC	EQ 15MG BASE	A202456 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A202456 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A202456 003	Feb 13, 2013	Jan	NEWA

POLYMYXIN B SULFATE

POWDER; FOR RX COMPOUNDING

POLY-RX

@ X GEN PHARMS 100,000,000 UNITS/BOT A061578 001 Mar DISC

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

CELGENE 1MG N204026 001 Feb 08, 2013 Feb NEWA

2MG N204026 002 Feb 08, 2013 Feb NEWA

CAPSULE; ORAL

POMALYST

	CELGENE	3MG	N204026 003	Feb 08, 2013	Feb	NEWA
+		4MG	N204026 004	Feb 08, 2013	Feb	NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB	AMNEAL PHARMS	10MEQ	A202128 001	Feb 22, 2013	Feb	NEWA
----	---------------	-------	-------------	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS GRP PTC	0.125MG	A091254 001	Nov 30, 2010	Mar	CAHN
AB		0.25MG	A091254 002	Nov 30, 2010	Mar	CAHN
AB		0.5MG	A091254 003	Nov 30, 2010	Mar	CAHN
AB		0.75MG	A091254 004	Nov 30, 2010	Mar	CAHN
AB		1MG	A091254 005	Nov 30, 2010	Mar	CAHN
AB		1.5MG	A091254 006	Nov 30, 2010	Mar	CAHN
AB	SUN PHARM INDS INC	0.125MG	A091683 001	Mar 27, 2013	Mar	NEWA
AB		0.25MG	A091683 002	Mar 27, 2013	Mar	NEWA
AB		0.5MG	A091683 003	Mar 27, 2013	Mar	NEWA
AB		0.75MG	A091683 004	Mar 27, 2013	Mar	NEWA
AB		1MG	A091683 005	Mar 27, 2013	Mar	NEWA
AB		1.5MG	A091683 006	Mar 27, 2013	Mar	NEWA

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMILIN

	AMYLIN PHARMS	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332 002	Sep 25, 2007	Jan	CAHN
		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332 003	Sep 25, 2007	Jan	CAHN
+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332 001	Mar 16, 2005	Jan	CAHN

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

	@ APOTEX INC	5MG/5ML	A040570 001	Aug 25, 2005	Apr	DISC
	@	15MG/5ML	A040571 001	Aug 25, 2005	Apr	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

>A>	AA	+	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117 001	Dec 14, 2000	May	CAHN
>D>	AA	+	SHIONOGI INC	EQ 15MG BASE/5ML	A075117 001	Dec 14, 2000	May	CAHN
			PREDNISOLONE SODIUM PHOSPHATE					
>D>	AA		NESHER PHARMS	EQ 15MG BASE/5ML	A076988 001	May 24, 2005	May	DISC
>A>		@		EQ 15MG BASE/5ML	A076988 001	May 24, 2005	May	DISC
		@	PHARM ASSOC	EQ 5MG BASE/5ML	A076123 001	Dec 23, 2002	Mar	DISC
		@	WE PHARMS	EQ 15MG BASE/5ML	A075250 001	Jul 12, 2002	Mar	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

>A>	AB		CONCORDIA PHARMS INC	EQ 10MG BASE	N021959 001	Jun 01, 2006	May	CAHN
>A>	AB			EQ 15MG BASE	N021959 002	Jun 01, 2006	May	CAHN
>A>	AB	+		EQ 30MG BASE	N021959 003	Jun 01, 2006	May	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
ORAPRED ODT

>D>	AB	SHIONOGI INC	EQ 10MG BASE	N021959 001	Jun 01, 2006	May	CAHN
	AB		EQ 10MG BASE	N021959 001	Jun 01, 2006	Mar	CFTG
>D>	AB		EQ 15MG BASE	N021959 002	Jun 01, 2006	May	CAHN
	AB		EQ 15MG BASE	N021959 002	Jun 01, 2006	Mar	CFTG
>D>	AB	+	EQ 30MG BASE	N021959 003	Jun 01, 2006	May	CAHN
	AB	+	EQ 30MG BASE	N021959 003	Jun 01, 2006	Mar	CFTG

PREDNISOLONE SODIUM PHOSPHATE

AB	MYLAN PHARMS INC	EQ 10MG BASE	A202179 001	Apr 10, 2013	Mar	NEWA
AB		EQ 15MG BASE	A202179 002	Apr 10, 2013	Mar	NEWA
AB		EQ 30MG BASE	A202179 003	Apr 10, 2013	Mar	NEWA

PREDNISONE

TABLET; ORAL
PREDNISONE

>A>	AB	HIKMA PHARMS	1MG	A040890 001	Nov 01, 2010	May	CAHN
>A>	AB		2.5MG	A040538 001	Jan 08, 2004	May	CAHN
>A>	AB		5MG	A080292 001		May	CAHN
>A>	AB		10MG	A088832 001	Dec 04, 1985	May	CAHN
>A>	AB		20MG	A083677 001		May	CAHN
>A>	AB		50MG	A088465 001	Jun 01, 1984	May	CAHN
>D>	AB	WEST WARD	2.5MG	A040538 001	Jan 08, 2004	May	CAHN
>D>	AB		5MG	A080292 001		May	CAHN
>D>	AB		10MG	A088832 001	Dec 04, 1985	May	CAHN
>D>	AB		20MG	A083677 001		May	CAHN
>D>	AB	WEST WARD PHARM CORP	1MG	A040890 001	Nov 01, 2010	May	CAHN
>D>	AB		50MG	A088465 001	Jun 01, 1984	May	CAHN

PRIMIDONE

TABLET; ORAL
PRIMIDONE

@ DR REDDYS LABS LTD	50MG	A040862 001	Oct 03, 2008	Apr	DISC
@	250MG	A040862 002	Oct 03, 2008	Apr	DISC

PROBENECID

TABLET; ORAL
PROBENECID

>D>	AB	IVAX SUB TEVA PHARMS	500MG	A083740 001	May 09, 1984	May	DISC
>A>	@		500MG	A083740 001	May 09, 1984	May	DISC

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

>D>	AB	ABBOTT LABS	100MG	N019781 001	May 14, 1998	May	CAHN
>D>	AB	+	200MG	N019781 002	Oct 15, 1999	May	CAHN
>D>	@		300MG	N019781 003	Oct 15, 1999	May	CAHN
>A>	AB	ABBVIE INC	100MG	N019781 001	May 14, 1998	May	CAHN
>A>	AB	+	200MG	N019781 002	Oct 15, 1999	May	CAHN
>A>	@		300MG	N019781 003	Oct 15, 1999	May	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HYDROCHLORIDE

AP	+	TEVA PHARMS USA	25MG/ML	A040454 001	Aug 22, 2002	Mar	CAHN
AP	+		50MG/ML	A040454 002	Aug 22, 2002	Mar	CAHN

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

>A>	AA	CARACO	6.25MG/5ML	A040891	001	Mar 13, 2009	May	CAHN
>D>	AA	SUN PHARM INDS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	May	CAHN

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

>A>	AB	CARACO	12.5MG	A040863	001	Dec 30, 2008	May	CAHN
>A>	AB		25MG	A040863	002	Dec 30, 2008	May	CAHN
>A>	AB		50MG	A040863	003	Dec 30, 2008	May	CAHN
>D>	AB	SUN PHARM INDS INC	12.5MG	A040863	001	Dec 30, 2008	May	CAHN
>D>	AB		25MG	A040863	002	Dec 30, 2008	May	CAHN
>D>	AB		50MG	A040863	003	Dec 30, 2008	May	CAHN

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

AB	TEVA PHARMS USA	10MG/ML	A075102	001	Jan 04, 1999	Mar	CAHN
----	-----------------	---------	---------	-----	--------------	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	GLATT AIR	60MG	A078065	001	Jan 26, 2007	Feb	CAHN
AB		80MG	A078065	002	Jan 26, 2007	Feb	CAHN
AB		120MG	A078065	003	Jan 26, 2007	Feb	CAHN
AB		160MG	A078065	004	Jan 26, 2007	Feb	CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

@	TEVA WOMENS	5MG	N016012	001		Mar	CAHN
@		10MG	N016012	002		Mar	CAHN

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+	AMEDRA PHARMS	25MG	N008578	001		Apr	CAHN
---	---------------	------	---------	-----	--	-----	------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	EQ 25MG BASE	A202152	001	Mar 27, 2012	Apr	CAHN	
AB		EQ 50MG BASE	A202152	002	Mar 27, 2012	Apr	CAHN	
AB		EQ 100MG BASE	A202152	003	Mar 27, 2012	Apr	CAHN	
AB		EQ 200MG BASE	A202152	004	Mar 27, 2012	Apr	CAHN	
AB		EQ 300MG BASE	A202152	005	Mar 27, 2012	Apr	CAHN	
AB		EQ 400MG BASE	A202152	006	Mar 27, 2012	Apr	CAHN	
>A>	AB	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	May	CAHN
>A>	AB		EQ 50MG BASE	A201762	002	Feb 27, 2013	May	CAHN
>A>	AB		EQ 100MG BASE	A201762	003	Feb 27, 2013	May	CAHN
>A>	AB		EQ 150MG BASE	A201762	004	Feb 27, 2013	May	CAHN
>A>	AB		EQ 200MG BASE	A201762	005	Feb 27, 2013	May	CAHN
>A>	AB		EQ 300MG BASE	A201762	006	Feb 27, 2013	May	CAHN
>A>	AB		EQ 400MG BASE	A201762	007	Feb 27, 2013	May	CAHN
>D>	AB	ACTAVIS PHARMA	EQ 25MG BASE	A201762	001	Feb 27, 2013	May	CAHN
	AB		EQ 25MG BASE	A201762	001	Feb 27, 2013	Feb	NEWA
>D>	AB		EQ 50MG BASE	A201762	002	Feb 27, 2013	May	CAHN

TABLET; ORAL

QUETIAPINE FUMARATE

	AB	ACTAVIS PHARMA	EQ 50MG BASE	A201762 002	Feb 27, 2013	Feb	NEWA
>D>	AB		EQ 100MG BASE	A201762 003	Feb 27, 2013	May	CAHN
	AB		EQ 100MG BASE	A201762 003	Feb 27, 2013	Feb	NEWA
>D>	AB		EQ 150MG BASE	A201762 004	Feb 27, 2013	May	CAHN
	AB		EQ 150MG BASE	A201762 004	Feb 27, 2013	Feb	NEWA
>D>	AB		EQ 200MG BASE	A201762 005	Feb 27, 2013	May	CAHN
	AB		EQ 200MG BASE	A201762 005	Feb 27, 2013	Feb	NEWA
>D>	AB		EQ 300MG BASE	A201762 006	Feb 27, 2013	May	CAHN
	AB		EQ 300MG BASE	A201762 006	Feb 27, 2013	Feb	NEWA
>D>	AB		EQ 400MG BASE	A201762 007	Feb 27, 2013	May	CAHN
	AB		EQ 400MG BASE	A201762 007	Feb 27, 2013	Feb	NEWA
	AB	ALKEM LABS LTD	EQ 25MG BASE	A201504 001	Feb 12, 2013	Jan	NEWA
	AB		EQ 50MG BASE	A201504 002	Feb 12, 2013	Jan	NEWA
	AB		EQ 100MG BASE	A201504 003	Feb 12, 2013	Jan	NEWA
	AB		EQ 150MG BASE	A201504 004	Feb 12, 2013	Jan	NEWA
	AB		EQ 200MG BASE	A201504 005	Feb 12, 2013	Jan	NEWA
	AB		EQ 300MG BASE	A201504 006	Feb 12, 2013	Jan	NEWA
	AB		EQ 400MG BASE	A201504 007	Feb 12, 2013	Jan	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	@ APOTEX INC	EQ 5MG BASE	A076240 001	Jan 26, 2006	Mar	DISC
	@	EQ 10MG BASE	A076240 002	Jan 26, 2006	Mar	DISC
	@	EQ 20MG BASE	A076240 003	Jan 26, 2006	Mar	DISC
	@	EQ 40MG BASE	A076240 004	Jan 26, 2006	Mar	DISC
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A202725 001	Apr 29, 2013	Apr	NEWA
AB		EQ 10MG BASE	A202725 002	Apr 29, 2013	Apr	NEWA
AB		EQ 20MG BASE	A202725 003	Apr 29, 2013	Apr	NEWA
AB		EQ 40MG BASE	A202725 004	Apr 29, 2013	Apr	NEWA

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

	EISAI INC	5MG	N204736 001	Mar 26, 2013	Mar	NEWA
	+	10MG	N204736 002	Mar 26, 2013	Mar	NEWA

>A> RADIUM RA-223 DICHLORIDE

>A> SOLUTION; INTRAVENOUS

>A> XOFIGO

>A>	+	BAYER HLTHCARE	162MCI/6ML (27MCI/ML)	N203971 001	May 15, 2013	May	NEWA
-----	---	----------------	-----------------------	-------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	25MG/ML	A091534 001	Feb 22, 2013	Feb	NEWA
----	----------------------	---------	-------------	--------------	-----	------

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

	@ APOTEX INC	EQ 15MG BASE/ML	A077602 001	Sep 17, 2007	Apr	DISC
AA	BIO PHARM INC	EQ 15MG BASE/ML	A090102 001	May 26, 2009	Apr	CAHN
AA	CARACO	EQ 15MG BASE/ML	A091091 001	Sep 20, 2011	Apr	CAHN

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

	@ WATSON LABS	EQ 150MG BASE	A074864 001	Oct 20, 1997	Jan	DISC
--	---------------	---------------	-------------	--------------	-----	------

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@ WATSON LABS	EQ 300MG BASE	A074864 002	Oct 20, 1997	Jan	DISC
@ WATSON LABS INC	EQ 150MG BASE	A077426 001	Dec 19, 2005	Mar	DISC
@	EQ 300MG BASE	A077426 002	Dec 19, 2005	Mar	DISC

RESERPINE

TABLET; ORAL

>D>	SERPALAN				
>D>	BP LANNETT	0.1MG	N010124 001	May	DISC
>A>	@	0.1MG	N010124 001	May	DISC
>D>	BP	0.25MG	N010124 002	May	DISC
>A>	@	0.25MG	N010124 002	May	DISC

RILUZOLE

TABLET; ORAL

RILUTEK

AB +	COVIS PHARMA SARL	50MG	N020599 001	Dec 12, 1995	Apr CAHN
------	-------------------	------	-------------	--------------	----------

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

@ COREPHARMA	100MG	A075916 001	Nov 02, 2001	Feb	DISC
--------------	-------	-------------	--------------	-----	------

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

>A>	AA	BIO PHARM INC	1MG/ML	A078909 001	Jul 29, 2009	May CAHN
>D>	AA	DR REDDYS LABS LTD	1MG/ML	A078909 001	Jul 29, 2009	May CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	MYLAN PHARMS INC	0.25MG	A091537 006	Feb 12, 2013	Feb NEWA
AB	PAR PHARM	0.25MG	A077494 001	Apr 30, 2009	Feb CTEC
AB	SUN PHARM INDS LTD	0.5MG	A078464 001	Apr 08, 2013	Mar NEWA
AB		1MG	A078464 002	Apr 08, 2013	Mar NEWA
AB		2MG	A078464 003	Apr 08, 2013	Mar NEWA
AB		3MG	A078464 004	Apr 08, 2013	Mar NEWA
AB		4MG	A078464 005	Apr 08, 2013	Mar NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB	APOTEX INC	EQ 1.5MG BASE	A091072 001	May 16, 2013	Apr NEWA
AB		EQ 3MG BASE	A091072 002	May 16, 2013	Apr NEWA
AB		EQ 4.5MG BASE	A091072 003	May 16, 2013	Apr NEWA
AB		EQ 6MG BASE	A091072 004	May 16, 2013	Apr NEWA

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

AB	CIPLA LTD	EQ 5MG BASE	A077526 001	Mar 26, 2013	Mar NEWA
AB		EQ 10MG BASE	A077526 002	Mar 26, 2013	Mar NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

		@ ORGANON USA INC	10MG/ML (10MG/ML)	N020214	002	Mar 17, 1994	Jan	CAHN
AP	+		50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Jan	CAHN
AP	+		100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Jan	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

AB	+	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Mar	CAHN
AB			EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Mar	CAHN
AB			EQ 1MG BASE	N020658	003	Sep 19, 1997	Mar	CAHN
AB			EQ 2MG BASE	N020658	004	Sep 19, 1997	Mar	CAHN
AB			EQ 3MG BASE	N020658	006	Jan 27, 1999	Mar	CAHN
AB			EQ 4MG BASE	N020658	007	Jan 27, 1999	Mar	CAHN
AB			EQ 5MG BASE	N020658	005	Sep 19, 1997	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB	+	GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Mar	CAHN
		@	EQ 3MG BASE	N022008	002	Jun 13, 2008	Mar	CAHN
AB			EQ 4MG BASE	N022008	003	Jun 13, 2008	Mar	CAHN
AB			EQ 6MG BASE	N022008	006	Apr 10, 2009	Mar	CAHN
AB			EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar	CAHN
AB			EQ 12MG BASE	N022008	005	Oct 31, 2008	Mar	CAHN

ROPINIROLE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 2MG BASE	A090869	001	May 17, 2012	Apr	CAHN
AB			EQ 4MG BASE	A090869	002	May 17, 2012	Apr	CAHN
AB			EQ 6MG BASE	A090869	003	May 17, 2012	Apr	CAHN
AB			EQ 8MG BASE	A090869	004	May 17, 2012	Apr	CAHN
AB			EQ 12MG BASE	A090869	005	May 17, 2012	Apr	CAHN
AB		ALEMBIC LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	Apr	NEWA
AB			EQ 4MG BASE	A202786	002	Apr 22, 2013	Apr	NEWA
AB			EQ 6MG BASE	A202786	003	Apr 22, 2013	Apr	NEWA
AB			EQ 8MG BASE	A202786	004	Apr 22, 2013	Apr	NEWA
AB			EQ 12MG BASE	A202786	005	Apr 22, 2013	Apr	NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

AB		SB PHARMCO	EQ 2MG BASE	N021071	002	May 25, 1999	Jan	CFTG
AB			EQ 4MG BASE	N021071	003	May 25, 1999	Jan	CFTG
AB	+		EQ 8MG BASE	N021071	004	May 25, 1999	Jan	CFTG

ROSIGLITAZONE MALEATE

AB		TEVA	EQ 2MG BASE	A076747	001	Jan 25, 2013	Jan	NEWA
AB			EQ 4MG BASE	A076747	002	Jan 25, 2013	Jan	NEWA
AB			EQ 8MG BASE	A076747	003	Jan 25, 2013	Jan	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

>D>		UCB INC	2MG/24HR	N021829	001	May 09, 2007	May	CRLD
>A>	+		2MG/24HR	N021829	001	May 09, 2007	May	CRLD
>D>	+		8MG/24HR	N021829	006	Apr 02, 2012	May	CRLD
>A>			8MG/24HR	N021829	006	Apr 02, 2012	May	CRLD

SAQUINAVIR MESYLATE

TABLET; ORAL
INVIRASE

+ HOFFMAN LA ROCHE EQ 500MG BASE N021785 001 Dec 17, 2004 Feb CAHN

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HYDROCHLORIDE
@ DAVA PHARMS INC 5MG

A074641 001 Aug 02, 1996 Jan DISC

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

@ DR REDDYS LABS LTD EQ 25MG BASE
@ EQ 50MG BASE
@ EQ 100MG BASE

A076442 001 Apr 30, 2007 Apr DISC

A076442 002 Apr 30, 2007 Apr DISC

A076442 003 Apr 30, 2007 Apr DISC

SILDENAFIL CITRATE

TABLET; ORAL
SILDENAFIL CITRATE

AB ACTAVIS GRP PTC EQ 20MG BASE
AB ACTAVIS PHARMA EQ 20MG BASE
AB AMNEAL PHARMS EQ 20MG BASE

A200149 001 Feb 25, 2013 Apr CAHN

A200149 001 Feb 25, 2013 Feb NEWA

A202025 001 Feb 28, 2013 Feb NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%
MEDEFIL INC

18MG/2ML (9MG/ML)
22.5MG/2.5ML (9MG/ML)
27MG/3ML (9MG/ML)
45MG/5ML (9MG/ML)
90MG/10ML (9MG/ML)

N202832 002 Jan 06, 2012 Mar NEWA

N202832 003 Jan 06, 2012 Mar NEWA

N202832 004 Jan 06, 2012 Mar NEWA

N202832 005 Jan 06, 2012 Mar NEWA

N202832 006 Jan 06, 2012 Mar NEWA

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
MEDEFIL INC 9MG/ML (9MG/ML)

N202832 001 Jan 06, 2012 Mar CPOT

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
@ BAXTER HLTHCARE 450MG/100ML

N017864 001 Jan DISC

SODIUM PHENYLBUTYRATE

POWDER; ORAL
BUPHENYL

AB + MEDICIS 3GM/TEASPOONFUL
SODIUM PHENYLBUTYRATE
AB SIGMAPHARM LABS LLC 3GM/TEASPOONFUL

N020573 001 Apr 30, 1996 Mar CFTG

A202819 001 Mar 22, 2013 Mar NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KAYEXALATE

AA + COVIS PHARMA SARL 453.6GM/BOT

N011287 001 Apr CAHN

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
@ ROXANE 15GM/60ML

A089049 001 Nov 17, 1986 Mar DISC

STAVUDINE

CAPSULE; ORAL

STAVUDINE

AB	HETERO LABS LTD III	15MG	A078957 001	Dec 29, 2008	Apr	CAHN
AB		20MG	A078957 002	Dec 29, 2008	Apr	CAHN
AB		30MG	A078957 003	Dec 29, 2008	Apr	CAHN
AB		40MG	A078957 004	Dec 29, 2008	Apr	CAHN

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

+	TEVA PHARMS USA	1GM/VIAL	N050577 001	May 07, 1982	Apr	CAHN
---	-----------------	----------	-------------	--------------	-----	------

SUCCIMER

CAPSULE; ORAL

CHEMET

>D>	+	LUNDBECK LLC	100MG	N019998 002	Jan 30, 1991	May	CAHN
>A>	+	RECORDATI RARE	100MG	N019998 002	Jan 30, 1991	May	CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARON

AB	+	VALEANT BERMUDA	10%	N019931 001	Dec 23, 1996	Feb	CAHN
----	---	-----------------	-----	-------------	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

+	TEVA PHARMS USA	80MG/ML;16MG/ML	A073303 001	Oct 31, 1991	Mar	CAHN
---	-----------------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

SULFAMETHOPRIM

@ NOVEL LABS INC	400MG;80MG	A070022 001	Feb 15, 1985	Mar	DISC
------------------	------------	-------------	--------------	-----	------

SULFAMETHOPRIM-DS

@ NOVEL LABS INC	800MG;160MG	A070032 001	Feb 15, 1985	Mar	DISC
------------------	-------------	-------------	--------------	-----	------

SULINDAC

TABLET; ORAL

SULINDAC

AB	HERITAGE PHARMS INC	150MG	A073262 002	Sep 06, 1991	Apr	CMFD
AB		200MG	A073262 001	Sep 06, 1991	Apr	CMFD

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP	AUROBINDO PHARMA LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758 001	Apr 23, 2013	Apr	NEWA
AP	SAGENT AGILA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641 001	Jul 28, 2010	Feb	CAHN
AP	TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907 001	Feb 06, 2009	Mar	CAHN

SYSTEM; IONTOPHORESIS

ZECUITY

+	NUPATHE	EQ 6.5MG BASE/4HR	N202278 001	Jan 17, 2013	Jan	NEWA
---	---------	-------------------	-------------	--------------	-----	------

TABLET; ORAL

SUMATRIPTAN SUCCINATE

>A>	AB	HIKMA PHARMS	EQ 25MG BASE	A078298 001	May 21, 2013	May	NEWA
>A>	AB		EQ 50MG BASE	A078298 002	May 21, 2013	May	NEWA

		TABLET; ORAL			
		SUMATRIPTAN SUCCINATE			
>A>	AB	HIKMA PHARMS	EQ 100MG BASE	A078298 003	May 21, 2013 May NEWA
<u>TAMSULOSIN HYDROCHLORIDE</u>					
		CAPSULE; ORAL			
		TAMSULOSIN HYDROCHLORIDE			
	AB	AUROBINDO PHARMA LTD	0.4MG	A202433 001	Apr 30, 2013 Apr NEWA
<u>TECHNETIUM TC-99M TILMANOCEPT</u>					
		INJECTABLE; INJECTION			
		LYMPHOSEEK KIT			
	+	NAVIDEA BIOPHARMS	N/A	N202207 001	Mar 13, 2013 Mar NEWA
<u>TENIPOSIDE</u>					
		INJECTABLE; INJECTION			
		VUMON			
	+	CORDEN PHARMA	10MG/ML	N020119 001	Jul 14, 1992 Apr CAHN
<u>TERBUTALINE SULFATE</u>					
		INJECTABLE; INJECTION			
		TERBUTALINE SULFATE			
	@	TEVA PHARMS USA	1MG/ML	A076853 001	Jul 20, 2004 Mar CAHN
<u>TESTOSTERONE</u>					
		GEL; TRANSDERMAL			
		TESTOSTERONE			
		PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098 002	Jan 31, 2013 Jan NEWA
			50MG/5GM PACKET	N203098 003	Jan 31, 2013 Jan NEWA
		GEL, METERED; TRANSDERMAL			
		TESTOSTERONE			
		PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098 001	Jan 31, 2013 Jan NEWA
<u>TESTOSTERONE CYPIONATE</u>					
		INJECTABLE; INJECTION			
		TESTOSTERONE CYPIONATE			
>A>	AO	SUN PHARM INDS LTD	100MG/ML	A201720 001	Jun 03, 2013 May NEWA
>A>	AO		200MG/ML	A201720 002	Jun 03, 2013 May NEWA
<u>TESTOSTERONE ENANTHATE</u>					
		INJECTABLE; INJECTION			
		DELATESTRYL			
AO	+	ENDO PHARMS	200MG/ML	N009165 003	Jan CAHN
	@		200MG/ML	N009165 001	Jan CAHN
<u>THEOPHYLLINE</u>					
		TABLET, EXTENDED RELEASE; ORAL			
		THEOPHYLLINE			
AB	+	TEVA PHARMS	450MG	A081236 001	Nov 09, 1992 Mar CAHN
<u>THIABENDAZOLE</u>					
		SUSPENSION; ORAL			
		MINTEZOL			
>D>	@	MERCK	500MG/5ML	N016097 001	May CAHN
>A>	@	MERCK SHARP DOHME	500MG/5ML	N016097 001	May CAHN

TABLET, CHEWABLE; ORAL

MINTEZOL

>D>	@ MERCK	500MG	N016096 001	May	CAHN
>A>	@ MERCK SHARP DOHME	500MG	N016096 001	May	CAHN

THIOGUANINE

TABLET; ORAL

THIOGUANINE

+	ASPEN GLOBAL INC	40MG	N012429 001	Mar	CAHN
---	------------------	------	-------------	-----	------

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

ISTALOL

>A>	BT	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516 001	Jun 04, 2004	May	CAHN
>D>	BT	+	ISTA PHARMS	EQ 0.5% BASE	N021516 001	Jun 04, 2004	May	CAHN

TIMOLOL MALEATE

@	APOTEX INC	EQ 0.25% BASE	A075411 001	Sep 08, 2000	Apr	DISC
@		EQ 0.5% BASE	A075412 001	Sep 08, 2000	Apr	DISC

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOPTIC-XE

AB	+	VALEANT PHARMS LLC	EQ 0.25% BASE	N020330 001	Nov 04, 1993	Jan	CAHN
AB	+		EQ 0.5% BASE	N020330 002	Nov 04, 1993	Jan	CAHN

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

>D>	AB		MYLAN LABS	EQ 2MG BASE	A091502 001	Nov 09, 2012	May	CAHN
>D>	AB			EQ 4MG BASE	A091502 002	Nov 09, 2012	May	CAHN
>D>	AB			EQ 6MG BASE	A091502 003	Nov 09, 2012	May	CAHN
>A>	AB		MYLAN PHARMS INC	EQ 2MG BASE	A091502 001	Nov 09, 2012	May	CAHN
>A>	AB			EQ 4MG BASE	A091502 002	Nov 09, 2012	May	CAHN
>A>	AB			EQ 6MG BASE	A091502 003	Nov 09, 2012	May	CAHN

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

@	MYLAN PHARMS INC	EQ 2MG BASE	A076282 001	Dec 16, 2003	Feb	DISC
@		EQ 4MG BASE	A076282 002	Dec 16, 2003	Feb	DISC

TOBRAMYCIN

POWDER; INHALATION

TOBI PODHALER

+	NOVARTIS	28MG	N201688 001	Mar 22, 2013	Mar	NEWA
---	----------	------	-------------	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

@	APOTEX INC	0.3%	A065087 001	Feb 25, 2002	Apr	DISC
---	------------	------	-------------	--------------	-----	------

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

	MYLAN PHARMS INC	250MG	A070259 001	Jan 02, 1986	Mar	CTEC
+		500MG	A070259 003	Mar 17, 1986	Mar	CTEC
@	WATSON LABS	250MG	A070514 001	Jan 09, 1986	Mar	DISC
@		500MG	A070515 001	Jan 09, 1986	Mar	DISC

TOPIRAMATE

TABLET; ORAL

TOPAMAX

AB	JANSSEN PHARMS	25MG	N020505 004	Dec 24, 1996	Apr	CRLD
AB	+	100MG	N020505 001	Dec 24, 1996	Apr	CRLD
TOPIRAMATE						
AB	ACTIVIS TOTOWA LLC	25MG	A078637 001	Feb 27, 2013	Feb	NEWA
AB		50MG	A078637 002	Feb 27, 2013	Feb	NEWA
AB		100MG	A078637 003	Feb 27, 2013	Feb	NEWA
AB		200MG	A078637 004	Feb 27, 2013	Feb	NEWA
AB	UNICHEM LABS LTD	200MG	A090162 004	Feb 19, 2013	Feb	NEWA

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

>D>	+	GTX INC	EQ 60MG BASE	N020497 001	May 29, 1997	May	CAHN
>A>	+	PROSTRAKAN INC	EQ 60MG BASE	N020497 001	May 29, 1997	May	CAHN

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	HETERO LABS LTD III	5MG	A079234 001	Jan 27, 2009	Apr	CAHN
AB		10MG	A079234 002	Jan 27, 2009	Apr	CAHN
AB		20MG	A079234 003	Jan 27, 2009	Apr	CAHN
AB		100MG	A079234 004	Jan 27, 2009	Apr	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ACCORD HLTHCARE INC	50MG	A202390 001	May 16, 2013	Apr	NEWA
AB	CSPC OUYI PHARM CO	50MG	A091498 001	Mar 29, 2013	Mar	NEWA

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

@	PURDUE PHARMA	100MG	N021745 001	Dec 30, 2008	Jan	DISC
@		200MG	N021745 002	Dec 30, 2008	Jan	DISC
@		300MG	N021745 003	Dec 30, 2008	Jan	DISC

TRAMADOL HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	100MG	A091609 001	Jun 27, 2012	Apr	CAHN	
AB2		200MG	A091609 002	Jun 27, 2012	Apr	CAHN	
AB2		300MG	A091609 003	Jun 27, 2012	Apr	CAHN	
AB1	PAR PHARM INC	100MG	A078783 001	Nov 13, 2009	Feb	CRLD	
AB2	+	SUN PHARMA GLOBAL	100MG	A091607 001	Dec 30, 2011	Feb	CRLD

>A> TRAMETINIB DIMETHYL SULFOXIDE

>A> TABLET; ORAL

>A> MEKINIST

>A>	GLAXOSMITHKLINE LLC	EQ 0.5MG NON-SOLVATED PARENT	N204114 001	May 29, 2013	May	NEWA
>A>		EQ 1MG NON-SOLVATED PARENT	N204114 002	May 29, 2013	May	NEWA
>A>	+	EQ 2MG NON-SOLVATED PARENT	N204114 003	May 29, 2013	May	NEWA

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

@	DR REDDYS LABS LTD	1MG	A078493 001	Aug 25, 2008	Apr	DISC
---	--------------------	-----	-------------	--------------	-----	------

TABLET; ORAL

TRANDOLAPRIL

@ DR REDDYS LABS LTD

2MG

A078493 002 Aug 25, 2008 Apr DISC

@

4MG

A078493 003 Aug 25, 2008 Apr DISC

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVOPROST

PAR PHARM

0.004%

A091340 001 Mar 01, 2013 Feb NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB TEVA PHARMS USA

50MG

A071523 001 Dec 11, 1987 Mar CAHN

AB

100MG

A071524 001 Dec 11, 1987 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

>D> OLEPTRO

>D> + ANGELINI LLC

150MG

N022411 001 Feb 02, 2010 May DISC

>A> @

150MG

N022411 001 Feb 02, 2010 May DISC

>D>

300MG

N022411 002 Feb 02, 2010 May DISC

>A> @

300MG

N022411 002 Feb 02, 2010 May DISC

>A> TREPROSTINIL

>A> INJECTABLE; IV (INFUSION)-SC

>A> REMODULIN

>A> UNITED THERAP

1MG/ML

N021272 001 May 21, 2002 May CAIN

>A>

2.5MG/ML

N021272 002 May 21, 2002 May CAIN

>A>

5MG/ML

N021272 003 May 21, 2002 May CAIN

>A> SOLUTION; INHALATION

>A> TYVASO

>A> + UNITED THERAP

EQ 0.6MG BASE/ML

N022387 001 Jul 30, 2009 May CAIN

>D> TREPROSTINIL SODIUM

>D> INJECTABLE; IV (INFUSION)-SC

>D> REMODULIN

>D> UNITED THERAP

1MG/ML

N021272 001 May 21, 2002 May CAIN

>D>

2.5MG/ML

N021272 002 May 21, 2002 May CAIN

>D>

5MG/ML

N021272 003 May 21, 2002 May CAIN

>D> SOLUTION; INHALATION

>D> TYVASO

>D> + UNITED THERAP

EQ 0.6MG BASE/ML

N022387 001 Jul 30, 2009 May CAIN

TRETINOIN

GEL; TOPICAL

ATRALIN

+ DOW PHARM

0.05%

N022070 001 Jul 26, 2007 Apr CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

KENALOG

@ APOTHECON

0.025%

N011601 003

Apr DISC

@

0.1%

N011601 006

Apr DISC

TRIACET

@ TEVA

0.025%

A084908 001

Apr DISC

@

0.5%

A084908 003

Apr DISC

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	+	FOUGERA PHARMS	0.025%	A085692 001		Apr	CRLD
AT	+		0.1%	A085692 003		Apr	CRLD
>D>	AT	G AND W LABS	0.025%	A089797 001	May 31, 1991	May	DISC
>A>	@		0.025%	A089797 001	May 31, 1991	May	DISC
	@	TARO	0.025%	A086277 001		Apr	DISC
	@		0.1%	A086276 001		Apr	DISC
	@		0.5%	A086275 001		Apr	DISC

INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL

>D>		TRIVARIS					
>D>	+	ALLERGAN	8MG/0.1ML (8MG/0.1ML)	N022220 001	Jun 16, 2008	May	DISC
>A>	@		8MG/0.1ML (8MG/0.1ML)	N022220 001	Jun 16, 2008	May	DISC

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT		VERSAPHARM INC	0.025%	A202374 001	May 08, 2013	Apr	NEWA
AT			0.1%	A202374 002	May 08, 2013	Apr	NEWA
AT	+	WOCKHARDT EU OPERATN	0.025%	A088450 001	Apr 01, 1985	Apr	CAHN

OINTMENT; TOPICAL

KENALOG

@	APOTHECON	0.025%	N011600 003		Apr	DISC
@		0.1%	N011600 001		Apr	DISC

TRIAMCINOLONE ACETONIDE

>D>	AT	TARO	0.025%	A040374 001	Jun 05, 2001	May	DISC
>D>	AT		0.025%	A040040 001	Sep 30, 1994	May	DISC
>A>	@		0.025%	A040040 001	Sep 30, 1994	May	DISC
>A>	@		0.025%	A040374 001	Jun 05, 2001	May	DISC
>D>	AT		0.1%	A087902 001	Dec 27, 1982	May	DISC
>A>	@		0.1%	A087902 001	Dec 27, 1982	May	DISC
>D>	AT		0.5%	A040386 001	Jun 05, 2001	May	DISC
>A>	@		0.5%	A040386 001	Jun 05, 2001	May	DISC

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROSPIUM CHLORIDE

>A>	AB	PADDOCK LLC	60MG	A201291 001	May 24, 2013	May	NEWA
-----	----	-------------	------	-------------	--------------	-----	------

URSODIOL

TABLET; ORAL

URSODIOL

AB		PAR PHARM	250MG	A202540 001	Feb 14, 2013	Feb	NEWA
AB			500MG	A202540 002	Feb 14, 2013	Feb	NEWA
	@	TEVA PHARMS USA	250MG	A079184 001	May 13, 2009	Apr	DISC
	@		500MG	A079184 002	May 13, 2009	Apr	DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		ACTAVIS GRP PTC	EQ 500MG BASE	A090370 001	Mar 16, 2011	Mar	CAHN
AB			EQ 1GM BASE	A090370 002	Mar 16, 2011	Mar	CAHN

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

AB		SUN PHARM INDS LTD	250MG	A091037 001	Feb 22, 2013	Feb	NEWA
----	--	--------------------	-------	-------------	--------------	-----	------

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	TEVA PHARMS USA	10MG/VIAL	A074688 001	Aug 25, 1999	Apr	CAHN
AP		20MG/VIAL	A074688 002	Aug 25, 1999	Apr	CAHN

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

@ INTL MEDICATION 2.5MG/ML

A070451 001 Dec 16, 1985 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

>A>	AB	CARACO	120MG	A090529 001	Dec 30, 2011	May	CAHN
>A>	AB		180MG	A090529 002	Dec 30, 2011	May	CAHN
>A>	AB		240MG	A090529 003	Dec 30, 2011	May	CAHN
>D>	AB	SUN PHARM INDS INC	120MG	A090529 001	Dec 30, 2011	May	CAHN
>D>	AB		180MG	A090529 002	Dec 30, 2011	May	CAHN
>D>	AB		240MG	A090529 003	Dec 30, 2011	May	CAHN

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

+ VALEANT PHARMS INC 15MG/VIAL

N021119 001 Apr 12, 2000 Jan CAHN

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCRIStINE SULFATE PFS

AP	TEVA PHARMS USA	1MG/ML	A075493 001	Sep 01, 1999	Apr	CAHN
----	-----------------	--------	-------------	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

AP	TEVA PHARMS USA	EQ 10MG BASE/ML	A076028 001	Feb 03, 2003	Apr	CAHN
----	-----------------	-----------------	-------------	--------------	-----	------

VORICONAZOLE

FOR SUSPENSION; ORAL

VFEND

>D>	+	PFIZER	200MG/5ML	N021630 001	Dec 19, 2003	May	CFTG
>A>	AB	+	200MG/5ML	N021630 001	Dec 19, 2003	May	CFTG
>A>		VORICONAZOLE					
>A>	AB	MYLAN PHARMS INC	200MG/5ML	A202361 001	May 28, 2013	May	NEWA

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB	AMNEAL PHARMS	1MG	A202202 001	Mar 04, 2013	Feb	NEWA
AB		2MG	A202202 002	Mar 04, 2013	Feb	NEWA
AB		2.5MG	A202202 003	Mar 04, 2013	Feb	NEWA
AB		3MG	A202202 004	Mar 04, 2013	Feb	NEWA
AB		4MG	A202202 005	Mar 04, 2013	Feb	NEWA
AB		5MG	A202202 006	Mar 04, 2013	Feb	NEWA
AB		6MG	A202202 007	Mar 04, 2013	Feb	NEWA
AB		7.5MG	A202202 008	Mar 04, 2013	Feb	NEWA
AB		10MG	A202202 009	Mar 04, 2013	Feb	NEWA

ZALEPLONCAPSULE; ORAL
SONATA

AB	PFIZER	5MG	N020859	001	Aug 13, 1999	Apr	CAHN
AB	+	10MG	N020859	002	Aug 13, 1999	Apr	CAHN

ZIDOVUDINETABLET; ORAL
RETROVIR

	@ VIIIV HLTHCARE	300MG	N020518	002	Oct 04, 1996	Apr	DISC
	ZIDOVUDINE						
AB	HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	Feb	CMFD
	@	300MG	A202058	001	Oct 07, 2011	Jan	DISC
AB	+	HETERO LABS LTD III	A090092	001	Apr 25, 2008	Apr	CRLD

ZOLEDRONIC ACIDINJECTABLE; INJECTION
ZOLEDRONIC ACID

AP	DR REDDYS LABS LTD	EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar	NEWA
AP	EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar	NEWA

INJECTABLE; IV (INFUSION)
RECLAST

AP	+	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar	CTEC
		ZOLEDRONIC ACID						
AP		ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Feb	NEWA
AP		AGILA SPECLTS	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Feb	NEWA
AP		DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Feb	NEWA
AP		EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar	NEWA
>A>	AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	May	NEWA
	AP	HOSPIRA INC	EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar	NEWA
	AP	PHARMACEUTICS	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Feb	NEWA
	AP	PHARMS	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Apr	NEWA
		+	SUN PHARMA GLOBAL	A090018	001	Mar 04, 2013	Feb	NEWA
	AP		EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Feb	NEWA
		ZOMETA						
AP	+	NOVARTIS	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Feb	CFTG

ZOLMITRIPTANTABLET; ORAL
ZOLMITRIPTAN

AB	APOTEX INC	2.5MG	A202078	001	May 14, 2013	Apr	NEWA
AB		5MG	A202078	002	May 14, 2013	Apr	NEWA
AB	GLENMARK GENERICS	2.5MG	A201779	001	May 14, 2013	Apr	NEWA
AB		5MG	A201779	002	May 14, 2013	Apr	NEWA
AB	MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013	Apr	NEWA
AB		5MG	A203186	002	May 14, 2013	Apr	NEWA

ZOMIG

AB	IPR	2.5MG	N020768	001	Nov 25, 1997	Apr	CFTG
AB	+	5MG	N020768	002	Nov 25, 1997	Apr	CFTG

TABLET, ORALLY DISINTEGRATING; ORAL
ZOLMITRIPTAN

AB	APOTEX INC	2.5MG	A202476	001	May 14, 2013	Apr	NEWA
AB		5MG	A202476	002	May 14, 2013	Apr	NEWA
AB	GLENMARK GENERICS	2.5MG	A202560	001	May 14, 2013	Apr	NEWA
AB		5MG	A202560	002	May 14, 2013	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTAN

AB	ZYDUS PHARMS USA INC	2.5MG	A202890 001	May 15, 2013	Apr	NEWA
AB		5MG	A202890 002	May 15, 2013	Apr	NEWA

ZOMIG-ZMT

AB	ASTRAZENECA	2.5MG	N021231 001	Feb 13, 2001	Apr	CFTG
AB	+	5MG	N021231 002	Sep 17, 2001	Apr	CFTG

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@	DR REDDYS LABS LTD	5MG	A077985 001	Apr 23, 2007	Apr	DISC
@		10MG	A077985 002	Apr 23, 2007	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB	ACTAVIS ELIZABETH	6.25MG	A078179 002	Oct 13, 2010	Apr	CAHN
AB		12.5MG	A078179 001	Jun 06, 2011	Apr	CAHN
AB	WATSON LABS INC FL	6.25MG	A090153 001	Mar 25, 2013	Mar	NEWA
AB		12.5MG	A090153 002	Mar 25, 2013	Mar	NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

@	COREPHARMA	25MG	A077876 001	Feb 21, 2007	Feb	DISC
@		50MG	A077876 002	Feb 21, 2007	Feb	DISC
@		100MG	A077876 003	Feb 21, 2007	Feb	DISC
@	DR REDDYS LABS LTD	25MG	A077645 002	Sep 29, 2006	Mar	DISC
@		50MG	A077645 003	Sep 29, 2006	Mar	DISC
@		100MG	A077645 001	Dec 22, 2005	Mar	DISC

OTC DRUG PRODUCT LIST - 33RD EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

2-1

ASPIRIN

CAPSULE; ORAL

ASPIRIN

	+	PLX PHARMA	325MG	N203697	001	Jan 14, 2013	Jan	NEWA
--	---	------------	-------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	@	APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008	Apr	DISC
>A>		BIO PHARM INC	5MG/5ML	A090474	002	Mar 30, 2009	May	CAHN
>A>		CARACO	5MG/5ML	A091327	001	Oct 17, 2011	May	CAHN
>D>		DR REDDYS LABS LTD	5MG/5ML	A090474	002	Mar 30, 2009	May	CAHN
>D>		SUN PHARM INDS INC	5MG/5ML	A091327	001	Oct 17, 2011	May	CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	@	APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008	Apr	DISC
>A>		BIO PHARM INC	5MG/5ML	A090474	001	Mar 30, 2009	May	CAHN
>A>		CARACO	5MG/5ML	A091327	002	Oct 17, 2011	May	CAHN
>D>		DR REDDYS LABS LTD	5MG/5ML	A090474	001	Mar 30, 2009	May	CAHN
>D>		SUN PHARM INDS INC	5MG/5ML	A091327	002	Oct 17, 2011	May	CAHN

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

+	SANDOZ	10MG	A078692	002	Feb 14, 2008	Apr	CRLD
---	--------	------	---------	-----	--------------	-----	------

CHILDREN'S ZYRTEC ALLERGY

	@	MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Apr	DISC
+			5MG	N021621	003	Nov 16, 2007	Feb	CRLD
	@		10MG	N021621	004	Nov 16, 2007	Feb	DISC

CHILDREN'S ZYRTEC HIVES RELIEF

	@	MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Apr	DISC
+			5MG	N021621	005	Nov 16, 2007	Feb	CRLD
	@		10MG	N021621	006	Nov 16, 2007	Feb	DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

DYNA-HEX

	BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997	Apr	CAHN
--	-------------------	-------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

PREVANTICS MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CTNA
---	------------	-------------------	---------	-----	--------------	-----	------

PREVANTICS SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CTNA
---	------------	-----------------	---------	-----	--------------	-----	------

PREVANTICS SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CTNA
---	------------	-------------------	---------	-----	--------------	-----	------

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

	AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Feb	NEWA
--	-------------	-----------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD 30MG

A202978 001 Jan 18, 2013 Jan NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD 30MG

A202978 002 Jan 18, 2013 Jan NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

KETOTIFEN FUMARATE

@ APOTEX INC EQ 0.025% BASE

A077354 001 May 09, 2006 Apr DISC

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

LUPIN LTD 0.75MG

A091328 001 Jan 23, 2013 Jan NEWA

AB NOVEL LABS INC 1.5MG

A202508 001 Feb 22, 2013 Feb NEWA

PLAN B ONE-STEP

+ TEVA BRANDED PHARM 1.5MG

N021998 001 Jul 10, 2009 Apr CAHN

LORATADINE

SYRUP; ORAL

LORATADINE

@ APOTEX INC 1MG/ML

A075565 001 Oct 05, 2004 Apr DISC

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

@ WATSON LABS INC FL 5MG;120MG

A076208 001 Jan 28, 2004 Feb DISC

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE NITRATE

APHENA PHARMA MD 2%

A074366 001 Feb 22, 1996 Jan CAHN

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

@ APOTEX INC 2%

A074924 001 Apr 29, 1998 Apr DISC

MINOXIDIL (FOR WOMEN)

@ APOTEX INC 2%

A074924 002 Apr 29, 1998 Apr DISC

MINOXIDIL EXTRA STRENGTH (FOR MEN)

@ APOTEX INC 5%

A075839 001 Oct 01, 2001 Apr DISC

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC 0.025%;0.3%

A202795 001 Jan 24, 2013 Jan NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL FOR WOMEN

+ MSD CONSUMER 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

PAR PHARM

17GM/SCOOPFUL

A079214 001 Jan 31, 2013 Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@ WATSON LABS

EQ 75MG BASE

A075212 001 Jan 14, 2000 Mar DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2013

NO MAY 2013 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2013 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539	001	8399445	Aug 24, 2025	U-1373		
<u>ACYCLOVIR - SITAVIG</u>						
N203791	001				NP	Apr 12, 2016
<u>ADAPALENE - DIFFERIN</u>						
N022502	001	>A> 8435502	Sep 15, 2026	DP U-1078		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320	001				NPP	Feb 01, 2016
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271	001	6150383	Jun 19, 2016	U-1330	NCE	Jan 25, 2018
		6211205	Jun 19, 2016	U-1331		
		6303640	Aug 09, 2016	U-1332		
		6303661	Apr 24, 2017	U-1333		
		6329404	Jun 19, 2016	DP U-1334		
		6890898	Feb 02, 2019	U-1335		
		7078381	Feb 02, 2019	U-1335		
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Mar 15, 2025	DS		
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271	002	6150383	Jun 19, 2016	U-1330	NCE	Jan 25, 2018
		6211205	Jun 19, 2016	U-1331		
		6303640	Aug 09, 2016	U-1332		
		6303661	Apr 24, 2017	U-1333		
		6329404	Jun 19, 2016	DP U-1334		
		6890898	Feb 02, 2019	U-1335		
		7078381	Feb 02, 2019	U-1335		
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Mar 15, 2025	DS		
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271	003	6150383	Jun 19, 2016	U-1330	NCE	Jan 25, 2018
		6211205	Jun 19, 2016	U-1331		
		6303640	Aug 09, 2016	U-1332		
		6303661	Apr 24, 2017	U-1333		
		6329404	Jun 19, 2016	DP U-1334		
		6890898	Feb 02, 2019	U-1335		
		7078381	Feb 02, 2019	U-1335		
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Mar 15, 2025	DS		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N203414 001	5965584	Jun 19, 2016	U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N203414 002	5965584	Jun 19, 2016	U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 001	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 002	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 003	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 004	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 005	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 006	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 001	8349843	Oct 07, 2015	DS DP			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 002	8349843	Oct 07, 2015	DS DP			
<u>AMOXICILLIN - MOXATAG</u>						
N050813 001	8357394	Dec 08, 2026	DP			
<u>APIXABAN - ELIQUIS</u>						
N202155 001	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1200			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1200			
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N202971 001	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N202971 002	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N022117 001	>A> 5763476	Jun 09, 2020	DP U-326			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N022117 002	>A> 5763476	Jun 09, 2020	DP U-326			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N200153 001	>A> 5846966	Sep 21, 2013	DP U-1400		>A> NC	May 03, 2016
	>A> 5846966*PED	Mar 21, 2014				
	>A> RE42461	Oct 25, 2016	DS DP U-1400			
	>A> RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N200153 002	>A> 5846966	Sep 21, 2013	DP U-1400		>A> NC	May 03, 2016
	>A> 5846966*PED	Mar 21, 2014				
	>A> RE42461	Oct 25, 2016	DS DP U-1400			
	>A> RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N200153 003	>A> 5846966	Sep 21, 2013	DP U-1400		>A> NC	May 03, 2016
	>A> 5846966*PED	Mar 21, 2014				
	>A> RE42461	Oct 25, 2016	DS DP U-1400			
	>A> RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N200153 004	>A> 5846966	Sep 21, 2013	DP U-1400		>A> NC	May 03, 2016
	>A> 5846966*PED	Mar 21, 2014				
	>A> RE42461	Oct 25, 2016	DS DP U-1400			
	>A> RE42461*PED	Apr 25, 2017				
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002					>A> NCE	Feb 25, 2016
					>A> NC	Dec 20, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZTREONAM - CAYSTON</u>						
N050814 001	8399496	Dec 20, 2021	DP U-1377			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N204384 001	7498343	Oct 02, 2024	DS DP U-1321		ODE	Dec 28, 2019
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001	>A> 8436190	Oct 26, 2030	DP			
	>A> 8436190*PED	Apr 26, 2031				
	>A> 8445524	Mar 26, 2029	DS DP U-1402			
	>A> 8445524*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002	>A> 8436190	Oct 26, 2030	DP			
	>A> 8436190*PED	Apr 26, 2031				
	>A> 8445524	Mar 26, 2029	DS DP U-1402			
	>A> 8445524*PED	Sep 26, 2029				
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N022288 001	6780877	Sep 09, 2019	DS DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N022308 001	8415342	Nov 07, 2030	U-80			
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001					M-126 NPP	Feb 27, 2016 Feb 13, 2016
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N204251 001					NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8354409	Apr 19, 2022	DP U-1371			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N203168 001	8129431	Sep 11, 2025	DS DP		NP	Apr 05, 2016
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N020866 001	7888310	Jul 25, 2023	U-976			
	7888310	Jul 25, 2023	U-1379			
	8137992	Jul 25, 2023	U-1380			
	8137993	Jul 25, 2023	U-1379			
	8137994	Jul 25, 2023	U-1379			
	8431155	Apr 30, 2032	DP U-1379			
<u>BUDESONIDE - UCERIS</u>						
N203634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8387615	Nov 10, 2024	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8387615	Nov 10, 2024	DP			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 001					ODE	Nov 29, 2019

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756	002				ODE	Nov 29, 2019
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N021406	001	RE43580	Feb 02, 2021	DP U-227		
<u>CANAGLIFLOZIN - INVOKANA</u>						
N204042	001	7943582	Feb 26, 2029	DS DP U-493	NCE	Mar 29, 2018
		7943788	Jul 14, 2027	DS DP		
		8222219	Jul 30, 2024	U-493		
<u>CANAGLIFLOZIN - INVOKANA</u>						
N204042	002	7943582	Feb 26, 2029	DS DP U-493	NCE	Mar 29, 2018
		7943788	Jul 14, 2027	DS DP		
		8222219	Jul 30, 2024	U-493		
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A078702	001				>A> PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A078702	002				>A> PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A078702	003				>A> PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A078702	004				>A> PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE</u>						
A090704	003				PC	Jun 02, 2013
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N022556	001	8062667	Mar 29, 2029	DP		
<u>CELECOXIB - CELEBREX</u>						
N020998	001	RE44048	Jun 02, 2015	U-247		
		RE44048	Jun 02, 2015	U-1352		
		RE44048	Jun 02, 2015	U-1351		
		RE44048	Jun 02, 2015	U-1350		
		RE44048	Jun 02, 2015	U-1349		
		RE44048	Jun 02, 2015	U-1348		
		RE44048*PED	Dec 02, 2015			
<u>CELECOXIB - CELEBREX</u>						
N020998	002	RE44048	Jun 02, 2015	U-247		
		RE44048	Jun 02, 2015	U-1352		
		RE44048	Jun 02, 2015	U-1351		
		RE44048	Jun 02, 2015	U-1350		
		RE44048	Jun 02, 2015	U-1349		
		RE44048	Jun 02, 2015	U-1348		
		RE44048*PED	Dec 02, 2015			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N020998 003	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N020998 004	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 002	>A> 7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 005	>A> 7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 007	>A> 7422388	Apr 25, 2027	DP U-1397			
<u>CICLESONIDE - ALVESCO</u>						
N021658 002	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - ALVESCO</u>						
N021658 003	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - OMNARIS</u>						
N022004 001	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	8371292	Aug 25, 2027	U-1357			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N202535 001	>A> 8450338	Oct 10, 2028	DP			
<u>CLOBAZAM - ONFI</u>						
N203993 001					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A201402 001					PC	Jul 31, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N203100 001	>A> 5814639*PED	Mar 29, 2016				
	>A> 5914331*PED	Jan 02, 2018				
	>A> 5922695*PED	Jan 25, 2018				
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230*PED	Jan 25, 2018				
	>A> 6642245*PED	May 04, 2021				
	>A> 6703396*PED	Sep 09, 2021				
	7635704	Oct 26, 2026	DS DP U-257			
<u>COLCHICINE - COLCRYS</u>						
N202352 001	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	>A> 8440721	Feb 17, 2029	U-1007			
	>A> 8440722	Feb 17, 2029	U-1020			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N203389 001	>A> 8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	>A> 8129433	Jan 26, 2027	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N203389 002	>A> 8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	>A> 8129433	Jan 26, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N202806 001					>A> NCE	May 29, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N202806 002					>A> NCE	May 29, 2018
<u>DALFAMPRIDINE - AMPYRA</u>						
N022250 001	8354437	Dec 22, 2026	U-1030			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 006					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001					D-135 PED	Feb 01, 2016 Aug 01, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - EXJADE</u>						
N021882	001				I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N021882	002				I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N021882	003				I-665	Jan 23, 2016
<u>DESOXIMETASONE - TOPICORT</u>						
N204141	001				NDF	Apr 11, 2016
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992	001	6673838	Feb 11, 2022	DS DP U-860		
		6673838	Feb 11, 2022	DS DP U-1364		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992	002	6673838	Feb 11, 2022	DS DP U-860		
		6673838	Feb 11, 2022	DS DP U-1364		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N021038	001	4910214	Jul 15, 2013	DS DP U-421		
		4910214*PED	Jan 15, 2014			
		6716867	Mar 31, 2019	U-572		
		6716867*PED	Oct 01, 2019			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N021038	002	>A> 4910214	Jul 15, 2013	DS DP U-421		
		>A> 4910214*PED	Jan 15, 2014			
		>A> 6716867	Mar 31, 2019	U-572		
		6716867*PED	Oct 01, 2019			
		>A> 8242158	Jan 04, 2032	DP		
		>A> 8242158*PED	Jul 04, 2032			
		>A> 8338470	Jan 04, 2032	DP		
		>A> 8338470*PED	Jul 04, 2032			
		>A> 8455527	Jan 04, 2032	U-421		
		>A> 8455527*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N021038	003	>A> 4910214	Jul 15, 2013	DS DP U-421		
		>A> 4910214*PED	Jan 15, 2014			
		>A> 6716867	Mar 31, 2019	U-572		
		6716867*PED	Oct 01, 2019			
		>A> 8242158	Jan 04, 2032	DP		
		>A> 8242158*PED	Jul 04, 2032			
		>A> 8338470	Jan 04, 2032	DP		
		>A> 8338470*PED	Jul 04, 2032			
		>A> 8455527	Jan 04, 2032	U-421		
		>A> 8455527*PED	Jul 04, 2032			
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212	001	6114319	May 18, 2019	DP	I-653	Jun 13, 2015
		6114319*PED	Nov 18, 2019		M-127	Mar 22, 2016
					ODE	Jun 13, 2019
					PED	Dec 13, 2019
					PED	Sep 22, 2016
					PED	Dec 13, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	8394405	Dec 24, 2025	DP U-925			
	8394406	Dec 24, 2025	DP U-925			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 004 >A>	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 005 >A>	6958161	Dec 15, 2022	DP U-918		D-136 NS	Apr 11, 2016 Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N021876 001	6340695	Jun 21, 2021	DP U-1382		NP	Apr 08, 2016
	7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001 >A>	5223510	Jul 26, 2016	DS DP U-992			
	>A> 5223510	Jul 26, 2016	DS DP U-1261			
	8410167	Apr 16, 2029	U-1388			
	8410167	Apr 16, 2029	U-1387			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N021676 001	RE43916	Jun 30, 2014	U-1326			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N022532 001	RE43916	Jun 30, 2014	U-1326			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004					M-61 PED	Oct 18, 2015 Apr 18, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
EFAVIRENZ - SUSTIVA								
N020972 001	5519021	May	21, 2013	DS DP		>A> NPP	May	02, 2016
	5519021*PED	Nov	21, 2013			>A> PED	Nov	02, 2016
	5663169	Sep	02, 2014	U-257				
	5663169*PED	Mar	02, 2015					
	6238695	Apr	06, 2019	DP				
	6238695*PED	Oct	06, 2019					
	6555133	Apr	06, 2019	U-248				
	6555133*PED	Oct	06, 2019					
	6639071	Feb	14, 2018	DS				
	6639071*PED	Aug	14, 2018					
	6939964	Jan	20, 2018	DS				
	6939964*PED	Jul	20, 2018					
EFAVIRENZ - SUSTIVA								
N020972 002	5519021	May	21, 2013	DS DP				
	5519021*PED	Nov	21, 2013					
	5663169	Sep	02, 2014	U-257				
	5663169*PED	Mar	02, 2015					
	6238695	Apr	06, 2019	DP				
	6238695*PED	Oct	06, 2019					
	6555133	Apr	06, 2019	U-248				
	6555133*PED	Oct	06, 2019					
	6639071	Feb	14, 2018	DS				
	6639071*PED	Aug	14, 2018					
	6939964	Jan	20, 2018	DS				
	6939964*PED	Jul	20, 2018					
EFAVIRENZ - SUSTIVA								
N020972 003	5519021	May	21, 2013	DS DP		>A> NPP	May	02, 2016
	5519021*PED	Nov	21, 2013			>A> PED	Nov	02, 2016
	5663169	Sep	02, 2014	U-257				
	5663169*PED	Mar	02, 2015					
	6238695	Apr	06, 2019	DP				
	6238695*PED	Oct	06, 2019					
	6555133	Apr	06, 2019	U-248				
	6555133*PED	Oct	06, 2019					
	6639071	Feb	14, 2018	DS				
	6639071*PED	Aug	14, 2018					
	6939964	Jan	20, 2018	DS				
	6939964*PED	Jul	20, 2018					
EFAVIRENZ - SUSTIVA								
N021360 001	5519021	May	21, 2013					
	5519021*PED	Nov	21, 2013					
	5663169	Sep	02, 2014					
	5663169*PED	Mar	02, 2015					
	6639071	Feb	14, 2018	DS				
	6639071*PED	Aug	14, 2018					
	6939964	Jan	20, 2018	DS				
	6939964*PED	Jul	20, 2018					

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - SUSTIVA</u>						
N021360 002	5519021	May 21, 2013	DS DP		>A> NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			>A> PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-248			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	>A> 8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	>A> 8425462	Nov 23, 2024	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 001	8318802	Mar 15, 2027	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 002	8318802	Mar 15, 2027	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 001	>A> 6900221	Nov 09, 2020	DS DP U-875		>A> I-671	May 14, 2016
	>A> 6900221	Nov 09, 2020	DS DP U-659			
	>A> 6900221	Nov 09, 2020	DS DP U-1403			
	>A> 6900221	Nov 09, 2020	DS DP U-1046			
	>A> 7087613	Nov 09, 2020	U-659			
	>A> 7087613	Nov 09, 2020	U-1403			
	>A> 7087613	Nov 09, 2020	U-1045			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 002	>A> 6900221	Nov 09, 2020	DS DP U-875		>A> I-671	May 14, 2016
	>A> 6900221	Nov 09, 2020	DS DP U-659			
	>A> 6900221	Nov 09, 2020	DS DP U-1403			
	>A> 6900221	Nov 09, 2020	DS DP U-1046			
	>A> 7087613	Nov 09, 2020	U-659			
	>A> 7087613	Nov 09, 2020	U-1403			
	>A> 7087613	Nov 09, 2020	U-1045			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 003	>A> 6900221	Nov 09, 2020	DS DP U-875		>A> I-671	May 14, 2016
	>A> 6900221	Nov 09, 2020	DS DP U-659			
	>A> 6900221	Nov 09, 2020	DS DP U-1403			
	>A> 6900221	Nov 09, 2020	DS DP U-1046			
	>A> 7087613	Nov 09, 2020	U-659			
	>A> 7087613	Nov 09, 2020	U-1403			
	>A> 7087613	Nov 09, 2020	U-1045			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 001	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 002	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 003	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 004	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESZOPICLONE - LUNESTA</u>						
N021476	003				M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N204061	001	8415332	Mar 11, 2029	DP	NP	Mar 28, 2016
	>A>	8450299	Oct 07, 2025	U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N203667	001	>A> 5552394	Jul 22, 2014	U-1	>A> NDF	May 08, 2016
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N204426	001	5552394	Jul 22, 2014	U-1		
		6652880	Mar 29, 2020	DP		
<u>EVEROLIMUS - AFINITOR</u>						
N022334	001	8410131	May 22, 2025	DS DP U-1368		
		8410131*PED	Nov 22, 2025			
	>A>	8436010	Feb 22, 2022	DS DP U-1396		
	>A>	8436010*PED	Aug 22, 2022			
<u>EVEROLIMUS - AFINITOR</u>						
N022334	002	8410131	May 22, 2025	DS DP U-1368		
		8410131*PED	Nov 22, 2025			
	>A>	8436010	Feb 22, 2022	DS DP U-1396		
	>A>	8436010*PED	Aug 22, 2022			
<u>EVEROLIMUS - AFINITOR</u>						
N022334	003	8410131	May 22, 2025	DS DP U-1368		
		8410131*PED	Nov 22, 2025			
	>A>	8436010	Feb 22, 2022	DS DP U-1396		
	>A>	8436010*PED	Aug 22, 2022			
<u>EVEROLIMUS - AFINITOR</u>						
N022334	004	8410131	May 22, 2025	DS DP U-1368		
		8410131*PED	Nov 22, 2025			
	>A>	8436010	Feb 22, 2022	DS DP U-1396		
	>A>	8436010*PED	Aug 22, 2022			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560	001	5665772	Sep 09, 2019	DS DP U-1365	I-668	Feb 15, 2016
		5665772	Sep 09, 2019	DS DP U-1049		
		5665772*PED	Mar 09, 2020			
		6004973	Jul 12, 2016	DP U-1365		
		6004973	Jul 12, 2016	DP U-1049		
		6004973*PED	Jan 12, 2017			
		6440990	Sep 24, 2013	DP U-1365		
		6440990	Sep 24, 2013	DP U-1049		
		6440990*PED	Mar 24, 2014			
		6455518	Jul 29, 2017	U-1365		
		6455518	Jul 29, 2017	U-1049		
		6455518*PED	Jan 29, 2018			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1365		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1049			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1365			
	6004973	Jul 12, 2016	DP U-1049			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1365			
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1365			
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1365		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1049			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1365			
	6004973	Jul 12, 2016	DP U-1049			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1365			
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1365			
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	>A> 8431685	Apr 13, 2025	DP U-412			
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519 001	>A> 8449910	Jul 18, 2026	DP			
<u>FEBUXOSTAT - ULORIC</u>						
N021856 001	>A> 5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N021856 002	>A> 5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	8338478	May 11, 2019	DS DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	8338478	May 11, 2019	DS DP U-913			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	8347879	Apr 01, 2027	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N204275 001	>A> 5873360	Feb 23, 2016	DP			
	>A> 6537983	Aug 03, 2021	DP U-1401			
	>A> 6759398	Aug 03, 2021	DP U-1401			
	>A> 6878698	Aug 03, 2021	U-1401			
	>A> 7101866	Aug 03, 2021	DS DP U-1401			
	>A> 7361787	Mar 23, 2023	DS DP U-1401			
	>A> 7439393	Sep 11, 2022	DS DP U-1401			
	>A> 7629335	Aug 03, 2021	DP			
	>A> 7776895	Sep 11, 2022	DP			
	>A> 8113199	Oct 23, 2027	DP			
	>A> 8161968	Feb 05, 2028	DP			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 001	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 002	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 003	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 004	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>GABAPENTIN - GRALISE</u>						
N022544 001	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	8333992	Oct 25, 2022	DP U-1114			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	8394356	Feb 01, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	8394356	Feb 01, 2015	U-1112			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 004					NCE	Mar 20, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N022090 002					NCE	Jul 03, 2013
<u>GANIRELIX ACETATE - GANIRELIX ACETATE INJECTION</u>						
N021057 001	6653286	Jun 16, 2018	U-1354			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N020622 002	8367605	May 24, 2014	DS			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N203284 001	5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	8404215	Mar 09, 2032	U-1383		ODE	Feb 01, 2020
<u>GLYCOPYRROLATE - ROBINUL</u>						
N012827 001	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N012827 002	7091236	Apr 24, 2024	U-877	Y		
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903 001	8415337	Mar 02, 2032	DS DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057 001	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	>A> 8445003	Apr 29, 2030	U-1287			
	>A> 8445013	Apr 29, 2030	U-1287			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	RE43932	Jan 16, 2019	DS DP		ODE	Jan 25, 2020
	RE43932*PED	Jul 16, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002	7544799	Jan 16, 2019	DS DP	Y	I-666 ODE	Jan 25, 2016
	RE43932	Jan 16, 2019	DS DP			Jan 25, 2020
	RE43932*PED	Jul 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N022383 001	8067437	Jun 02, 2020		U-1168		
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N022290 001					I-669	Mar 20, 2016
<u>IRON SUCROSE - VENOFER</u>						
N021135 005					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	8367102	Sep 21, 2021		U-1347		
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	8367102	Sep 21, 2021		U-1347		
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	8367102	Sep 21, 2021		U-1347		
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	8367102	Sep 21, 2021		U-1347		
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	8410274	Dec 28, 2026	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8377982	May 28, 2024		U-1363		
	8377982*PED	Nov 28, 2024				
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	8404717	Apr 11, 2023		U-1215		
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	8404717	Apr 11, 2023		U-1215		
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	8404717	Apr 11, 2023		U-1215		
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	8404717	Apr 11, 2023		U-1215		
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	8404717	Apr 11, 2023		U-1215		
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 001					PC	Feb 16, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 002					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 003					PC	Feb 16, 2013
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 002	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 003	6500829	Mar 07, 2022	DS DP			
<u>LEVONORGESTREL - SKYLA</u>						
N203159 001	5785053	Dec 05, 2015	DP		NP	Jan 09, 2016
	7252839	Nov 13, 2023	DP			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 001	>A> 7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 002	>A> 7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 003	>A> 7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 004	>A> 7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 005	>A> 7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 006	>A> 7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 007	>A> 7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 008	>A> 7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 009	>A> 7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 010	>A> 7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 011	>A> 7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 012	>A> 7101569	Oct 02, 2023		U-759		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 001	5712279	Feb 21, 2015	DS	U-1317	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 002	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 003	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N202872 001	5800807	Jan 29, 2017	DP			
<u>LOXAPINE - ADASUVE</u>						
N022549 001	6716416	May 20, 2022	DP			
	7052679	Mar 20, 2022	DP			
	7078020	Oct 26, 2021	DP U-1375			
	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 26, 2021	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Oct 26, 2021	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	6414016	Sep 05, 2020	U-717		I-670	Apr 19, 2016
	6414016	Sep 05, 2020	U-1392			
	6982283	Dec 04, 2022	U-1391			
	>A> 7064148	Aug 30, 2022	U-739			
	>A> 7064148	Aug 30, 2022	U-1404			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1393			
	8071613	Sep 05, 2020	U-1203			
	8097653	Nov 14, 2022	U-1394			
	8097653	Nov 14, 2022	U-1214			
	8389542	Nov 14, 2022	DP U-1395			
	8389542	Nov 14, 2022	DP U-1345			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001	5532372	Jul 02, 2018	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002	5532372	Jul 02, 2018	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 003	5532372	Jul 02, 2018	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 004	5532372	Jul 02, 2018	DS			
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N203595 001					NC	Jan 18, 2016
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 001	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025			U-539	
	8283379	Nov 22, 2025			U-539	
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025			U-539	
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 002	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025			U-539	
	8283379	Nov 22, 2025			U-539	
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025			U-539	
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 003	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025			U-539	
	8283379	Nov 22, 2025			U-539	
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025			U-539	
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 004	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025			U-539	
	8283379	Nov 22, 2025			U-539	
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025			U-539	
<u>MESALAMINE - CANASA</u>						
N021252 002	>A> 8217083	Jun 06, 2028	DP			
	>A> 8436051	Jun 06, 2028	DP			
<u>MESALAMINE - DELZICOL</u>						
N204412 001	5541170	Jul 30, 2013	DP U-141			
	5541171	Jul 30, 2013	DP U-141			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N200678 001	>A> RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N200678 002	>A> RE44186	Jul 31, 2023	DS DP U-1097			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N200678 003	>A> RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 001	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP U-1036			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 002	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP U-1036			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	8420663	Sep 30, 2029	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	8420663	Sep 30, 2029	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 003	8420663	Sep 30, 2029	U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N201922 001	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N201922 003	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N201922 005	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N203568	001	5914396	Jun 22, 2016	DS	NCE	Jan 29, 2018
		6166197	Dec 26, 2017	DS	ODE	Jan 29, 2020
		6222025	Mar 06, 2015	DS		
		6451991	Feb 11, 2017	DS		
		7015315	Mar 21, 2023	DS		
		7101993	Sep 05, 2023	DS		
		7407943	Aug 01, 2021	U-1353		
		7511131	Dec 13, 2025	DS		
<u>MOMETASONE FUROATE - ELOCON</u>						
N019625	002				NP	Apr 19, 2016
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N022428	001	>A> 8450311	May 29, 2029	DP		
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050703	001	5569672	Oct 29, 2013	U-1358		
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050746	001	5569672	Oct 29, 2013	U-1358		
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N050791	001	>A> 6306900	Feb 27, 2018	DP		
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N050791	002	>A> 6306900	Feb 27, 2018	DP		
<u>NEPAFENAC - NEPAFENAC</u>						
N203491	001	5475034	Jun 06, 2014	U-100		
		6403609	Jul 17, 2018	DP		
		7947295	Jun 08, 2024	DP		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068	001	8389537	Jul 18, 2026	DS DP	U-1374	
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068	002	8389537	Jul 18, 2026	DS DP	U-1374	
<u>NIMODIPINE - NYMALIZE</u>						
N203340	001				>A> ODE	May 10, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N020845	002	8431163	Jun 30, 2029	U-1286		
		8431163*PED	Dec 30, 2029			
<u>NITRIC OXIDE - INOMAX</u>						
N020845	003	8431163	Jun 30, 2029	U-1286		
		8431163*PED	Dec 30, 2029			
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N021861	001	8399508	Sep 17, 2022	U-726		
		8399508*PED	Mar 17, 2023			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID OTC</u>						
N022281	001	6489346	Jul 15, 2016	DP	U-1025	Y
		6645988	Jul 15, 2016	DP		Y
		6699885	Jul 15, 2016	DP		Y

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087	001				NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087	002				NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087	003				NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246	001				NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246	002				NPP	Dec 21, 2015
<u>OSPENIFENE - OSPHENA</u>						
N203505	001	6245819	Jul 21, 2020	U-1369	NCE	Feb 26, 2018
		8236861	Aug 11, 2026	U-1370		
		8236861	Aug 11, 2026	U-1369		
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N202211	001	5601839	Apr 26, 2015	DP U-1329	NP	Jan 25, 2016
		5834010	Apr 26, 2015	DP U-1329		
		6743441	Apr 26, 2020	DP U-1329		
		7081249	Apr 26, 2020	DP U-1329		
		7081250	Apr 26, 2020	DP U-1329		
		7081251	Apr 26, 2020	DP U-1329		
		7081252	Apr 26, 2020	DP U-1329		
		7179483	Apr 26, 2020	U-1329		
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080	001	8409616	Nov 26, 2023	DP		
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080	002	8409616	Nov 26, 2023	DP		
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A079087	006				PC	Jul 07, 2013
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725	005				M-93 NCE	Jul 29, 2019 Apr 30, 2014
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088	001	>A> 8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088	002	>A> 8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088	003	>A> 8440170	Mar 14, 2029	DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363	001	>A> 5856336	Jan 01, 2021	DS U-998		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363	002	>A> 5856336	Jan 01, 2021	DS U-998		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363	003	>A> 5856336	Jan 01, 2021	DS U-998		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	RE42152	Dec 10, 2018	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N204026 001	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N204026 002	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N204026 003	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N204026 004	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 001					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 002					ODE	Dec 14, 2019
<u>PRALATREXATE - FOLOTYN</u>						
N022468 001	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N022468 002	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 001	8404703	Mar 02, 2022	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 002	8404703	Mar 02, 2022	U-1381			
<u>PREDNISONE - RAYOS</u>						
N202020 001	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N202020 002	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N202020 003	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREGABALIN - LYRICA</u>						
N022488 001					I-651	Jun 20, 2015
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N204736 001	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N204736 002	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N203971 001	>A> 6635234	Jan 03, 2020	U-1405		>A> NCE	May 15, 2018
<u>REGORAFENIB - STIVARGA</u>						
N203085 001					I-667 ODE	Feb 25, 2016 Feb 25, 2020

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N022417 001	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A078173 001					PC	Jun 29, 2013
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A078173 002					PC	Jun 29, 2013
<u>ROFLUMILAST - DALIRESP</u>						
N022522 001	>A> 8431154	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 001	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 003	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 004	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 005	5670524	Sep 23, 2014	DS DP U-833			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 001	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 002	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 003	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 004	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 005	8415362	Dec 24, 2027	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	8318745	Nov 17, 2024	DP			
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N020628 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N021785 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 001	>A> RE44186	Jul 31, 2023	DS DP U-995			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 002	>A> RE44186	Jul 31, 2023	DS DP U-995			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N020990 001	>A> 7067555	Oct 11, 2019	DP			
	>A> 7067555*PED	Apr 11, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	8343130	Oct 18, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N202207 001					NCE	Mar 13, 2018
<u>TEDUGLUTIDE - GATTEX KIT</u>						
N203441 001	5789379	Apr 14, 2015	DS DP U-1320		ODE	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320			
	7847061	Nov 01, 2025	U-1320			
<u>TELAPREVIR - INCIVEK</u>						
N201917 001	>A> 8431615	May 30, 2028	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	6635618	Sep 11, 2023	DS DP U-728			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	6635618	Sep 11, 2023	DS DP U-728			
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001					M-124	Jan 28, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001					M-124	Jan 28, 2016
<u>TESTOSTERONE - AXIRON</u>						
N022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Jul 05, 2027	U-1390			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098 001					NP	Jan 31, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098	002				NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098	003				NP	Jan 31, 2016
<u>TICAGRELOR - BRILINTA</u>						
N022433	001 >A> 8425934	Dec 18, 2029	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N021821	001 8372995	Oct 08, 2030	DP			
<u>TOBRAMYCIN - BETHKIS</u>						
N201820	001 6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022	U-1324			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N201688	001 7097827	Jun 27, 2021	DP		NP	Mar 22, 2016
	7368102	Dec 19, 2022	DP U-909			
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N021228	001 6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020	DP U-544			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N021228	002 >A> 6911217	Nov 11, 2019	DP U-544			
	>A> 6911217*PED	May 11, 2020	DP U-544			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N204114	001 >A> 7378423	Sep 13, 2025	DS DP		>A> NCE	May 29, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N204114	002 >A> 7378423	Sep 13, 2025	DS DP		>A> NCE	May 29, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N204114	003 >A> 7378423	Sep 13, 2025	DS DP		>A> NCE	May 29, 2018
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A202093	001				PC	Jul 02, 2013
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994	001 8388941	Sep 20, 2027	DP			
<u>TROSPIUM CHLORIDE - TROSPIUM CHLORIDE</u>						
A091289	001				PC	Apr 10, 2013
<u>ULIPRISTAL ACETATE - ELLA</u>						
N022474	001 8426392	Jun 12, 2030	U-1389			
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N021214	001 6770675	Nov 24, 2018	DP U-1322			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817	001 8052987	Oct 27, 2023	U-1199			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
-----------------	-----------	------------------------------	-----------------	-------------------------------	-------------------------	-----------------------------------

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 33rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>